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ABSTRACT 
Dietary L-arginine Supplementation Reduces Fat Mass in Diet-Induced  
Obese Rats. (August 2007)  
Wenjuan Shi Jobgen, B.S., University of Science and Technology of China; 
M.S., Virginia Tech  
Chair of Advisory Committee: Dr. Guoyao Wu 
 
This study was conducted to test the hypothesis that dietary arginine supplementation 
reduces fat mass in diet-induced obese rats. Male Sprague-Dawley rats were fed either 
low- or high-fat diets for 15 wks (16 rats/diet).  Thereafter, lean or obese rats continued 
to be fed their same respective diets and received drinking water containing either 1.51% 
L-arginine-HCl or 2.55% alanine (isonitrogenous control) (n=8/treatment group).   
Twelve weeks after the initiation of the arginine treatment, rats were euthanized to 
obtain tissues for biochemical analyses. Results were statistically analyzed as a 2x2 
factorial experimental design using ANOVA. High-fat diet increased the mass of white 
adipose tissues at different anatomical locations by 49-96% compared to the low-fat diet.  
Concentrations of serum cholesterol as well as lipids in skeletal muscle and liver were 
higher in obese rats than in lean rats. L-Arginine supplementation reduced white adipose 
tissue mass by 20-40% while increasing brown adipose tissue mass by 15-20%.  In 
addition, arginine treatment decreased adipocyte size, serum concentrations of glucose, 
triglycerides and leptin, improved glucose tolerance, and enhanced glucose and oleic 
  
iv 
acid oxidation in skeletal muscles. The mRNA levels for hepatic fatty acid synthase and 
stearoyl-CoA desaturase were reduced, but mRNA levels for hepatic AMP-activated 
protein kinase (AMPK), PPAR coactivator-1  and carnitine palmitoyltransferase I 
(CPT-I)  as well as muscle CPT-I were increased in response to the arginine treatment.  
Subsequent experiments were conducted with cell models to define the direct effects of 
arginine on energy-substrate metabolism in insulin-sensitive cells.  In BNL CL.2 mouse 
hepatocytes, C2C12 mouse myotubes and 3T3-L1 mouse adipocytes, increasing 
extracellular concentrations of arginine from 0 to 400 µM increased AMPK expression 
as well as glucose and oleic acid oxidation. Inhibition of nitric oxide synthesis 
moderately attenuated the arginine-stimulated increases of substrate oxidation as well as 
AMPK and ACC phosphorylation in BNL CL.2 cells, but had no effect in C2C12 and 
3T3-L1 cells. Collectively, these results suggest that arginine increases AMPK 
expression and energy-substrate oxidation in a cell-specific manner, thereby reducing fat 
mass in diet-induced obese rats. The findings have important implications for treating 
obesity in humans and companion animals as well as decreasing fat deposition in 
livestock species. 
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CHAPTER I 
INTRODUCTION AND LITERATURE REVIEW 
 
Introduction 
Fat deposition in humans or animals depends on the balance between dietary caloric 
intake and whole-body energy expenditure. A chronic imbalance in energy metabolism 
(more energy input than energy output) due to complex genetic and/or environmental 
factors results in excess fat accretion or obesity in humans, which is currently a major 
public health problem worldwide (Hill et al. 2003; Bell et al. 2001). The 1999-2000 
National Health and Nutrition Examination Survey found that 65% and 31% of the U.S. 
adult population were overweight (a body mass index > 25 kg/m2) and obese (a body 
mass index > 30 kg/m2), respectively (Hill et al. 2003). The prevalence of overweight 
and obesity increased by 16% and 35%, respectively, compared with the survey 
conducted between 1988 and 1994. Children and adolescents have not been immune to 
this epidemic, as 15% of them in the U.S. are obese, representing a 36% increase within 
the past decade (Hill et al. 2003).   Most other countries are also experiencing the 
obesity crisis. For example, the prevalence of overweight in China doubled in women 
and almost tripled in men between 1989 and 1997 (Bell et al. 2001).  Worldwide, more 
than 300 million adults are obese and over one billion are overweight  (Hill et al. 2003). 
Obesity  is  a  major  risk  factor  for insulin resistance,  type II diabetes,  atherosclerosis,  
___________________ 
This dissertation follows the style and format of British Journal of Nutrition.  
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stroke, hypertension, impaired vascular function, sleep disorders, and some types of 
cancer (including colon and breast cancers) (Nisoli & Carruba, 2004). Consequently, 
obesity claims an increasing number of lives and contributes to tremendous costs of 
health care worldwide. In the U.S. alone, about 300,000 people die of obesity-related 
diseases every year, the incidence of type II diabetes among children has increased 10-
fold over the past decade, and obesity accounts for 6-8% of all health care expenditures 
(Hill et al. 2003). Unfortunately, clinicians have few tools to fight the obesity epidemic, 
because current anti-obesity drugs are not highly effective and are fraught with side 
effects (Nisoli & Carruba, 2004). Because even a modest (5-7%) weight loss in obese 
subjects is associated with a significant improvement in risk factors for cardiovascular 
disease and diabetes (Nisoli & Carruba, 2004), identifying new means to reduce body fat 
will be extremely beneficial for human health.    
Nitric oxide (NO), a signaling molecule that regulates nutrient metabolism, is a free 
radical produced from L-arginine by various isoforms of NO synthase (NOS). This 
synthetic reaction occurs in virtually all mammalian cells and tissues, including 
adipocytes, brain, endothelial cells, heart, hepatocytes, macrophages, and skeletal muscle 
(Lee et al. 2003; Wu & Morris, 1998; Wu et al. 2001; Wu & Meininger, 2002). As a 
small, hydrophilic gas molecule, NO readily diffuses into cells and acts on the heme of 
target molecules. Through multiple cGMP-dependent pathways, NO plays a crucial role 
in regulating vascular tone, neurotransmission, host immunity, and whole-body 
homeostasis (Alderton et al. 2001; Shi et al. 2004). We recently found that dietary 
supplementation with L-arginine reduced fat mass and enhanced expression of key genes 
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responsible for glucose and fatty acid oxidation in the Zucker diabetic fatty (ZDF) rat, an 
animal model of type II diabetes secondary to a defect in the leptin receptor (Fu et al. 
2005). Physiological levels of NO stimulate glucose uptake and oxidation as well as 
fatty acid oxidation in insulin-sensitive tissues (muscle, heart, liver, and adipose tissue), 
inhibit the synthesis of glucose, glycogen and fat in target tissues (e.g., liver and 
adipose), and enhance lipolysis in adipocytes. The underlying mechanisms may involve 
multiple cGMP-dependent pathways: 1) phosphorylation of AMP-activated protein 
kinase (AMPK); 2) phosphorylation of hormone-sensitive lipase and perilipins; 3) 
increased expression of peroxisome proliferator-activated receptor-γ (PPARγ) 
coactivator 1 (PGC-1); and 4) increased blood flow to tissues. Modulation of the 
arginine-NO pathway may provide a potentially novel means to reduce fat mass in obese 
subjects.  
NO synthesis in animal cells 
NO synthases     
The biosynthesis of NO by NOS requires L-arginine (a basic amino acid at physiological 
pH) and oxygen as substrates, as well as tetrahydrobiopterin (BH4), NADPH, Ca2+, 
calmodulin, FMN, and FAD (Wu & Morris, 1998). There are three isoforms of the NOS: 
nNOS (type-1 NOS), which was first discovered in neuronal tissues; iNOS (type-2 
NOS), which was originally found to be inducible under certain conditions in 
macrophages and hepatocytes; and eNOS (type-3 NOS), which was first identified in 
endothelial cells. These NOS isoforms are encoded by three different genes, and their 
nucleotide sequences are 51-57% homologous (Alderton et al. 2001). NOS can be 
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present in plasma membrane, cytoplasm, nucleus, rough endoplasmic reticulum, and 
mitochondria of cells. Notably, there is complex intracellular compartmentation for the 
NOS isoforms in animal cells and tissues (Buchwalow et al. 2005). In general, eNOS, 
nNOS, and iNOS are localized primarily in plasma membrane and cytoplasm, 
mitochondria and cytoplasm, and cytoplasm, respectively. The intracellular 
compartmentation of NOS isoforms may play a role in regulating NO synthesis in 
animal cells. While nNOS and eNOS are expressed constitutively at low levels in a 
variety of cell types and tissues, iNOS is normally not expressed at a significant level in 
cells or tissues (Wu & Morris, 1998). When induced by certain immunological stimuli 
(including inflammatory cytokines or bacterial endotoxin), iNOS is highly expressed in 
many cell types and produces a large amount of NO. Due to its high affinity for calcium 
and tight binding with calmodulin, iNOS is fully active in the absence of exogenous Ca2+ 
or calmodulin. All of the NOS isoforms can be induced under certain stimuli through 
transcriptional and translational mechanisms (Wu & Morris, 1998).  
A small quantity of NO is produced by eNOS and nNOS, relative to the amount of 
NO generated by iNOS. For example, NO production by unstimulated bovine venular 
endothelial cells is 0.24 nmol/106 cells/h (Wu et al. 2001), which is only approximately 
7% of that by LPS-activated RAW 264.7 macrophages (3.3 nmol/106 cells/h) (Meininger 
et al. 2000). Similarly, in vivo systemic production of NO is low in rats (e.g., 15 µmol/kg 
body wt/24 h), but increases 15-fold in response to immunological challenge (Wu et al. 
1999a). Compelling evidence shows that NO synthesis is regulated not only by the 
amount and/or phosphorylation of the NOS protein but also by the availability of 
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cofactors (particularly NADPH, BH4, and Ca2+) and arginine (Wu & Meininger, 2002). 
Arginine, BH4, and heme promote formation of and also stabilize the active dimeric 
form of all isoforms of the NOS (Alderton et al. 2001). Although the Km values of NOS 
for arginine are 3 to 20 µM depending on the isoform, increasing extracellular arginine 
concentrations from 0.05 to 5 mM dose-dependently increases NO synthesis in a variety 
of cells, including activated macrophages and endothelial cells (Wu & Morris, 1998). It 
is now clear that arginine increases the transcription of iNOS in macrophages (Lee et al. 
2003) and BH4 synthesis in endothelial cells (Shi et al. 2004), resulting in increased NO 
production in both cell types. Additionally, arginine-dependent NO synthesis is affected 
by various amino acids, including glutamine, lysine, glutamate, phenylalanine, and 
taurine (Wu & Meininger, 2002). 
NOS expression in insulin-sensitive tissues 
Because of an important role for skeletal muscle, adipose tissue, heart, and liver in NO 
synthesis (Kobzik et al. 1994; Nakane et al. 1993; Bates et al. 1996; Kobzik et al. 1995; 
Gath et al. 1996; Punkt et al. 2002) and the metabolism of energy substrates (Nisoli & 
Carruba, 2004; Digirolamo et al. 1993), here we review briefly the pertinent literature 
related to NOS expression in these insulin-sensitive tissues.  In mammalian skeletal and 
cardiac muscle, all three isoforms of the NOS are constitutively expressed (Kobzik et al. 
1994; Nakane et al. 1993; Bates et al. 1996; Kobzik et al. 1995; Gath et al. 1996; Punkt 
et al. 2002). The NOS isoforms are present mainly in sarcolemma (plasma membrane), 
sarcoplasm (cytoplasm), sarcoplasmic reticulum, and mitochondria of muscle fibers 
(Buchwalow et al. 2005; Frandsen et al. 1996). In addition to myocytes, all three NOS 
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isoforms can be detected in capillaries and arterioles of the skeletal musculature 
(Buchwalow et al. 2005). The expression and activity of the NOS in skeletal muscle are 
regulated by several factors, which include fiber type, contraction, developmental stage, 
and pathological state (Punkt et al. 2002; Kapur et al. 1997; Stamler & Meissner, 2001). 
Brown adipose tissue contains both eNOS and iNOS in the cytoplasm and nucleus, as 
well as eNOS in the plasma membrane (Giordano et al. 2002). In contrast, both eNOS 
and iNOS appear to be absent from the nucleus but are present in the cytoplasm and 
plasma membrane of white adipose tissue (Elizalde et al. 2000; Ribiere et al. 1996). 
Interestingly, nNOS is weakly expressed only in the cytoplasm of brown and white 
adipose tissues and is absent from mitochondria or plasma membranes (Elizalde et al. 
2000; Ribiere et al. 1996; Giordano et al. 2002). In liver, eNOS is uniformly distributed 
in hepatocytes and in the endothelium of hepatic arteries, terminal hepatic venules, 
sinusoids, and the epithelium of biliary ducts, whereas iNOS is constitutively expressed 
primarily in the cytoplasm of periportal hepatocytes (McNaughton et al. 2002). While 
still under debate, most biochemical and genetic studies have shown that nNOS is the 
isoform found in the mitochondria of brain, heart, kidneys, liver, and skeletal muscle 
(Ghafourifar & Cadenas, 2005). Thus, the insulin-sensitive tissues are significant sites of 
NO production in the body, and the compartmentation of NO synthesis is likely related 
to specific cell functions. 
NO targets  
The target cells for NO action can be the NO-producing cell itself, neighboring cells via 
its direct release, or distant cells via transport by glutathione and red blood cells (Stamler 
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& Meissner; 2001). A soluble guanylyl cyclase is a major receptor for physiological 
levels of NO (Denninger & Marletta, 1999). The membrane-permeable NO binds to the 
prosthetic heme group of the enzyme, thereby activating the production of cyclic 
guanosine-3’,5’-monophosphate (cGMP) from guanosine triphosphate (GTP) in target 
cells. cGMP is an intracellular signaling molecule, which plays an important role in 
regulating various cellular events through activation of cGMP-dependent protein kinase 
(PKG), cGMP-gated ion channels, and cGMP-dependent phosphodiesterases 
(Ghafourifar & Cadenas, 2005; Denninger & Marletta, 1999; Russwurm & Koesling, 
2002). As a highly reactive free radical molecule, high levels of NO produced by iNOS 
can oxidize biomolecules (including proteins, fatty acids, and DNA), thereby damaging 
cell membranes, inhibiting vital biochemical reactions (e.g., the mitochondrial Krebs 
cycle and respiratory chain), and even causing cell death (Fang et al. 2002). Therefore, 
effects of NO on cell metabolism critically depend on its concentrations at the reaction 
site.   
Interorgan metabolism of energy substrates 
Small intestine 
The metabolism of dietary energy substrates in animals and humans requires the 
cooperation of multiple organs and tissues, particularly the small intestine, liver, skeletal 
muscle, heart, kidneys, brain, and adipose tissue. The small intestine is responsible for 
the terminal digestion of fat, protein, and carbohydrate in monogastric animals, whereas 
fermentation of these substances occurs in the rumen of ruminants to produce short-
chain fatty acids (acetate, propionate, and butyrate). The small intestine is also the 
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primary site for the absorption of fatty acids, glucose, amino acids, and other nutrients in 
both monogastric and ruminant animals (reviewed in Wu, 1998). In most mammals 
(including humans, pigs, cattle, and rats), extensive catabolism of dietary glutamine, 
glutamate, and aspartate takes place in enterocytes (Wu, 1998).  Glutamine, glutamate, 
and proline are substrates for the net production of both citrulline and arginine in 
neonates and of citrulline in adults (Wu & Morris, 1998). The circulating citrulline is 
taken up by extraintestinal and extrahepatic tissues (primarily the kidneys) and by almost 
all cell types (except for hepatocytes) for conversion into arginine by argininosuccinate 
synthase and argininosuccinate lyase (Wu & Morris, 1998).  The small intestine also 
plays an important role in the catabolism of many dietary essential and nonessential 
amino acids (including branched-chain amino acids, lysine, phenylalanine, methionine, 
glycine, and serine), although the responsible cell types have not yet been identified 
(Wu, 1998). Interestingly, oxidation of glucose and long-chain fatty acids is limited in 
the small intestine under fed conditions. After feeding, the small intestine releases amino 
acids, glucose, and lipoproteins (mainly as chylomicrons and very-low-density-
lipoprotein, VLDL) (Jungas et al. 1992). Amino acids and glucose enter the portal vein 
through the mucosal vasculature, and then reach the liver. In mammals, triacylglycerols 
(TAG) packaged as soluble chylomicrons and VLDL leave the small intestine via 
exocytosis, are transported through lymph vessels, and enter blood circulation through 
the thoracic duct and cranial vena cava. In birds, the intestinal lymphatic system is 
poorly developed and the VLDL synthesized in the avian small intestine are absorbed 
directly into the portal vein. Absorption of long-chain fatty acids (LCFA) and release of 
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chylomicrons by the small intestine of ruminants are much lower in comparison with 
monogastric animals, because the lower content of dietary fat (< 5% of dry matter 
intake) is necessary to prevent interference with ruminal microbial metabolism (Bergen 
& Mersmann, 2005). Lipoprotein lipase (LPL), which is present on the wall of blood 
capillaries in peripheral tissues, hydrolyzes the TAG of chylomicrons and VLDL to form 
free fatty acids, glycerol, and low-density-lipoprotein (LDL). LDL is the major carrier of 
cholesterol in humans, pigs, rabbits, sheep, and guinea pigs (Bergen & Mersmann, 
2005). During fasting, ketone bodies produced by the liver are the major energy 
substrates for the small intestine of most animals except for pigs that have limited 
hepatic ketogenesis and thus very low plasma levels of these fuels.   
Liver 
Although the liver represents only 2-3% of the total body weight, it accounts for 
approximately 20% of the total energy expenditure under basal conditions (Jungas et al. 
1992). Gluconeogenesis (formation of glucose from noncarbohydrate precursors), 
ketogenesis (production of acetoacetate and -hydroxybutyrate), amino acid oxidation, 
urea cycle, as well as syntheses of cholesterol, bile acids, and VLDL occur primarily in 
the liver. The liver also synthesizes and releases high-density-lipoproteins (HDL) into 
the circulation. Importantly, this organ is a major site for the oxidation of fatty acids in 
all animals studied, including humans, pigs, cattle, rats, mice, and chickens (Bergen & 
Mersmann, 2005). During fasting, the rates of gluconeogenesis (from amino acids, 
lactate and glycerol in all animals and also from propionate in ruminants), 
glycogenolysis, and ketogenesis (from acetyl-CoA) in liver increase markedly to supply 
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glucose and ketone bodies to the brain, peripheral tissues, and cells of the immune 
system as well as glucose for red blood cells (Jungas et al. 1992).  Because of the blood-
brain barrier, plasma long-chain fatty acids cannot be utilized for oxidation by the brain 
(Bergen & Mersmann, 2005), and instead ketone bodies serve as major energy substrates 
for this tissue when plasma glucose level is reduced (e.g., < 4.5 mM in adult humans) 
during fasting (Wu & Marliss, 1992).  In the fed state, glucose, which enters the portal 
circulation from the small intestine (with exception of roughage-fed ruminants), is either 
stored as glycogen or metabolized via the pentose cycle and fatty acid synthesis in the 
liver, or it enters the systemic circulation for utilization by extrahepatic cells and tissues 
(Wu & Marliss, 1992).  In humans, cats, dogs, rabbits, rodents, and avian species (e.g., 
chickens and ducks), the liver is a major site for de novo fatty acid synthesis from 
glucose and amino acids, whereas, in pigs and ruminants, this synthetic event is virtually 
absent from the liver.  
Skeletal muscle and heart 
Skeletal muscle is quantitatively the largest organ in the body, representing about 40-
45% of the total body mass and accounting for 30% of the resting metabolic rate in 
adults (Ceddia, 2005). Skeletal and cardiac muscles are the major sites for the oxidation 
of fatty acids and glucose, the transamination of branched-chain amino acids (leucine, 
isoleucine, and valine), and the release of glutamine and alanine (major glucogenic 
substrates) (Wu & Marliss, 1992). Glutamine and alanine derive their -amino groups 
from branched-chain amino acids, and their carbon skeletons primarily from glucose. 
Thus, muscle plays an important role in the regulation of plasma levels of glucose and 
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fatty acids. The fatty acids utilized by skeletal muscle and heart can be derived from 
either the lipolysis of TAG in adipose tissue or the hydrolysis of the circulating TAG-
rich chylomicrons and VLDL by LPL (Rasmussen & Wolfe, 1999).  Among animal 
tissues, LPL is expressed mainly in muscle and adipose tissue, where the enzyme binds 
to the capillary endothelium (Frayn et al. 2005).  Interestingly, the muscle and adipose-
tissue LPL are regulated differentially by hormones and nutritional factors. Fasting 
increases LPL activity in the muscle to facilitate TAG hydrolysis, but decreases LPL 
activity in adipose tissue to reduce its uptake of TAG and thus fat storage (Fried et al. 
1993a). Acetyl-CoA, a common intermediate of glucose, fatty acid and amino acid 
oxidation, either enters the Krebs cycle for complete oxidation or is utilized for 
lipogenesis in skeletal and cardiac muscles, depending on the intracellular energy status 
and activity of acetyl-CoA carboxylase (ACC) (Jungas et al. 1992). In the muscles, as in 
the liver, malonyl-CoA, a product of the ACC reaction, is an allosteric inhibitor of 
carnitine palmitoyl transferase-I (CPT-I), the enzyme that transfers the long-chain fatty 
acyl-CoA into mitochondria for β-oxidation (Rasmussen & Wolfe, 1999). Intracellular 
concentrations of malonyl-CoA are regulated not only by its synthesis from acetyl-CoA 
but also by its decarboxylation. Therefore, conditions that result in reduced or increased 
intracellular levels of malonyl-CoA favor LCFA oxidation or lipogenesis, respectively 
(Rasmussen & Wolfe, 1999; Ruderman et al. 2003). Thus, the level of malonyl-CoA is 
decreased in skeletal and cardiac muscles during exercise or fasting, thereby promoting 
fatty acid oxidation in these tissues (Rasmussen & Wolfe, 1999). 
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Adipose tissues 
There are white and brown adipose tissues in animals, the amounts varying with species, 
developmental stage, and environment (Rothwell & Stock, 1985). Most mammals are 
born with significant amounts of both white and brown adipose tissues, with an 
exception of pigs that possess no brown adipose tissue at birth or in adult life 
(Mersmann, 1974). With an increase in age, the amounts of white adipose tissue 
normally increase. For example, in pigs, fat content is only 1% at term birth and reaches 
12% by 14 days of age (Wu et al. 2004a). In contrast, the amounts of brown adipose 
tissue normally decrease in rodents with increasing age, and virtually disappear shortly 
after birth in large mammals. Thus, brown adipose tissue is present at relatively low 
levels in adult rats and is virtually absent from adult humans.  Interestingly, under 
certain conditions (e.g., an increase in NO production, PGC-1α expression, or 
eukaryotic-translation-initiation-factor-4E binding protein), white adipose tissue may be 
converted into brown adipose tissue that expresses high levels of uncoupling protein 
(UCP)-1 (Nisoli & Carruba, 2004). Because of the presence of large amounts of 
mitochondria and uncoupling proteins, brown adipose tissue is a major site for heat 
production in newborn mammals and may play an important role in the oxidation of 
energy substrates in adults.   
White adipose tissue is the major site responsible for the substantial change in whole 
body fat, and plays an important role in energy balance. Adipose tissue fat accretion 
depends on the balance between the rates of accumulation and breakdown of TAG in 
adipocytes (Frayn et al. 2005). Significant oxidation of glucose and fatty acids occurs in 
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adipose tissues of animals (Digirolamo et al. 1993; Fu et al. 2005) and humans (Wu & 
Marliss, 1992). Whether de novo fatty acid synthesis occurs in adipose tissue depends on 
animal species and age/obesity.  For example, fatty acid synthesis is nearly absent from 
the adipose tissue of humans, chickens or adult rats. Interestingly, white adipose tissue is 
the major site for de novo fatty acid synthesis in pigs and ruminants under normal fed 
conditions. White adipose tissue, like the liver, is the primary site for de novo 
lipogenesis in dogs, cats, rabbits, and young rodents (Bergen & Mersmann, 2005).  In 
some monogastric animals (e.g., pigs and young rats) and ruminants (e.g., cattle and 
sheep), glucose and acetate are the major precursors for lipogenesis in adipose tissue, 
respectively (Bergen & Mersmann, 2005; Wu & Marliss, 1992). As noted above, in fed 
animals, adipose LPL hydrolyzes chylomicrons and VLDL to produce free fatty acids 
for TAG synthesis and storage in adipocytes.  There are fat depot-specific differences in 
LPL expression in humans in response to hormonal and nutritional changes (Fried et al. 
1993a). Interestingly, Kratky et al. (2005) recently reported that there was an alternative 
lipase called endothelial lipase in LPL-deficient mouse adipose tissue that could provide 
free fatty acids to adipocytes for re-esterification.  This endothelial lipase appears to be a 
phospholipase that utilizes HDL as its main substrate.  
During food deprivation, adipose-tissue TAG is hydrolyzed by hormone-sensitive 
lipase (HSL) and monoacylglycerol lipase into glycerol and free fatty acids. HSL, often 
considered to be a key regulatory enzyme in lipolysis, is present in the cytoplasm under 
basal, unstimulated conditions. Interestingly, another lipase, adipose triglyceride lipase 
localized in lipid droplets, was recently discovered to play a role in initiating the 
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hydrolysis of TAG to produce diacylglycerol, the preferred substrate for HSL 
(Zimmermann et al. 2004). The adipose triglyceride lipase is highly expressed in the 
white adipose tissue of humans and mice, but its expression in domestic animals remains 
to be established. Finally, monoglyceride lipase hydrolyzes monoacyglycerol to form 
glycerol and free fatty acids, thereby completing the hydrolysis of TAG (Frayn et al. 
2005; Zechner et al. 2005). Owing to a lack of glycerol kinase in adipose tissue, glycerol 
is not utilized by this tissue but is released from adipocytes into the circulation. The 
TAG-derived glycerol can be used for hepatic and renal gluconeogenesis. Long-chain 
free fatty acids released from TAG hydrolysis can be oxidized to provide ATP in 
adipocytes or are released from the cells. Because of their hydrophobic properties, long-
chain fatty acids are transported in blood by albumin and oxidized by most tissues to 
provide ATP except in the brain (Frayn, 2002). Because white adipose tissue represents 
a significant portion (15-40% depending on sex and obesity) of total body mass, the 
metabolism of adipose tissue likely contributes significantly to the whole body 
homeostasis of glucose and fatty acids (Ceddia, 2005; Shepherd et al. 1993). Thus, 
selective overexpression of the glucose transporter GLUT-4 in adipose tissue enhances 
glucose transport by adipocytes and improves whole-body insulin sensitivity in mice 
(Shepherd et al. 1993). 
Regulation of lipolysis and fatty acid oxidation 
Lipolysis and its regulation 
Lipolysis is an early, critical event in the utilization of the stored TAG in adipose tissue 
and other tissues. Lipolysis is tightly regulated by hormones and perilipin.  Perilipins are 
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proteins that coat the surface of lipid droplets in adipocytes and have a protective effect 
on lipolysis in their non-phosphorylated state (Holm, 2003). The perilipin is part of the 
PAT-family of proteins, which include perilipin, adipophilin (adipose differentiation-
related protein), and TIP47 (the tail-interacting protein of 47 kDa) (Holm, 2003). These 
proteins are associated with the neutral lipid droplets and share similarities in their 
nucleotide sequences (Tansey et al. 2004). At present, the precise roles of adipophilin 
and TIP47 in fat metabolism are not known. Upon activation of the lipolysis cascade by 
adrenergic or other agonists, both HSL and perilipins are phosphorylated by cAMP-
dependent protein kinase (PKA), and HSL is also phosphorylated by cGMP-dependent 
protein kinase (PKG) and AMPK. Phosphorylation activates HSL and also promotes the 
interaction of perilipins (particularly perilipin A) with HSL.  Such an association triggers 
the translocation of HSL from the cytosolic compartment to the lipid droplet surface to 
initiate lipolysis (Tansey et al. 2004). Glucagon (in young rodents but not in humans) 
and -adrenergic agonists (including catecholamines) increase intracellular cAMP levels 
by activating adenylyl cyclase, whereas insulin reduces intracellular cAMP 
concentrations by stimulating phosphodiesterase-3B activity (Holm, 2003). Likewise, 
guanylyl-cyclase activators (e.g., NO and CO) and Viagra (sildenafil citrate) increase 
intracellular cGMP levels in many cell types (including vascular smooth muscle cells 
and endothelial cells) by increasing cGMP production and inhibiting phosphodiesterase-
5 activity, respectively.   
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Fatty acid oxidation and its regulation 
The mitochondrial ß-oxidation pathway is quantitatively the major pathway for 
oxidation of short (<C8), medium (C8-C12), and long (C14-C20) chain fatty acids in 
animals. Long-chain fatty acyl-CoA enters mitochondria through the carnitine 
palmitoyltransferase system.  Mitochondrial β-oxidation of long-chain fatty acyl-CoA 
yields acetyl-CoA, which is oxidized via the mitochondrial Krebs cycle and electron 
transport system to yield CO2, water, and ATP.  ß-Oxidation of long chain (C14-20) and 
very long-chain (> C20) fatty acids, as well as dicarboxylic acids, branched-chain fatty 
acids, and bile acid derivatives, can also occur in peroxisomes, which is independent of 
the carnitine transport system. Peroxisomal systems I and II are responsible for ß-
oxidation of straight, very-long-chain fatty acids and branched, very-long-chain fatty 
acids, respectively. The short-chain fatty acids produced via the peroxisomal systems 
enter mitochondria for complete oxidation. The mitochondrial ß-oxidation of fatty acids 
is enhanced in response to mitochondrial biogenesis induced by transcription factors, 
such as nuclear respiration factor (NRF)-1, NRF-2, PPARα, and mitochondrial 
transcription factor A (mtTFA). PGC-1α upregulates the expression of these 
transcription factors and uncoupling proteins in a cGMP-dependent mechanism (Nisoli 
et al. 2003). Thus, PGC-1α is a master regulator of mitochondrial biogenesis and 
oxidative phosphorylation. Like PPARα, PPARβ (also called PPARδ) enhances fatty 
acid oxidation in tissues (e.g., liver, heart, and skeletal muscle) through increases in 
expression of CPT-1 and enzymes of the β-oxidation pathway (Desvergne et al. 2004). 
PPARγ is expressed predominantly in adipose tissue, and plays an important role in 
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adipogenesis and lipid storage through increases in LPL expression and TAG synthesis. 
Synthetic ligands for PPARα, PPARβ, and PPARγ include hypolipidemic drugs 
(fibrates), HDL, and hypoglycemic drugs (thiazolidinediones, TZDs), respectively 
(Desvergne et al. 2004). Natural/biological PPAR ligands include long-chain and very 
long-chain fatty acids, high-fat diet, the adrenal steroid dehydroepiandrosterone, and 
eicosanoids derived from arachidonic acid via the lipoxygenase and cyclooxygenase 
pathways (Kota et al. 2005). The activated PPAR interacts with retinoid X receptor 
(RXR) to form PPAR/RXR heterodimers, which bind to the peroxisome proliferator 
response elements localized in numerous gene promotors to increase expression of 
specific genes. Like any metabolic pathway, although protein phosphorylation and 
allosteric regulation of key enzymes provide a rapid mechanism for regulation of 
lipolysis and fatty acid oxidation via changes in the specific activity of an enzyme, gene 
expression is the most effective mechanism for long-term regulation of these events 
through alterations in the amount of enzyme protein.    
NO and AMPK 
AMPK and substrate oxidation 
AMP-activated protein kinase (AMPK) plays a crucial role in regulating glucose and 
fatty acid metabolism in animals. It is a heterotrimeric enzyme consisting of 3 subunits: 
a catalytic  subunit as well as regulatory  and γ units (Kahn et al. 2005a). AMPK acts 
as a sensor for cellular energy and is activated by an increased [AMP]/[ATP] ratio.  
Activation of AMPK occurs via phosphorylation by an established upstream AMPK 
kinase, LKB1.  Adiponectin and leptin exert their physiological effects on cells (e.g., 
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adipocytes) through activation of AMPK (Kahn et al. 2005a). The overall effect of 
AMPK activation is to switch off the ATP-consuming pathways such as lipogenesis or 
gluconeogenesis while switching on the ATP-producing pathways such as fatty acid and 
glucose oxidation. Available evidence suggests that AMPK activity is rapidly altered 
through protein phosphorylation and dephosphorylation, but a change in its protein level 
may be regulated at the gene transcriptional level and/or via protein degradation. 
Multiple mechanisms are responsible for the action of AMPK on the metabolism of 
energy substrates. The activation of AMPK stimulates GLUT-4 translocation and 
glucose transport in both skeletal muscle and cardiac muscle (Hayashi et al. 1998; 
Russell et al. 1999; Li et al. 2004). This results in an increase in whole-body glucose 
utilization. In addition, activated AMPK phosphorylates and, thus, inactivates ACC. As 
a result, the intracellular malonyl-CoA level is reduced, which allows for an increase in 
fatty acid oxidation (Winder & Hardie, 1996). AMPK also activates malonyl-CoA 
decarboxylase, the enzyme responsible for the degradation of malonyl-CoA (Park et al. 
2002a). Glycerol-3-phosphate acyltransferase, the enzyme that catalyzes the first 
reaction of TAG synthesis, is another target regulated by AMPK.  In liver, adipose tissue 
and muscle, AMPK inhibits glycerol-3-phosphate acyltransferase activity (Park et al. 
2002a; Muoio et al. 1999). AMPK may also enhance expression of PGC-1α in cells 
(Nisoli et al. 2003), thereby promoting mitochondrial biogenesis and oxidative 
phosphorylation. Finally, AMPK may increase mTOR activity and expression, thereby 
increasing the synthesis of adipophilin in adipocytes (Chung et al. 2005). This may 
result in reduced expression of perilipin, and, therefore, adipophilin can bind to the 
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neutral lipid droplets to facilitate TAG hydrolysis. Thus, through multiple mechanisms, 
AMPK stimulates the catabolism and oxidation of energy substrates.  
NO and AMPK 
There is an emerging body of evidence indicating that there is a relationship between 
NO and AMPK expression/activity in cells (Chen et al. 1999; Chen et al. 2000; Fryer et 
al. 2000; Shearer et al. 2004; Zou et al. 2003; Pilon et al. 2004; Zou et al. 2004). Such a 
relationship cooperatively promotes glucose and fatty acid oxidation. There is ample 
evidence showing that AMPK regulates NO production in cells. For example, eNOS is 
phosphorylated by AMPK at position Ser1177 (Chen et al. 1999). Thus, an increase in 
AMPK activity under various physiological and pathological conditions can lead to an 
increase in NO synthesis by eNOS.  Indeed, the activation of AMPK in human skeletal 
muscle during exercise was associated with an increase in the phosphorylation and 
activation of eNOS (Chen et al. 2000). This will increase blood flow and nutrient uptake, 
thereby favoring the oxidation of both glucose and fatty acids by skeletal muscle. In 
addition to physiological stimuli, AMPK can be activated by pharmacological agents. 
For example, AMPK activator, 5-aminoimidazole-4-carboxamide-1-B-D-ribofuranoside 
(AICAR), enhances NOS activity and glucose transport in muscle cells (Fryer et al. 
2000).  It is noteworthy that both in vivo investigations (Shearer et al. 2004) and in vitro 
studies involving isolated skeletal (Fryer et al. 2000) or cardiac muscles (Li et al. 2004) 
demonstrated that NOS inhibitors diminished AICAR-stimulated glucose uptake, 
indicating an important role for NO in mediating the role of AMPK in promoting 
glucose uptake. Most recently, activation of AMPK has been shown to decrease iNOS 
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expression in myocytes, macrophages, and adipocytes (Pilon et al. 2004), suggesting an 
anti-inflammatory role for AMPK in cells.  
While AMPK can regulate NO synthesis, NO can modulate AMPK activity through 
two mechanisms: a change in gene expression and AMPK activation via peroxynitrite.  
For example, dietary supplementation of arginine to ZDF rats increased AMPK mRNA 
levels in adipose tissue approximately 2-fold (Fu et al. 2005). Recently, a novel pathway 
to activate AMPK has been shown in animal cells without a change in [AMP]/[ATP] 
ratio (Zou et al. 2003). Peroxynitrite (ONOO-), generated from the spontaneous reaction 
of NO with superoxide anion (O2-), activates AMPK through a c-Src-mediated and 
phosphatidylinositol 3-kinase (PI3K)-dependent pathway in cultured bovine aortic 
endothelial cells as well as mouse aorta and hearts (Zou et al. 2003).  Although ONOO- 
at high levels (>100 µM) can cause oxidative stress, ONOO- at 1-10 µM activates 
AMPK (Zou et al. 2004). The anti-diabetic drug metformin enhances AMPK activity 
through this distinct pathway by increasing ONOO- production within a physiological 
range (Zou et al. 2004). Conversely, an inhibition of ONOO- formation either by 
scavenging O2- or by using NOS inhibitor NG-nitro-L-arginine methyl ester (L-NAME) 
diminished metformin-induced AMPK activation. Importantly, in eNOS knock-out mice, 
metformin had no effect on AMPK activity in endothelial cells, which emphasizes the 
importance of endogenous NO synthesis in AMPK activation. The PI3K activation by 
ONOO- may specifically increase the association of AMPK with its upstream kinase 
LKB1 without changing the activity of LKB1 (Zou et al. 2004).  These findings support 
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the conclusion that physiological levels of free radicals are signaling molecules involved 
in metabolic regulation (Wu et al. 2004c).    
NO and mitochondrial function 
NO and mitochondrial respiration 
Recently, much attention has been directed towards the identification of mitochondrial 
NOS and the effect of NO on mitochondrial respiration (Ghafourifar & Richter, 1997; 
Tatoyan & Giulivi, 1998; Clementi & Nisoli, 2005). There is substantial evidence 
showing the presence of nNOS in the mitochondria (also known as mitochondrial NOS 
or mtNOS) of many mammalian tissues, such as brain, liver, muscle, heart, and kidney 
(Bates et al. 1996). Thus, it is reasonable to expect that NO plays a role in mitochondrial 
oxidation and oxygen sensitivity of respiration in tissues. NO regulates mitochondrial 
respiration through distinct mechanisms. First, physiological levels of NO increase blood 
flow, therefore increasing the supply of metabolic substrates and oxygen to 
mitochondria. Second, high levels of NO may directly modulate the activity of the 
mitochondrial electron transport system (Brown, 2001). For example, at concentrations 
that were likely above physiological levels of NO in mitochondria, exogenous NO was 
shown to reversibly bind the oxygen-binding site of cytochrome c oxidase (the terminal 
enzyme in the mitochondrial respiratory chain), thus inhibiting electron transport and 
oxygen consumption. The result was a reduced supply of ATP from substrate oxidation 
and enhanced glycolysis as a significant alternative ATP-producing pathway (Nisoli et 
al. 2003; Brown, 2001; Nisoli et al. 2004a). This mechanism may play an important role 
in acute oxygen sensing and in adaptation to low-oxygen conditions when NO levels are 
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high. However, under normal physiological conditions, acetyl-CoA produced from 
energy substrates is readily oxidized in mitochondria (Jungas et al. 1992). Thus, it is 
unlikely that endogenous NO generated by nNOS and eNOS inhibits mitochondrial 
respiration in animal cells when iNOS is expressed at a low level.     
NO and mitochondrial biogenesis 
NO has been shown to have a beneficial effect on mitochondrial biogenesis, i.e. 
mitochondrial proliferation and activation (Nisoli et al. 2003).  NO-induced 
mitochondrial biogenesis is a key to long-term regulation of cellular metabolism 
(Clementi & Nisoli, 2005). In a variety of mammalian cell lines, such as brown 
adipocytes, 3T3-L1 cells, skeletal muscle L6 cells, and immortalized Hela cells, NO 
triggers mitochondrial biogenesis and enhances coupled respiration and ATP 
concentrations (Nisoli et al. 2003; Nisoli et al. 2004a). This process is mediated via a 
cGMP-dependent signaling pathway that activates the expression of PGC-1, a master 
regulator of mitochondrial biogenesis and oxidative phosphorylation (Nisoli et al. 2003). 
As noted above, PGC-1 is a key transcriptional cofactor regulating the expression of 
PPAR, which in turns stimulates the expression of NRF-1 and mtTFA (Wu et al. 
1999b). Collectively, these transcription factors regulate expression of nuclear and 
mitochondrial genes encoding proteins that are involved in the respiratory chain as well 
as mitochondrial DNA transcription and replication (Bossy-Wetzel & Lipton, 2003; 
Nisoli et al. 2004b). Thus, eNOS-knockout mice exhibited a reduced level of 
mitochondrial content in many tissues, such as brain, liver, and muscle, which is 
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accompanied by reduced O2 consumption, reduced steady-state ATP levels, defective 
energy expenditure, and increased body- fat gain (Nisoli et al. 2003; Nisoli et al. 2004a).   
The actions of NO on mitochondrial function are coordinated to meet the energy 
requirement of the cell.  The mitochondrion is an important site for the oxidation of 
glucose, fatty acids, and amino acids, where the released chemical energy is either 
coupled with ATP synthesis or dissipated as heat. Therefore, mitochondria play a crucial 
role in regulating energy balance (Bossy-Wetzel & Lipton, 2003). Since NO stimulates 
the formation of metabolically active new mitochondria, the endogenous or exogenous 
provision of NO is of great interest regarding its effect on the treatment of obesity. In rat 
skeletal muscle, incubation with sodium nitroprusside (SNP; an NO donor) increased the 
oxidation of glucose, pyruvate, palmitate and leucine via a cGMP-dependent pathway 
(Young et al. 1997; Young & Leighton, 1998a). Likewise, dietary supplementation of 
arginine to ZDF rats increased expression of PGC-1 as well as the oxidation of glucose 
and fatty acids in abdominal fat tissue (Fu et al. 2005). These findings provide a 
promising solution to reducing fat mass through modulation of the arginine-NO pathway 
in animals and humans and emphasize the metabolic basis for the pharmacotherapy of 
arginine (Flynn et al. 2002). 
The role for the arginine-NO pathway in glucose metabolism  
NO and gluconeogenesis/glycogen synthesis 
There is evidence suggesting a role for NO in regulating hepatic gluconeogenesis. The 
conversion of lactate and pyruvate into glucose in rat hepatocytes is inhibited by NO 
donors in a dose-dependent manner (Horton et al. 1994). The mechanism may involve 
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an inhibition of the activity and/or expression of phosphoenol-pyruvate carboxykinase 
(Horton et al. 1994), which is now known to be mediated by AMPK (Kahn et al. 2005a).  
On the other hand, glycogen synthesis from glucose is inhibited by NO in hepatocytes 
(Spranger et al. 1998) and 3T3-L1 cells (Egan et al. 1995) due to a decreased activity of 
glycogen synthase (Spranger et al. 1998).  Thus, elevated levels of NO are expected to 
increase the release of glucose from the liver under conditions of iNOS induction.  
Interestingly, NO also reduces glycolysis in hepatocytes by decreasing the activities of 
key enzymes such as glucokinase (Monti et al. 2000) and glyceraldehyde-3-phosphate 
dehydrogenase (Stadler et al. 1995) in coordinate action to spare glucose utilization.  
However, the net effect of NO on hepatic glucose metabolism likely depends on the 
balance between the two opposing effects (synthesis and utilization).  We recently found 
that dietary supplementation of arginine, which increased NO synthesis in various 
tissues within physiological ranges (Alderton et al. 2001), normalized plasma glucose 
levels in streptozotocin-induced diabetic rats (Kohli et al. 2004), and attenuated 
hyperglycemia in ZDF rats (Fu et al. 2005).   
NO and glucose transport 
Glucose transport across the cell membrane by glucose transporter 4 (GLUT-4) is a key 
regulatory step for glucose utilization in skeletal muscle, heart, and adipose tissue.  
Insulin is a major hormone regulating glucose uptake by these tissues. It stimulates the 
phosphorylation of an insulin receptor substrate (IRS) and the activation of PI3K. In 
skeletal muscle, in addition to insulin, contraction or exercise also enhances glucose 
uptake (Barnard & Youngren, 1992; Nesher et al. 1985). However, unlike the insulin 
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signaling pathway, exercise/contraction has no effect on insulin receptor 
phosphorylation or PI3K activity (Jessen & Goodyear, 2005). Two different intracellular 
pools of GLUT-4 may exist in skeletal muscle and respond to the two different signaling 
pathways (Jessen & Goodyear, 2005). When activated, GLUT-4 undergoes translocation 
from an intracellular tubulovesicular reservoir to the plasma membrane of skeletal 
muscle cells (Coderre et al. 1995; Kahn, 1992) or adipocytes (McPherson & Jones, 
2003).  Compelling evidence shows that NO mediates the stimulatory effect of exercise 
on glucose transport by skeletal muscle. For example, NO donors dose-dependently 
increased glucose transport in isolated skeletal muscle (Jessen & Goodyear, 2005; Balon 
& Nadler, 1997; Bradley et al. 1999). Exercise increases eNOS gene expression (Sessa 
et al. 1994), eNOS protein levels (Balon & Nadler, 1997), and eNOS activity (Roberts et 
al. 1999) in skeletal muscle, as well as vascular NO production (Sessa et al. 1994; 
Matsumoto et al. 1994; Patil et al. 1993).  Conversely, an inhibition of NOS activity 
reduced both basal and exercise-stimulated glucose transport in muscle (Balon & Nadler, 
1997). Further, Roberts et al. (1997) reported that exercise increased sarcolemma 
GLUT-4 content in rat skeletal muscle, and this effect was blunted by administration of 
L-NAME, a competitive NOS inhibitor.  Thus, the infusion of an NOS inhibitor during 
cycling exercise reduced leg glucose uptake, which was overcome by co-infusion with 
L-arginine (Bradley et al. 1999). In addition to muscle, NO stimulates glucose transport 
in 3T3-L1 adipocytes through GLUT-4 translocation to the plasma membrane via a 
mechanism independent of the insulin-signaling pathway (Tanaka et al. 2003).   
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NO may mediate the effect of insulin in stimulating glucose transport in skeletal 
muscle and adipose tissue. Administration of L-NAME impaired insulin secretion and 
resulted in reduced glucose tolerance in rats (Roy et al. 1998; Balon et al. 1999; Baron et 
al. 1995b) and humans (Laakso et al. 1992). Another competitive NOS inhibitor, NG-
monomethyl-L-arginine (L-NMMA), also attenuated the insulin-mediated increase in 
glucose uptake by muscles, including heart, soleus muscle, extensor digitorum longus 
(EDL) muscle, and gastrocnemius muscle (Roy et al. 1998).  Infusion of L-NMMA to 
rats also inhibited glucose uptake in many adipose tissue depots, such as brown 
interscapular, retroperitoneal and gonadal adipose tissues (Roy et al. 1998). This is 
consistent with the recent observation that there is an inverse relationship between 
plasma levels of L-NMMA and glucose disposal in obese or aging subjects (Marliss et 
al. 2006). In cultured 3T3-L1 adipocytes, addition of SNP increased glucose uptake, 
while treatment with an NO scavenger or guanylate cylase inhibitor reduced the SNP-
stimulated glucose uptake to basal levels (Tanaka et al. 2003). Of note, some studies 
indicated that NOS inhibitors had no effect on insulin-stimulated glucose transport in 
incubated skeletal muscle (Balon & Nadler, 1997; Roberts et al. 1997), but NO 
production was not directly measured in these short-term experiments. The disparity 
between these in vitro and in vivo findings may be explained by: 1) microvascular 
involvement, which occurs in vivo but is virtually absent from an incubated tissue 
(Vincent et al. 2003); and 2) NO concentrations in the target site. Thus, the roles of NO 
in enhancing glucose uptake by insulin-sensitive tissues appear to involve both blood 
flow-dependent and independent mechanisms. NO is a major vasodilator, and thus an 
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increase in physiological levels of NO is expected to increase the delivery of glucose to 
muscle cells and adipocytes (Baron, 1994; Baron et al. 1995a). Consequently, an 
inhibition of NO synthesis by L-NMMA reduced endothelium-dependent blood flow and 
inhibited insulin-stimulated glucose uptake in humans (Baron et al. 1995b). 
NO and glycolysis/glucose oxidation 
In addition to increasing glucose transport, NO also mediates glucose metabolism via 
glycolysis and the Krebs cycle in skeletal muscle.  For example, incubation of rat soleus 
muscle with SNP significantly increased lactate release and glucose oxidation in a dose-
dependent manner (1-25 mM of SNP) (Young et al. 1997; Young & Leighton, 1998a; 
Young & Leighton, 1998b). This finding is interesting in that high levels of NO donors 
did not inhibit mitochondrial respiration in skeletal muscle. It is noteworthy that dietary 
arginine supplementation enhanced glucose oxidation in both retroperitoneal and 
epidydimal fat tissues of ZDF rats (Fu et al. 2005).  These findings support the view that 
physiological levels of NO stimulate glucose oxidation in skeletal muscle and adipose 
tissue.  
The mechanism for the action of NO on glucose metabolism in skeletal muscle and 
adipose tissue is mediated through cGMP production and PKG signaling. Soluble 
guanylate cyclase activity is present in skeletal muscle (Vesely, 1979; Kojima et al. 
1995) and adipose tissue (Engeli et al. 2004). Indeed, incubation with NO donors rapidly 
increased the cGMP level in skeletal muscle, whereas the addition of a guanylate cyclase 
inhibitor blocked this effect (Young & Leighton, 1998a; Young & Leighton, 1998b). 
The inhibitor also blocked NO donor-stimulated glucose transport and utilization 
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(Young et al. 1997; Young & Leighton, 1998a). Likewise, a cGMP analogue stimulates 
glucose metabolism in skeletal muscle (Young et al. 1997). In ZDF rats, an increase in 
cGMP level in response to an inhibition of its hydrolysis was associated with elevated 
glucose transport and glucose oxidation in soleus muscle (Young & Leighton, 1998b).  
However, in insulin-resistant obese Zucker rats, this inhibitor failed to increase the 
cGMP level or improve glucose utilization (Young & Leighton, 1998b). These results 
suggest that the NO/cGMP pathway is altered in skeletal muscle of obese or diabetic 
subjects.  
The role for the arginine-NO pathway in lipid metabolism  
NO synthesis by iNOS and obesity 
Obesity is associated with an increase in expression of iNOS and overproduction of NO. 
Gene expression of iNOS in subcutaneous adipose tissue and adipocytes was higher in 
obese compared with nonobese humans (Giordano et al. 2002). In adolescents, elevated 
serum NOx levels (an indicator of systemic NO synthesis) were strongly correlated with 
increased body adiposity (Choi et al. 2001). Although eNOS expression is also enhanced 
in adipocytes of obese subjects, iNOS is primarily responsible for the increased 
production of NO in obesity-related metabolic diseases.  In genetically obese and 
diabetic rodent models, such as ob/ob mice and ZDF rats, iNOS protein expression in 
both adipose tissue and skeletal muscle was higher in comparison with the lean, non-
obese wild-types (Fujimoto et al. 2005; Perreault & Marette, 2001). Remarkably, 
treatment with an iNOS inhibitor (Fujimoto et al. 2005) or selectively disrupting the 
gene encoding iNOS (Perreault & Marette, 2001) improved insulin sensitivity in ob/ob 
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mice and ZDF rats, thereby preventing these animals from diet-induced obesity. In 
support of these in vivo findings, high levels of NO in culture medium promoted the 
differentiation of pre-adipocytes of white adipocyte- or brown adipocyte-lineage into 
mature adipocytes (Yan et al. 2002; Nisoli et al. 1998). We hypothesize that an 
inhibition of inducible NO synthesis may inhibit PPARγ expression, and, thus, adipocyte 
differentiation and proliferation.  
NO and lipogenesis/lipolysis 
The release of nonesterified fatty acids (NEFA) from adipose tissue plays an important 
role in the development of obesity and insulin resistance (Wu et al. 2004a). There is 
some evidence showing that NO affects lipid metabolism in adipose tissue, including 
both lipogenesis and lipolysis. However, the current literature is rather confusing. 
Whether exogenous NO stimulates or inhibits lipid metabolism appears to depend on the 
types and doses of NO donors, tissue site, and intracellular redox state (Gaudiot et al. 
1998; Gaudiot et al. 2000; Fruhbeck & Gomez-Ambrosi, 2001). For example, we found 
that 1 to 5 µM SNP stimulated lipolysis, but 25 to 500 µM SNP inhibited lipolysis in the 
adipose tissue of obese humans in a concentration-dependent manner (Wu et al. 2007a). 
Of note, atrial natriuretic peptide (ANP) induced lipolysis in human adipose tissue via 
the NO-cGMP pathway, but had no effect in rat adipose tissue (Fain et al. 2003). 
Further, Gaudiot and coworkers demonstrated that different NO donors had differential 
effects on basal or stimulated lipolysis in isolated adipocytes (Gaudiot et al. 1998), and 
this modulation was mediated through an antioxidant-related effect (Gaudiot et al. 
2000). Additionally, some studies showed that NO donors increased basal lipolysis 
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(Fruhbeck & Gomez-Ambrosi, 2001) but inhibited isoprenaline-induced lipolysis in 
adipocytes (Lincova et al. 2002). It should be borne in mind that these in vitro studies 
involved NO donors at concentrations ranging from 20 µM to 2 mM (e.g. 0.5-2 mM S-
nitroso-N-acetyl-penicillamine (SNAP) or 20 µM – 2 mM SNP). Therefore, the 
physiological significance of the findings is not clear at present. High levels of NO may 
oxidize and inactivate catecholamines non-enzymatically, thereby reducing the rate of 
stimulated lipolysis in adipocytes. 
Although the responses of fat metabolism to exogenous NO donors appear to vary 
greatly, in vivo studies involving an inhibition of NO synthesis have consistently 
demonstrated that physiological levels of NO increase lipolysis in rats.  For example, 
NO mediates the stimulatory effect of leptin on lipolysis in adipose tissue of rats 
(Fruhbeck & Gomez-Ambrosi, 2001). In addition, dietary supplementation of arginine to 
adult ZDF rats, which increased NO synthesis, stimulated lipolysis and fatty acid 
oxidation in adipose tissue, contributing to a marked reduction in body fat mass (Fu et 
al. 2005).  
Hypocholesterolemic effect of NO 
Because hypercholesterolemia is a significant risk factor for endothelial dysfunction, 
there is increasing interest in its prevention through dietary and pharmacological means. 
As noted above, NO plays an important role in the regulation of fatty acid metabolism in 
liver. Compelling evidence shows that NO donors exhibit a hypocholesterolemic effect 
by mediating lipoprotein metabolism.  For example, administration of an NO donor to 
rabbits caused a decrease in plasma LDL level (Kurowska & Carroll, 1998), suggesting a 
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role for NO in inhibiting LDL production.  In support of this view, SNP reduced the 
release of apo B (the major protein component of LDL) from incubated hepatocytes 
(Kurowska & Carroll, 1998). Conversely, feeding the rats with NOS inhibitors (0.02% in 
the diet) resulted in marked increases in serum triglyceride, cholesterol, and VLDL, as 
well as body fat (Khedara et al. 1996). NO regulates hepatocyte lipid metabolism mainly 
by inhibiting de novo fatty acid synthesis and decreasing the activity of ACC (Garcia-
Villafranca et al. 2003). As a result, malonyl-CoA level is decreased in response to NO, 
which activates CPT-I activity and stimulates fatty acid oxidation in liver.   
The effects of competitive NOS inhibitors on elevating serum fatty acids, LDL and 
VLDL could be reversed by the co-administration of arginine (Khedara et al. 1999). 
Thus, in streptozotocin-induced diabetic rats, treatment with 2% arginine in their diet 
attenuated the elevated serum levels of TAG and LDL by about 20% (Miguez et al. 
2004). Likewise, arginine treatment improved lipid metabolism in genetically diabetic 
and fatty rats (Kawano et al. 2003).  Most recently, Fu et al. (2005) reported that a long-
term arginine treatment reduced retroperitoneal fat mass by 45% and had no effect on 
the weight of other tissues in ZDF rats.  Importantly, an increase in dietary arginine 
intake from 2.5 to 5-7.5 g/day is associated with a rise in the serum level of HDL and a 
decrease in systolic blood pressure in humans (Wells et al. 2005). Thus, in addition to its 
beneficial effect on endothelial function (Wu & Meininger, 2000), dietary arginine 
supplementation may reduce plasma levels of VLDL and triglycerides through NO 
production. 
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The role for the arginine-NO pathway in amino acid metabolism   
NO and amino acid oxidation/ureagenesis 
Although arginine is the nitrogenous substrate for NO synthesis, little is known about the 
effects of physiological levels of NO on the metabolism of amino acids in animal cells.  
Limited evidence suggests that high levels of exogenous NO may indirectly increase 
rates of amino acid oxidation in the liver on the basis of enhanced urea synthesis by rat 
hepatocytes perfused with 0.2 mM SNP (Farghali et al. 1997).  Interestingly, Stadler et 
al. (1995) reported that 0.05 to 5 mM SNAP did not affect urea production by rat 
hepatocytes incubated with 10 mM NH4Cl (~100 times the physiological level of plasma 
NH4+) as the major source of exogenous nitrogen.  Such a high level of ammonia might 
have maximized the capacity of hepatic ureagenesis, and, thus, urea production could not 
be further increased in response to NO provision.  
Recent studies indicate that PPARα is a negative regulator of the urea cycle via 
down-regulation of the expression of carbamoylphosphate synthase-I, ornithine 
carbamoyltransferase, argininosuccinate synthase, and argininosuccinate lyase in the 
liver (Desvergne et al. 2004).  Thus, in contrast to a high level of NO that may occur 
under conditions such as sepsis and inflammation, physiological levels of NO may 
reduce the expression of urea-cycle enzymes and thus urea synthesis from ammonia 
indirectly through enhanced expression of PPARα. This action of NO is expected to 
inhibit amino acid oxidation in the liver, thereby increasing the entry of dietary amino 
acids into the systemic circulation. It is likely that NO exhibits differential effects on 
amino acid synthesis and catabolism, depending on target cells and tissues, its local 
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concentration in the reaction site, interactions among signaling pathways, and nutritional 
states.   
NO and intracellular protein turnover 
In animal cells, amino acids are utilized for the synthesis of proteins, and proteins are 
continuously degraded to produce amino acids. This constitutes an intracellular protein 
turnover. At present, little is known about the effect of physiological levels of NO on 
protein turnover in cells. However, exposure of rat hepatocytes to high levels of 
exogenous NO has been reported to decrease protein synthesis (Curran et al. 1991), 
thereby increasing the availability of amino acids for catabolism. Interestingly, an 
increase in NO synthesis by iNOS mediates the effect of tumor necrosis factor-α on 
inhibiting protein synthesis and stimulating protein degradation in skeletal muscle (Buck 
& Chojkier, 1996). A catabolic effect of high levels of NO on protein metabolism in 
liver and skeletal muscle is consistent with the enhanced hepatic ureagenesis under 
septic and inflammatory conditions. Whether physiological levels of NO regulate protein 
turnover warrants investigation. Of note, physiological levels of NO stimulate the release 
of anabolic hormones (e.g., insulin and growth hormone) in both birds and mammals 
(Flynn et al. 2002), and, thus, are expected to promote a positive protein balance, 
particularly in young and growing animals.   
NO and polyamine synthesis   
Polyamines play a critical role in regulating DNA and protein synthesis, as well as cell 
proliferation and differentiation (Flynn et al. 2002). In vascular smooth muscle cells, the 
presence of extracellular NO donors (30 to 300 µM) inactivated ornithine decarboxylase, 
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thereby inhibiting polyamine synthesis from arginine/ornithine and cell proliferation in a 
dose-dependent manner (Ignarro et al. 2001). This effect of NO is beneficial in 
preventing atherosclerosis in animals and humans.  In contrast, culture of endothelial 
cells with a lower extracellular concentration of an NO donor (10 µM) or with 
sepiapterin (a precursor for BH4 synthesis) increased polyamine synthesis and cell 
proliferation (Marinos et al. 2001). Such an effect would play an important role in 
angiogenesis and wound healing under various physiological conditions.   
NO and the metabolic syndrome 
Available evidence shows that the oxidation of fatty acids, glucose, and amino acids 
involves the exquisite coordination of multiple organs in animals. Since its initial 
description by Reaven (1988), there has been considerable debate about the precise 
definition of the metabolic syndrome or Syndrome X (Kahn et al. 2005b). Nonetheless, a 
cluster of key characteristics of the metabolic syndrome includes obesity, hyperglycemia 
(fasting serum glucose > 6.1 mM), hyperinsulinemia, hyperlipidemia, hypertension, and 
insulin resistance (an impaired response of cells or tissues to physiological 
concentrations of insulin).  These factors, independently or collectively, contribute to a 
high risk for cardiovascular disease, a major cause of death in developed nations.  
Glucosamine, an inhibitor of NO synthesis by constitutive NOS (Wu et al. 2001), may 
contribute to the development of insulin resistance in the vasculature and skeletal muscle 
of obese or diabetic subjects.  As noted in the preceding sections, physiological levels of 
NO can ameliorate all of these adverse features of the metabolic syndrome in animal 
models of obesity.  Thus, administration of arginine can reduce plasma levels of glucose, 
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homocysteine, fatty acids, and triglycerides in streptozotocin-induced diabetic rats 
(Kohli et al. 2004) and ZDF rats (Fu et al. 2005), and can also improve insulin 
sensitivity in obese humans (Hardie, 2004; Khedara et al. 1999; Miguez et al. 2004; 
Piatti et al. 2001; Mendez & Balderas, 2001). A distinct advantage of arginine over 
drugs (e.g., metformin and thiazolidinediones) is that dietary arginine supplementation 
will not increase body fat mass. Another advantage of the arginine solution is to reverse 
endothelial dysfunction associated with major cardiovascular risk factors 
(hypercholesterolemia, smoking, hypertension, diabetes, obesity, insulin resistance, and 
aging) (Wu & Meininger, 2000) and to prevent ammonia toxicity and organ dysfunction 
brought about by hypoargininemia (Flynn et al. 2002; Wu et al. 2004b). Arginine or its 
effective precursor (citrulline) may provide a potentially novel, effective treatment for 
the prevention and treatment of the metabolic syndrome in humans and animals.        
Summary and objectives  
Nitric oxide (NO) is synthesized from L-arginine by NO synthase in virtually all cell 
types. Emerging evidence shows that NO regulates the metabolism of glucose, fatty 
acids, and amino acids in mammals. As an oxidant, pathological levels of NO inhibit 
nearly all enzyme-catalyzed reactions through protein oxidation. However, as a signaling 
molecule, physiological levels of NO stimulate glucose uptake as well as glucose and 
fatty-acid oxidation in skeletal muscle, heart, liver, and adipose tissue, inhibit the 
synthesis of glucose, glycogen and fat in target tissues (e.g., liver and adipose), and 
enhance lipolysis in adipocytes. Previous studies demonstrated that an inhibition of NO 
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synthesis causes hyperlipidemia and fat accretion in rats, whereas our laboratory showed 
that dietary arginine supplementation reduces fat mass in diabetic fatty rats.  
The overall objective was to evaluate the effect of dietary arginine supplementation 
on the growth rate, fat mass, and energy-substrate utilization of diet-induced-obese rats. 
Gene and protein levels in major insulin-sensitive tissues (liver, muscle and fat) were 
examined in an effort to explain, in part, the molecular mechanisms of the beneficial 
effect of dietary arginine on obesity. The findings from the current study will provide a 
scientific basis for designing a novel, safe and effective way to prevent and treat obesity 
and/or the metabolic syndrome in humans.   
Hypothesis 
Our hypothesis was that dietary arginine supplementation might increase NO production 
and activate AMPK in diet-induced obese (DIO) rats, thus improving glucose and fatty 
acid metabolism in insulin-sensitive tissues in these rats, thereby decreasing their body 
fat mass.  
Specific aims 
Specific aims were to 
1. evaluate the effect of dietary arginine supplementation on fat mass in DIO rats; 
2. determine the molecular mechanism for the effect of fat loss in response to arginine 
supplementation; 
3. define a role of NO in regulation of glucose and fatty acid metabolism in liver cells, 
muscle cells and adipocytes. 
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CHAPTER II 
DIETARY L-ARGININE SUPPLEMENTATION REDUCES FAT MASS AND 
IMPROVES INSULIN SENSITIVITY IN DIET-INDUCED OBESE RATS 
 
This study was conducted to test the hypothesis that dietary arginine supplementation 
reduced fat mass in diet-induced obese rats. Male Sprague-Dawley rats were fed either 
low- or high-fat diets for 15 wks (16 rats/diet).  Thereafter, lean or obese rats continued 
to be fed their same respective diets and received drinking water containing either 1.51% 
L-arginine-HCl or 2.55% alanine (isonitrogenous control) (n=8/treatment group).   
Twelve weeks after the initiation of the arginine treatment, serum and tissue samples 
were collected for biochemical assays. Results were statistically analyzed as a 2x2 
factorial experimental design using ANOVA. When compared with rats fed the low-fat 
diet, high-fat diet increased the mass of retroperitoneal (RP) adipose tissue, epididymal 
(EP) adipose tissue, subcutaneous (SC) adipose tissue, and mesenteric (MT) adipose 
tissue by 76%, 49%, 96% and 64%, respectively, resulting in a heavier body weight. 
Concentrations of cholesterol in serum as well as lipids in skeletal muscle and liver were 
higher in obese rats, in comparison with lean rats. Arginine supplementation reduced the 
mass of RP, EP, SQ and MT fat pads by 35%, 20%, 32%, and 40%, respectively, while 
increasing the mass of extensor digitorum longus and soleus muscles, compared with 
alanine-supplemented rats. Serum leptin was elevated in obese rats but reduced in 
arginine-supplemented rats, whereas serum levels of other hormones (insulin, 
adiponectin, growth hormone, corticosterone, total T3, and total T4) did not differ. 
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Notably, arginine treatment reduced serum levels of glucose and triglycerides, and 
improved glucose tolerance. Collectively, these findings indicate that through reducing 
excess fat and improving insulin sensitivity, dietary arginine supplementation may 
provide a novel means for the treatment of obesity.  
 
Obesity is caused by a chronic imbalance in energy metabolism, namely a greater energy 
intake than energy expenditure (Bray et al. 2004).  This metabolic disorder continues to 
increase worldwide with an alarming rate in the past decade. It is a major health problem 
that impacts both adults and children (Bray & Bellanger, 2006).  Particularly, obesity is 
closely associated with many diseases and is a major risk factor for insulin resistance, 
type II diabetes, atherosclerosis, stroke, hypertension, and some types of cancer (Nisoli 
& Carruba, 2004). The prevalence of obesity and the tremendous costs of its treatment 
necessitate the search for new alternative nutritional means.   
In our recent studies aimed at improving vascular function in the Zucker diabetic 
fatty (ZDF) rat, we found that dietary supplementation with arginine selectively reduced 
fat mass by stimulating nitric oxide synthesis (Fu et al. 2005).  The ZDF rat has a defect 
in the leptin receptor and is a genetically obese animal model of type II diabetes (Clark 
et al. 1983).  While the finding with this animal model is important, its relevance to diet-
induced obesity is not known. Although obesity results from complex interactions 
between genetic and environmental factors, recent studies indicate that diet plays a more 
important role in the current obesity epidemic than genetic factors (Hill & Peter, 1998). 
Therefore, the objective of the present study was to determine if dietary arginine 
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supplementation could decrease fat tissue and improve glucose tolerance in diet-induced 
obese (DIO) rats. 
 
Materials and methods 
Chemicals    
Hexokinase and glucose-6-phosphate dehydrogenase were obtained from Roche 
Diagnostics (Indianapolis, IN). HPLC-grade methanol and water were purchased from 
Fisher Scientific (Houston, TX). Unless indicated, all other chemicals were obtained 
from Sigma-Aldrich (St Louis, MO). 
Animals and diets   
Male Sprague-Dawley rats (23-d-old, 80-100 g) were purchased from Harlan 
Laboratories (Indianapolis, IN). Upon arrival at the Texas A&M University Kleberg 
animal facilities, all rats were housed in individual cages in a temperature- and humidity-
controlled room on a 12-h light:12-h dark cycle. After a 5-d period of adaptation during 
which animals were fed a regular rodent chow, rats were randomly assigned to either a 
low- (LF) or high-fat (HF) diet (n=16/diet) obtained from Research Diets (New 
Brunswick, NJ) (Table 2.1). The low- and high-fat diets provided 10% and 40% of total 
calories as fat, respectively. Body weight and food intake were recorded on a weekly 
basis during this initial phase of the study. After 15 wks of feeding, each group of rats 
was divided randomly into two sub-groups, which continued to be fed their same 
respective diets and received drinking water containing either 1.51% L-arginine-HCl 
(Arg) or 2.55% alanine (Ala; isonitrogenous control) (n=8/treatment group). The dosage 
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of arginine, as well as alanine as isonitrogenous control, was chosen on the basis of our 
previous studies with non-diabetic and diabetic rats (Kohli et al. 2004; Fu et al. 2005). 
Arginine-supplemented rats were individually pair-fed with alanine-supplemented rats 
on a kg body weight basis to ensure similar intakes of all nutrients except for arginine 
and alanine between the two groups of animals. Body weight, food intake and water 
intake of each rat were recorded on a daily basis throughout this supplementation phase 
of the study. After 12 wks of arginine supplementation, rats were fasted for 5 h to obtain 
blood samples (100 µL) for analyses of serum glucose and amino acids. Rats were then 
immediately anesthetized with CO2 and euthanized by cervical dislocation. Cardiac 
blood samples were collected and centrifuged immediately to obtain sera for analyses of 
lipids and hormones.  Tissues were dissected and weighed. Small portions of each tissue 
were either used freshly for metabolic assays or snap-frozen rapidly in liquid nitrogen 
for storage at -80oC.  This study was approved by the Institutional Animal Care and Use 
Committee of Texas A&M University. 
Oral glucose tolerance test (OGTT) 
An OGTT was performed at 10 wks after the initiation of arginine supplementation, as 
described by Vital et al. (2006) with modifications.  After a 5-h fast, glucose (2 g/kg 
body weight) in water was administrated orally into stomach by gavage. Blood samples 
(20 µL) were obtained from the tail vein into plain tubes using microhematocrit capillary 
tubes at 0, 30, 60, 90, 120, 150, and 180 min after gavage.  Blood samples were 
centrifuged immediately at 10,000 g for 1 min to obtain sera, which were stored at -80oC 
until analysis for glucose. 
  
41 
 
Table 2.1. Composition of low- and high-fat diets 
 Low-fat diet High-fat diet 
Ingredient g Kcal g Kcal  
Casein 200 800 200 800 
L-Cystine 3 12 3 12 
Corn Starch 315 1260 72.8 291 
Maltodextrin-10 35 140 100 400 
Sucrose 350 1400 172.8 691 
Cellulose 50 0 50 0 
Soybean Oil 25 225 25 225 
Lard 20 180 177.5 1598 
Mineral Mix S10026 10 0 10 0 
Dicalcium Phosphate 13 0 13 0 
Calcium Carbonate 5.5 0 5.5 0 
Potassium Citrate 16.5 0 16.5 0 
Vitamin Mix V10001 10 40 10 40 
Choline Bitartrate 2 0 2 0 
Yellow Dye 0.05 0 - 0 
Red Dye - 0 0.05 0 
Total 1055.05 4057 858.05 4057 
 
 
 
Biochemical analyses of serum  
Glucose was determined enzymatically using a fluorometric method involving 
hexokinase and glucose-6-phosphate dehydrogenase (Kohli et al. 2004).  Amino acids 
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were quantified using fluorometric HPLC methods after a derivatization reaction with o-
phthaldialdehyde (Kohli et al. 2004). Assay kits for rats were employed for the 
following analyses: triglycerides, total cholesterol (Thermo DMA, Louisville, CO), free 
fatty acid (FFA; Wako Chemicals, Richmond, VA), insulin, leptin, adiponectin, growth 
hormone (Linco, St. Louis, MO), T3, T4, and coricosterone (MP Biomedicals, 
Orangeburg, NY).  
Biochemical analyses of liver, skeletal muscle, and adipose tissue 
Lipids in liver, gastrocnemius muscle and retroperitoneal (RP) adipose tissue were 
determined using the Folch method, in which a chloroform and methanol mixture (2:1 
v/v) was used to extract lipid from tissues (Folch et al. 1957). Glycogen in liver and 
gastrocnemius muscle were measured by an enzymatic method involving 
amyloglucosidase, as described previously (Passoneau & Lauderdale, 1974). Glutathione 
(GSH; an indicator of oxidative stress (Wu et al. 2004c)) in liver was determined by an 
HPLC method after derivatization with dansyl chloride (Jones et al. 1998).  
Tetrahydrobiopterin (BH4; an indicator of the capacity for nitric oxide synthesis (Shi et 
al. 2004)) in liver was analyzed using an HPLC method (Meininger & Wu, 2002).   
Calculations and statistical analysis    
Results were expressed as means ± SEM.  Data on body weight were analyzed using the 
growth curve model, namely a mixed effect model that fits fixed effects and random 
effects. The fixed effects include diet, amino acid (AA) treatment, their interaction (diet 
x AA), a third order polynomial of age in weeks (slope by age effect, curvature by age x 
age, and third order effect by age x age x age), different slopes by diet (age x diet), and 
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different slopes by treatment (age x AA). The random effects allow different rats to have 
different slopes (random age). The SAS PROC MIXED procedure was used to fit the 
mixed effects model.  The oral glucose tolerance test was assessed by calculating the 
area under curve (AUC). Data on tissue weights, biochemical metabolites, and OGTT 
were analyzed statistically by two-way ANOVA using a General Linear Model by SPSS 
software (Version 12.0, Chicago, IL).  The Tukey multiple comparison test was used to 
determine the effects of two main factors (diet and AA), and their interaction (diet x 
AA).  Probability values  0.05 were taken to indicate statistical significance.  
 
Results 
Intakes of food, water and energy   
The high-fat diet contained more energy, protein, vitamins, and minerals than the low-fat 
diet.  However, rats fed the high-fat diet consumed (P<0.01) proportionally less food 
than those fed the low-fat diet.  Food intake did not differ (P>0.10) between arginine- 
and alanine-supplemented rats. Neither high-fat diet nor arginine supplementation 
affected (P>0.10) water consumption by rats. Total energy intake or intakes of nutrients 
(including alanine and arginine) from enteral diet did not differ (P>0.10) among the four 
groups of rats (Tables 2.2 and 2.3).   
Body weight   
Rats fed the high-fat diet gained 13.3% more body weight than rats fed the low-fat diet 
between 4 and 19 wks of age prior to arginine treatment (Fig. 2.1). After 15 wks of age, 
the growth rates of all rats slowed down.  At 31 wks of age when the study was 
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completed, the average body weight of rats fed the high-fat diet was 15.3% greater than 
that of rats fed the low-fat diet (P<0.0001). Arginine treatment for 12 wks tended (P = 
0.067) to reduce body weight.  
 
 
Table 2.2.  Intakes of food, water and energy by rats 
Low fat   High fat   P value 
Intake 
Alanine Arginine   Alanine Arginine   Diet AA 
Diet 
x AA 
Food (g/kg body wt⋅d) 33.1±0.5 32.9±0.6  29.7±0.3 29.5±0.3  0.006 0.78 0.95 
Water (mL/kg body wt⋅d) 70.8±1.1 77.7±1.8  74.8±1.8 73.8±1.9  0.97 0.46 0.30 
Protein (g/kg body wt⋅d) 5.94±0.18 5.88±0.17  6.03±0.18 5.90±0.16  0.71 0.64 0.78 
Minerals (mg/kg body wt⋅d) 905±27 901±27  911±23 902±25  0.88 0.82 0.92 
Vitamins (mg/kg body wt⋅d) 358±11 357±11  364±10 358±10  0.74 0.71 0.80 
Energy* (KJ/kg body wt⋅d) 600±18 589±17   603±19 583±17   0.96 0.82 0.32 
 
Rats were fed with either low- or high-fat diet. In each diet group, rats were randomly assigned to receive 
drinking water containing either 1.51% of L-arginine⋅HCl or 2.55% L-alanine (isonitrogenous control) for 
12 wks.  Data are expressed as means ± SEM (n=8). 
* Total energy intake from both diet and drinking water. 
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Table 2.3.  Intakes of arginine and alanine by rats 
Intake  Low fat   High fat   P value 
(mg/kg body wt⋅d) Alanine Arginine   Alanine Arginine   Diet AA 
Diet 
x AA 
Alanine from food 153±4.6 152±4.6  155±4.5 152±4.3  0.79 0.69 0.79 
Alanine from drinking water 2166±105 --  1814±178 --  0.11 -- -- 
Arginine from food 214±6.4 212±6.3  216±6.2 211±6.0  0.81 0.71 0.81 
Arginine from drinking water -- 1037±52    -- 994±60   0.64  -- --  
 
Rats were fed with either low- or high-fat diet. In each diet group, rats were randomly assigned to receive 
drinking water containing either 1.51% of L-arginine⋅HCl or 2.55% L-alanine (isonitrogenous control) for 
12 wks.  Data are expressed as means ± SEM (n=8).  
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Fig. 2.1. Body weights of rats before and after the initiation of arginine treatment.  Rats were fed 
either low- or high-fat diet between 4 and 19 wks of age.  Thereafter, rats in each dietary group 
continued to be fed their respective diets and received drinking water containing either 1.51% of L-
arginine⋅HCl or 2.55% L-alanine (isonitrogenous control) for 12 wks. Data are expressed as means ± 
SEM (n=8).  P (diet) < 0.0001; P (AA) = 0.067; P (diet x AA) = 0.004; P (age) < 0.0001; P (AA x 
age) = 0.010; P (diet x age) < 0.0001; P (age x age) < 0.0001; P (age x age x age) < 0.0001. 
 
 
 
 
 
 
 
 
 
 
Start arginine treatment 
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Tissue weight    
Effects of high-fat feeding and arginine supplementation on the absolute and relative 
weights of tissues are summarized in Tables 2.4 and 2.5, respectively. High-fat diet 
increased (P<0.01) the absolute weight of many tissues, including liver, heart, lungs, 
kidneys, adipose tissues, and skeletal muscles. Particularly, the absolute weights of RP, 
epididymal (EP), subcutaneous (SC), and mesenteric (MT) adipose tissues in rats fed the 
high-fat diet increased (P<0.01) by 56%, 48%, 96%, and 51%, respectively, when 
compared with rats fed the low-fat diet.  However, the relative weights of these tissues, 
except for adipose tissue, testes and brain (expressed as a percentage of the body 
weight), did not differ between the rats fed low- and high-fat diets (Table 2.5). Notably, 
the relative weights of RP, EP, SC, and MT adipose tissues in rats fed the high-fat diet 
increased (P<0.01) by 37%, 38%, 69%, and 39%, respectively, in comparison with rats 
fed the low-fat diet.   
Dietary arginine supplementation reduced (P<0.01) the absolute weights of RP, EP, 
SC, and MT fat pads by 36%, 20%, 33%, and 41%, respectively, when compared with 
alanine-supplemented rats. Similar effects of the arginine treatment on decreasing the 
relative weights of adipose tissue were also observed.  Interestingly, the absolute and 
relative weights of extensor digitorum longus (EDL) muscle, soleus muscle, and brown 
fat increased (P<0.05) in response to dietary arginine supplementation, compared to 
alanine-treated rats.   
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 Table 2.4. The absolute weights of tissues in rats 
Absolute weight (g) 
Tissues 
LF-Ala LF-Arg  HF-Ala HF-Arg  Diet AA 
Diet 
x AA 
Heart 1.67±0.07 1.71±0.07  2.05±0.10 1.94±0.10  0.002 0.66 0.36 
Lungs 1.73±0.04 1.76±0.08  2.13±0.06 2.08±0.07  0.001 0.86 0.53 
Liver 12.9±0.83 12.1±0.47  14.8±0.52 13.6±0.56  0.009 0.12 0.82 
Spleen 0.84±0.04 0.80±0.03  0.89±0.02 0.88±0.04  0.064 0.47 0.62 
Kidneys 2.85±0.10 2.85±0.08  3.13±0.06 3.04±0.10  0.011 0.62 0.61 
RP adipose tissue 7.41±0.69 4.51±0.33  11.14±1.34 7.44±0.46  0.0001 0.0005 0.62 
EP adipose tissue 7.45±0.63 5.89±0.33  10.96±0.86 8.79±0.60  0.001 0.01 0.64 
SC adipose tissue 6.78±0.46 4.54±0.27  13.31±1.18 8.83±0.76  0.001 0.001 0.15 
MT adipose tissue 3.16±0.35 1.75±0.16  4.57±0.63 2.84±0.18  0.003 0.001 0.68 
Brown adipose tissue 0.57±0.02 0.73±0.03  0.62±0.04 0.81±0.04  0.083 0.001 0.72 
Small intestine 6.41±0.45 5.85±0.29  7.64±0.33 6.41±0.40  0.022 0.022 0.37 
Pancreas 0.96±0.09 1.06±0.04  1.04±0.04 1.08±0.12  0.53 0.43 0.71 
Soleus muscle 0.16±0.01 0.18±0.004  0.19±0.01 0.20±0.01  0.001 0.015 0.67 
EDL muscle 0.17±0.003 0.18±0.003  0.19±0.004 0.20±0.003  0.001 0.002 0.99 
Testes 3.89±0.09 3.79±0.06  3.78±0.06 3.91±0.07  0.97 0.83 0.14 
Brain 1.75±0.06 1.80±0.05   1.69±0.07 1.83±0.03   0.83 0.086 0.46 
 
Lean and diet-induced obese rats were fed low- and high-fat diets, respectively.  Rats in each dietary group 
received drinking water containing either 1.51% of L-arginine⋅HCl or 2.55% L-alanine (isonitrogenous 
control) for 12 wks.  At the end of the experiment, tissues weights were measured. Data are expressed as 
means ± SEM (n=8/treatment group). 
Abbreviations used: RP, retroperitoneal; EP, epididymal; SC, subcutaneous; MT, Mesenteric; EDL, 
extensor digitorum longus. 
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Table 2.5. The relative weights of tissues in rats 
Proportional weight (g tissue /kg body wt) 
Tissues 
LF-Ala LF-Arg  HF-Ala HF-Arg  Diet AA 
Diet 
x AA 
Heart 3.57±0.13 3.79±0.17  3.80±0.22 3.73±0.18  0.63 0.68 0.44 
Lung 3.71±0.12 3.88±0.21  3.93±0.14 4.01±0.14  0.27 0.41 0.75 
Liver 27.5±1.55 26.6±1.16  27.2±1.12 26.3±0.36  0.79 0.45 0.98 
Spleen 1.79±0.08 1.76±0.06  1.64±0.04 1.70±0.08  0.12 0.89 0.48 
Kidney 6.09±0.22 6.28±0.19  5.78±0.20 5.85±0.17  0.07 0.51 0.79 
RP adipose tissue 14.8±1.2 9.76±0.62  20.8±2.1 14.3±0.8  0.0001 0.0005 0.60 
EP adipose tissue 14.7±1.1 12.9±0.7  21.3±1.3 16.7±1.0  0.001 0.004 0.20 
SC adipose tissue 14.6±1.1 10.0±0.6  24.5±2.1 17.0±1.4  0.001 0.001 0.31 
MT adipose tissue 6.29±0.76 3.79±0.34  8.52±1.51 5.49±0.36  0.006 0.001 0.69 
Brown adipose tissue 1.21±0.05 1.61±0.06  1.14±0.08 1.56±0.08  0.42 0.001 0.93 
Small intestine 13.7±1.02 12.9±0.64  14.1±0.61 12.4±0.73  0.90 0.11 0.56 
Pancreas 2.05±0.20 2.33±0.09  1.92±0.08 2.06±0.22  0.24 0.21 0.68 
Soleus muscle 0.34±0.01 0.39±0.01  0.34±0.01 0.38±0.01  0.77 0.002 0.77 
EDL muscle 0.36±0.01 0.40±0.01  0.35±0.01 0.39±0.01  0.08 0.001 0.87 
Testes 8.11±0.16 8.30±0.18  7.13±0.16 7.48±0.16  0.001 0.11 0.64 
Brain 3.74±0.11 3.97±0.10  3.12±0.13 3.54±0.07  0.001 0.004 0.37 
 
Lean and diet-induced obese rats were fed low- and high-fat diets, respectively.  Rats in each dietary group 
received drinking water containing either 1.51% of L-arginine⋅HCl or 2.55% L-alanine (isonitrogenous 
control) for 12 wks.   At the end of the experiment, tissues weights were measured. Data are expressed as 
means ± SEM (n=8/treatment group). 
Abbreviations used: RP, retroperitoneal; EP, epidydimal; SC, subcutaneous; MT, Mesenteric; EDL, 
extensor digitorum longus. 
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Serum concentrations of amino acids  
High-fat feeding increased (P<0.05) serum concentrations of most amino acids, 
including glutamine, citrulline, arginine, and branched-chain amino acids, in comparison 
with rats fed the low-fat diet (Table 2.6).  Serum concentrations of arginine (+105%) and 
ornithine (+64%) increased (P<0.01) but serum concentrations of glutamate (-28%), 
glutamine (-15%) and branched-chain amino acids (-22%) decreased in arginine-
supplemented rats, when compared with alanine-supplemented rats. Dietary arginine 
supplementation had no effect (P>0.05) on serum concentrations of other measured 
amino acids.  Serum concentrations of alanine were 65% greater (P<0.01) in alanine- 
than in arginine-supplemented rats (Table 2.6).   
Serum concentrations of glucose, lipids and hormones   
High-fat feeding increased serum concentrations of cholesterol and leptin by 45% and 
49%, respectively, and had no effect on serum concentrations of glucose, free fatty acids 
and triglycerides, when compared with rats fed the low-fat diet (Table 2.7). Dietary 
arginine supplementation reduced (P<0.05) serum concentrations of glucose, 
triglycerides, and leptin by 5%, 32%, and 37%, respectively, and did not affect (P>0.05) 
serum concentrations of free fatty acids and cholesterol, in comparison with alanine-
supplemented rats. Serum concentrations of insulin, adiponectin, growth hormone, T3, 
T4, and corticosterone were not affected by either high-fat diet or dietary arginine 
supplementation.  
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Table 2.6.  Serum concentrations of amino acids in rats 
Low fat   High fat   P value Amino Acids 
(nmol/mL) Alanine Arginine   Alanine Arginine   Diet AA Diet x AA 
Aspartic acid 27±4.6 20±1.7  24±2.7 21±2.5  0.73 0.17 0.66 
Glutamate 92±15 61±4.9  85±8.9 67±6.1  0.96 0.026 0.57 
Asparagine 48±3.1 46±2.3  59±9.0 64±8.3  0.03 0.81 0.60 
Serine 240±20 249±14  286±15 310±29  0.022 0.46 0.75 
Glutamine 657±39 531±28  769±31 685±36  0.001 0.007 0.57 
Histidine 53±4 49±3.3  84±8.4 77±9.0  0.000 0.42 0.84 
Glycine 209±25 240±16  323±17 354±29  0.000 0.23 0.99 
Threonine 188±12 203±11  247±13 214±18  0.024 0.53 0.11 
Citrulline 60±4.9 56±4.0  77±7.7 74±11  0.03 0.69 0.99 
Arginine 163±20 371±28  223±27 488±77  0.014 0.0005 0.20 
β-Alanine 11±1.0 8.5±0.6  13±1.0 13±1.5  0.007 0.50 0.18 
Taurine 385±41 369±25  427±20 417±38  0.23 0.72 0.93 
Alanine 603±61 370±60  755±92 454±62  0.13 0.001 0.65 
Tyrosine 58±4.2 62±4.7  87±8.5 69±8.2  0.011 0.33 0.14 
Tryptophan 67±3.9 66±3.8  94±12 74±10  0.049 0.22 0.27 
Methionine 34±2.4 31±2.5  64±7.7 54±6.3  0.0001 0.25 0.47 
Valine 158±9.0 119±9.4  236±31 168±24  0.006 0.016 0.51 
Phenylalanine 53±3.5 51±2.4  77±8.6 70±8.7  0.0001 0.17 0.29 
Isoleucine 82±5 62±4.7  97±9.4 80±8.1  0.037 0.020 0.84 
Leucine 131±6.8 104±7  161±9.3 138±8.4  0.002 0.006 0.85 
Ornithine 31±2.2 58±6.2  36±2.2 52±6.5  0.92 0.0005 0.24 
Lysine 284±20 307±36   439±36 394±37   0.0001 0.71 0.28 
 
Lean and diet-induced obese rats were fed low- and high-fat diets, respectively.  Rats in each dietary group 
received drinking water containing either 1.51% of L-arginine⋅HCl or 2.55% L-alanine (isonitrogenous 
control) for 12 wks.  At the end of the experiment, blood was obtained from tail vein and amino acids were 
measured in the serum. Data are expressed as means ± SEM (n=8/treatment group). 
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Table 2.7.  Serum concentrations of glucose, lipids and hormones in rats 
Low fat   High fat   P value 
Variables Alanine Arginine  Alanine Arginine  Diet AA 
Diet  
x AA 
Glucose (mmol/L) 5.99±0.09 5.76±0.15  6.08±0.15 5.74±0.13  0.81 0.039 0.69 
Triglycerides (mmol/L) 0.93±0.11 0.68±0.07  1.05±0.08 0.66±0.07  0.57 0.001 0.45 
Cholesterol (mg/dL) 177±10 164±6.8  231±20 262±15  0.0005 0.54 0.10 
FFA (mmol/L) 0.81±0.12 0.62±0.07  0.80±0.13 0.72±0.09  0.68 0.23 0.61 
Insulin (pmol/L) 95.9±20 116±27  113±25 105±13  0.62 0.56 0.20 
Leptin (µg/L) 7.73±1.22 3.35±0.36  9.22±1.41 7.28±0.94  0.017 0.006 0.27 
Adiponectin (µg/L) 4.95±0.30 5.64±0.33  4.98±0.23 5.03±0.13  0.26 0.16 0.22 
Growth Hormone (µg/L) 4.82±1.18 4.84±1.37  4.62±1.45 5.06±0.96  0.99 0.88 0.89 
Corticosterone (µg/L) 64.9±6.9 64.0±16.2  62.2±12.0 60.9±17.2  0.84 0.94 0.99 
Total T3 (ng/dL) 72.2±4.8 69.1±4.5  70.1±5.9 68.7±4.8  0.83 0.68 0.88 
Total T4 (ng/dL) 3.39±0.22 3.12±0.09   3.22±0.10 3.20±0.18   0.77 0.36 0.43 
 
Lean and diet-induced obese rats were fed low- and high-fat diets, respectively.  Rats in each dietary group 
received drinking water containing either 1.51% of L-arginine⋅HCl or 2.55% L-alanine (isonitrogenous 
control) for 12 wks.  At the end of the experiment, tail blood was obtained for the measurement of serum 
glucose and cardiac blood was collected for the measurement of serum lipid and hormones. Data are 
expressed as means ± SEM (n=8/treatment group). 
 
 
 
OGTT     
The basal serum concentrations of glucose in rats were approximately 5 mmol/L, and did 
not differ among the 4 treatment groups (Fig. 2.2).  In response to oral gavage with 
glucose, serum concentrations of glucose increased to peak values (8 to 9 mmol/L) at 30 
min in all the rats. Between 60 and 180 min post administration of glucose, serum 
concentrations of glucose were the highest in alanine-supplemented obese rats among 
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the 4 groups of rats, and were the lowest in arginine-supplemented rats fed the low-fat 
diet. At 180 min, serum concentrations of glucose in rats fed the low-fat diet decreased 
to approximately 6.5 mmol/L, whereas those in alanine-supplemented rats fed the high-
fat diet remained elevated (8.5 mmol/L).  The glucose tolerance was lower (P<0.05) in 
rats fed the high-fat diet than in rats fed the low-fat diet. Dietary arginine 
supplementation increased (P<0.05) glucose tolerance in rats, compared with alanine 
supplementation.  
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Fig. 2.2   Oral glucose tolerance test in rats. Rats were fed with either control diet or high-fat diet. In 
each diet group, rats were randomly assigned to receive drinking water containing either 1.51% of L-
arginine⋅HCl or 2.55% L-alanine (isonitrogenous control). At 10 wks after initiation of the arginine 
treatment, oral glucose tolerance test was performed in rats after a 5-h fast. Data are expressed as 
means ± SEM (n=8).   P (diet)=0.0005, P (AA)=0.024, P (diet x AA)=0.20. 
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Lipid, glycogen, GSH and BH4 in tissues 
Concentrations of lipids in liver and gastrocnemius muscle were greater (P<0.05) but 
concentrations of BH4 and GSH in liver were lower (P<0.05) in rats fed the high-fat 
diet, when compared with rats fed the low-fat diet (Table 2.8). Concentrations of 
oxidized glutathione (GS-SG) in liver were not detectable (< 0.05 µmol/g tissue) in all 
groups of rats.  Dietary arginine supplementation increased (P<0.05) concentrations of 
BH4 in liver, compared with alanine supplementation. Neither high-fat diet nor arginine 
supplementation affected concentrations of lipids (81-83%) in adipose tissue or 
concentrations of glycogen in liver and gastrocnemius muscle.  
 
 
Table 2.8.  Concentrations of lipids, BH4, glycogen, and GSH in tissues of rats  
Low fat   High fat   P value 
Variables  
Alanine Arginine   Alanine Arginine   Diet AA 
Diet 
x AA 
Lipids in liver (%) 3.85±0.11 3.64±0.06  4.59±0.24 4.66±0.17  0.001 0.67 0.40 
Lipids in muscle (%) 1.60±0.11 1.64±0.12  1.94±0.14 1.92±0.15  0.049 0.42 0.52 
Lipids in RP adipose tissue (%) 80.6±1.6 82.0±1.8  83.1±1.6 82.9±0.6  0.27 0.72 0.60 
BH4 in liver (nmol/g tissue) 4.02±0.38 5.06±0.43  3.13±0.15 4.35±0.13  0.02 0.002 0.79 
Glycogen in liver  (mg/g) 21.8±1.7 18.6±0.9  19.7±0.5 19.1±1.8  0.55 0.16 0.31 
Glycogen in muscle (mg/g) 1.26±0.19 1.13±0.20  1.01±0.13 1.05±0.11  0.36 0.80 0.65 
GSH in liver (µmol/g) 6.09±0.27 5.59±0.33   4.41±0.43 4.24±0.33   0.001 0.41 0.67 
 
Lean and diet-induced obese rats were fed low- and high-fat diets, respectively.  Rats in each dietary group 
received drinking water containing either 1.51% of L-arginine⋅HCl or 2.55% L-alanine (isonitrogenous 
control) for 12 wks. At the end of the experiment, tissues were collected and metabolites in tissues were 
measured. Data are expressed as means ± SEM (n=8/treatment group). 
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Discussion 
The DIO rat is a widely used animal model with which to develop new nutritional means 
to treat human obesity (Bray et al. 2004). In response to a high-fat diet, Sprague-Dawley 
rats usually gain more body weight and fat mass, compared with those fed a low-fat diet, 
therefore exhibiting complex metabolic abnormalities (Chalkley et al. 2002; Naderali et 
al. 2004; Barnard et al. 1998). Some studies suggested that the excess fat accretion in 
rats fed the high-fat diet resulted from an increased energy intake (Ghibaudi et al. 2002). 
However, when fed isocaloric high-energy diets, rats still accreted a greater amount of 
white adipose tissues in response to a high-fat diet than a high-carbohydrate diet (Boozer 
et al. 1995). These results indicate that dietary fat is more efficient in promoting energy 
storage in white adipose tissue, compared to carbohydrates.  Consistent with this view, 
we found that obesity developed in rats on a high-fat diet in comparison with rats fed a 
low-fat diet (Tables 2.4 and 2.5), even though dietary energy intakes did not differ 
between the two groups of rats (Table 2.2). Likewise, serum concentrations of leptin, a 
hormone released predominantly by white adipose tissue (Fruhbeck, 2006), were greater 
in rats fed the high-fat diet than in rats fed the low-fat diet (Table 2.7). Additionally, 
results of the present study demonstrate that the DIO rats exhibited oxidative stress 
(indicated by a reduced concentration of GSH in liver), an attenuated capacity for nitric 
oxide synthesis (indicated by a reduced availability of BH4), and impaired insulin action 
(indicated by a reduced disposal of oral glucose) (Table 2.8 and Fig. 2.2). Collectively, 
these findings established that the DIO rat provideds a useful model to define an effect 
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of dietary arginine supplementation on reducing fat mass in environmentally-induced 
obesity.  
Results of the present study demonstrate for the first time that dietary arginine 
supplementation was highly effective in reducing fat mass in DIO rats (Tables 2.3 and 
2.4), as reported for genetically obese ZDF rats (Fu et al. 2006) and obese patients with 
type-II diabetes mellitus (Lucotti et al. 2006). Accordingly, serum concentrations of 
leptin were lower in arginine- than in alanine-supplemented rats (Table 2.7). Arginine 
exerted a fat-reducing effect in rats fed either the low- and high-fat diet that provided 
similar amounts of energy, protein, vitamins and minerals (Table 2.2). The percentage 
loss of MT adipose tissue was the greatest in response to the arginine treatment, 
followed by RP, SC, and EP fat pads in decreasing order. The free fatty acids released 
from fat hydrolysis in the white adipose tissue of arginine-supplemented rats likely 
undergo increased oxidation in liver, skeletal muscle, and brown fat. In support of this 
view, serum concentrations of triglycerides were lower, in arginine- than in alanine-
supplemented rats (Table 2.7), as reported for chemically-induced diabetic rats (Kohli et 
al. 2004; Miguez et al. 2004) and ZDF rats (Fu et al. 2005). Further, the arginine 
treatment markedly increased the mass of brown fat in rats by 29% (Table 2.3) likely 
due to mitochondrial biogenesis induced by nitric oxide (Nisoli et al. 2003).  Brown 
adipose tissue is rich in mitochondria, where fatty acid and glucose oxidation results in 
the production of heat rather than ATP because of the presence of uncoupling protein-1 
(Cannon & Nedergaard, 2004).  An increase in brown-fat mass brought about by the 
arginine treatment is expected to augment the oxidation of fatty acids and glucose in this 
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tissue, thereby reducing their use for fat synthesis in white adipose tissue and their 
plasma concentrations. Therefore, our novel observation on the increase in brown 
adipose tissue may provide an explanation for the increased oxidation of energy 
substrates in arginine-supplemented rats.   
Elevated plasma concentrations of triglycerides are known to impair insulin 
sensitivity and reduce glucose utilization in skeletal muscle (Jobgen et al. 2006). In 
response to an oral glucose load, serum concentrations of glucose remained elevated for 
a longer period of time in obese than in lean rats (Fig. 2.2).  With a reduction in serum 
levels of triglycerides, dietary arginine supplementation is expected to ameliorate insulin 
resistance in obese animals (Jobgen et al. 2006).  Consistent with this notion are the 
following lines of evidence. First, serum levels of glucose were lower in arginine- than 
in alanine-supplemented rats (Table 2.7), as reported for chemically-induced diabetic 
rats (Kohli et al. 2004; Miguez et al. 2004) and ZDF rats (Fu et al. 2005).  Second, the 
glucose tolerance in obese rats was improved in response to the arginine treatment (Fig. 
2.2).  These beneficial effects of dietary arginine supplementation can result from both 
improved insulin sensitivity in skeletal muscle and an increase in its mass (Table 2.3).  
Little is known about an effect of high-fat feeding on plasma concentrations of 
amino acids.   Interestingly, serum concentrations of most amino acids increased in rats 
fed the high-fat diet in comparison with rats fed the low-fat diet (Table 2.6), despite 
similar intakes of dietary protein (Table 2.2). This result can be explained by an 
inhibition of hepatic amino acid oxidation in response to high-fat feeding (Estornell et 
al. 1994). Additionally, increased serum concentrations of glutamine in DIO rats, which 
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results partly from its elevated production by adipose tissue (Kowalski et al. 1997), may 
have important implications for obesity-related metabolic defects. Glutamine is a 
substrate for the synthesis of glucosamine, which impairs the generation of nitric oxide 
by endothelial cells (Wu et al. 2001) and contributes to insulin resistance in skeletal 
muscle (Buse, 2006).   
As reported for streptozotocin-induced diabetic rats (Kolhi et al. 2004) and ZDF rats 
(Fu et al. 2005), the administration of arginine via drinking water effectively increased 
serum concentrations of arginine and ornithine (Table 2.6). Arginase activity is 
widespread in animal tissues (Wu & Morris, 1998) and, therefore, the supplemental 
arginine is rapidly catabolized to yield ornithine in rats and other animals (Wu et al. 
2007b).  Importantly, dietary arginine supplementation reduced serum concentrations of 
glutamine in lean and DIO rats (Table 2.6), as reported for ZDF rats (Fu et al. 2005) as 
well as neonatal pigs (Kim et al. 2004) and gilts (Mateo et al. 2007). This consistent 
observation from studies with different animal models indicates a regulatory role for 
arginine in whole-body glutamine metabolism. As an allosteric activator of N-
acetylglutamate synthase, arginine maintains the urea cycle in an active state to convert 
ammonia into urea (Wu & Morris, 1998).  In addition, through the generation of nitric 
oxide, arginine may inhibit protein degradation (Jobgen et al. 2006) and, therefore, 
ammonia production.  A limited availability of ammonia is expected to reduce de novo 
synthesis of glutamine in tissues (including skeletal muscle and adipose tissue).  Another 
interesting finding is that serum concentrations of branched-chain amino acids were 
lower in arginine- than in alanine-supplemented rats (Table 2.6), which may be 
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explained by a reduction in their release from skeletal muscle due to an anabolic effect 
of arginine on protein accretion (Table 2.3).   
In contrast to ZDF rats (Fu et al. 2005), dietary arginine supplementation did not 
substantially reduce the body weight of DIO rats (Fig. 2.1).  This result can be explained 
by our observation that the mass of skeletal muscle was greater (both absolute and 
relative increases) in lean and DIO rats in response to the arginine treatment (Tables 2.3 
and 2.4).  Importantly, such an anabolic effect of arginine was achieved independent of 
changes in serum concentrations of insulin and growth hormone (Table 2.7). These 
findings suggest that, through yet unknown signaling pathways, arginine may regulate 
intracellular protein turnover, favoring net protein deposition in skeletal muscle, as 
recently reported for neonatal pigs (Frank et al. 2007). Alternatively, through nitric 
oxide generation, dietary arginine supplementation may increase insulin sensitivity and 
amplify its signaling mechanisms on net protein synthesis (Jobgen et al. 2006).   
In summary, results of the present study demonstrated for the first time that dietary 
arginine supplementation reduced excess fat mass, increased muscle mass, decreased 
serum concentrations of glucose and triglycerides, and improved insulin sensitivity in 
diet-induced obesity.  Arginine supplementation may represent a safe and an efficient 
nutritional treatment of obesity, a growing health problem worldwide.  Future studies are 
warranted to define the cellular and molecular mechanisms responsible for the beneficial 
effects of arginine in ameliorating the metabolic syndrome in obese subjects.  
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CHAPTER III 
DIETARY L-ARGININE SUPPLEMENTATION REGULATES GLUCOSE 
AND FATTY ACID METABOLISM IN RATS  
 
Dietary arginine supplementation reduced fat mass in diet-induced obese rats (Chapter 
II). This study was conducted to test the hypothesis that the arginine treatment  regulates 
glucose and fatty acid metabolism in insulin-sensitive tissues. Male Sprague-Dawley rats 
(4-week-old) were fed either low- or high-fat diets for 15 wks (n=16/diet).  Thereafter, 
lean or obese rats rats were fed their respective diets and received drinking water 
containing either 1.51% L-arginine-HCl or 2.55% alanine (isonitrogenous control)  (n = 
8/treatment group). After 12 wks of treatment, rats were euthanized and tissue samples 
were collected for biochemical assays. High-fat feeding increased the size of adipocytes 
isolated from retroperitoneal (RP) adipose tissue, while arginine treatment reduced their 
size. The total numbers of adipocytes did not differ among the four groups of rats. 
Glucose oxidation in extensor digitorum longus (EDL) muscle, soleus muscle and RP 
adipose tissue were reduced in response to high-fat feeding. On the contrary, oleic acid 
oxidation in RP adipose tissue was enhanced in rats fed the high-fat diet. Arginine 
treatment stimulated both glucose and oleic acid oxidation in EDL and soleus muscles, 
while having no effect on the glucose oxidation, oleic acid oxidation or basal lipolysis in 
RP adipose tissue. Collectively, these results indicate that dietary supplementation with 
arginine to diet-induced obese rats promoted the oxidation of energy substrates in 
skeletal muscle, thereby reducing body fat and improving insulin-sensitivity. 
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L-Arginine is a physiological precursor of nitric oxide (NO), a free radical that is 
synthesized in almost all cell types by NO synthase (NOS). Through cGMP-dependent 
and independent pathways, NO plays an important role in regulating vascular tone, 
neurotransmission, host immunity, and whole-body homeostasis (Alderton et al. 2001; 
Shi et al. 2004). There is growing evidence that the arginine-NO pathway is also 
involved in regulating energy-substrate metabolism, such as glycolysis, glucose transport 
and oxidation, gluconeogenesis, lipolysis, fatty acid synthesis and fatty acid oxidation 
(Jobgen et al. 2006). In our previous study, we found that dietary arginine 
supplementation reduced body fat mass, increased muscle weight, and improved whole-
body insulin sensitivity in both lean and diet-induced obese (DIO) rats (Chapter II). This 
anti-obesity effect of arginine has also been reported for Zucker diabetic fatty (ZDF) rats 
(Fu et al. 2005) and obese humans with type II diabetes (Lucotti et al. 2006).  
Additionally, short-term oral administration of arginine improved insulin sensitivity in 
obese humans with type-II diabetes mellitus (Wascher et al. 1997).  
Based on the previous findings that implicate an important role for NO in regulating  
the metabolism of energy substrates (Jobgen et al. 2006), we hypothesized that dietary 
arginine supplementation to DIO rats reduced fat mass through increasing the oxidation 
of glucose and fatty acids in insulin-sensitive tissues.  This hypothesis was tested with 
the use of 14C-labeled glucose and oleic acid as well as the measurement of lactate and 
glycerol release from adipose tissue. 
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Materials and methods 
Chemicals  
D-[U-14C]glucose and [1-14C]oleic acid were purchased from American Radiolabeled 
Chemicals (St Louis, MO). Collagenase (type I) was obtained from Worthington 
Biochemical Corporation (Lakewood, NJ). Bovine serum albumin (BSA) was procured 
from Intergen Company (Purchase, NY). HPLC-grade methanol and water were 
obtained from Fisher Scientific (Houston, TX). All other chemicals were purchased from 
Sigma-Aldrich (St Louis, MO).  
Animals    
Male Sprague-Dawley rats from Harlan Labs were used in this study. The experimental 
design was detailed in Chapter II.  Briefly, 4-wk-old male Sprague-Dawley rats were fed 
either a low- or high-fat diet for 15 wks (n=16/diet).  Thereafter, rats were fed their same 
respective diets and received drinking water containing either 1.51% L-arginine-HCl or 
2.55% alanine (isonitrogenous control)  (n=8/treatment group). After 12 wks of 
treatment, rats were euthanized and tissue samples were collected for biochemical 
assays. 
Determination of NO synthesis in freshly isolated tissues  
Retroperitoneal (RP) adipose tissue and gastrocnemius muscle (~100 mg) were minced 
and rinsed with oxygenated (95%O2/5%CO2) Krebs bicarbonate buffer (pH 7.4) 
containing 5 mM of D-glucose and 4% BSA (KRB). Tissues were then incubated with 
gentle shaking (70 oscillations/min) at 37oC in 1 mL of fresh KRB buffer containing 1 
mM arginine. At the end of a 3-h incubation period, incubation medium was collected 
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and analyzed for nitrite (a major stable end product of NO oxidation) by an HPLC 
method (Li et al. 2000). In all experiments, the incubation medum without tissues were 
included as blanks. 
Determination of lipolysis and lactate release from RP adipose tissue 
RP adipose tissue (~100 mg) was minced and rinsed with KRB, as described by Fried et 
al. (1993b), and was then incubated at 37oC in KRB containing 0 or 10 M 
norepinephrine (NE) to determine basal and NE-stimulated lipolysis, respectively. After 
a 2-h incubation period, all tubes were placed on ice immediately, and the incubation 
media were rapidly transferred into clean tubes for determination of glycerol (Laurell & 
Tibling, 1966) and lactate (Wu et al. 1995).  
Isolation of adipocytes and determination of RP adipose tissue cellularity 
Adipocytes from RP adipose tissue were isolated according to the method described by 
Rodbell (1964).  Briefly, RP adipose tissue (~1 g) was minced and rinsed with KRB, and 
then incubated with KRB containing 1 mg/mL collagenase for 45 min at 37oC with 
gentle shaking. After incubation, the cell suspensions were filtered through a 250-m 
nylon grid, and washed 3 times with KRB. After the cell suspension stood at room 
temperature for 3 min, the floating layer of adipocytes was collected into clean tubes and 
diluted with KRB to obtain a cell concentration of 10% (v/v). An aliquot of the cell 
suspension was spotted onto a slide and the sizes of adipocytes were determined under a 
microscope. For each slide, at least 120 cells were measured for their sizes, and the mean 
volume of adipocytes was calculated according to the method described by Goldrick 
(1967): V = pi/6 x d (d2 + 3σ2), where d is the mean diameter and σ is the variance of the 
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diameter of cells. The lipid content in RP adipose tissue on per gram basis was 
determined using the Folch method (Folch et al. 1957). Based on the assumption that 
adipocytes are primarily triolein droplets and the density of adipocytes is 0.915 
(Mandenoff et al. 1982), the lipid content per adipocyte and the number of adipocytes in 
the whole RP adipose tissue pad was calculated.  
Determination of glucose and fatty acid oxidation 
RP adipose tissue, extensor digitorum longus (EDL) muscle, and soleus muscle were 
minced and rinsed with KRB. The tissues were then placed in polystyrene tubes and 
incubated at 37oC for 2 h in 1 mL oxygenated KRB containing 3 nM insulin and either 
0.5 Ci D-[U-14C] glucose or  0.2 mM of oleic acid plus [1-14C] oleic acid (0.5 Ci).  
The tubes were filled with 95%O2/5%CO2, sealed with rubber stoppers and fitted with 
hanging center-wells. At the end of a 2-h incubation period, 0.2 mL NCS-II (Amersham, 
Piscataway, NJ) was added through the rubber stopper into a 500-L microcentrifuge 
tube placed in the center-well, followed by addition of 0.2 mL of 1.5 M HClO4 to the 
incubation medium.  After an additional 1-h incubation period, the microcentrifuge tubes 
were carefully transferred to scintillation vials. Fifteen milliliters of counting cocktail 
was added into the vials and 14C radioactivity was determined using a liquid scintillation 
counter (Packard Instrument Company, Downers Grove, IL). The specific activities of 
D-[U-14C] glucose and [1-14C] oleic acid in the incubation media were used to calculate 
the rate of 14CO2 production. 
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Data analysis    
Results were given as means ± SEM. Data for muscle tissues were expressed per gram 
tissue weight, and data for adipose tissue were expressed on the basis of both gram tissue 
and 106 adipocytes.  Statistical analysis was performed using two-way ANOVA with the 
Tukey multiple comparison to determine the effects of diet, amino acid (AA), and the 
interaction between diet and AA (diet x AA).  Probability values  0.05 were taken to 
indicate statistical significance.   
 
Results 
The size and number of adipocytes in RP adipose tissue 
The high-fat diet enhanced (P<0.005) the mean diameter of adipocytes isolated from RP 
adipose tissue by 11% and 20% in alanine- and arginine-supplemented rats, respectively 
(Table 3.1). Adipocytes isolated from arginine-supplemented rats fed the low-fat diet 
exhibited the smallest size (mean diameter 77±3 µm), when compared to other three 
groups of rats (mean diameter > 90 µm) (Fig. 3.1). Dietary arginine supplementation 
reduced (P<0.005) the mean diameter of adipocytes by 15% and 7% in rats fed the low-
fat and high-fat diets, respectively (Table 3.1). Arginine treatment resulted in a shift of 
adipocyte size toward a smaller diameter, compared with alanine supplementation (Fig. 
3.2). The total numbers of adipocytes in the entire RP adipose tissue did not differ 
among the four groups of rats. However, high-fat feeding reduced (P<0.005) the density 
of adipocytes per gram of RP adipose tissue due to the increased lipid filling, compared 
with rats fed the low-fat diet (Table 3.1). In contrast, dietary arginine supplementation 
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increased (P<0.005) the density of adipocytes, in comparison with alanine-supplemented 
rats (Table 3.1).  
 
 
Table 3.1. Cellularity of RP adipose tissue  
Low fat   High fat   P  value 
Variables 
Alanine Arginine  Alanine Arginine  Diet AA 
Diet 
 x AA 
Adipocyte size (µm) 90.4±1.9 77.1±3.1  99.9±2.8 92.7±2.5  0.001 0.001 0.26 
Total adipocytes (106 cells) 15.6±1.6 14.4±0.7  17.2±0.9 15.1±1.1  0.33 0.14 0.70 
Adipocyte density  
(106 cells/g tissue) 2.13±0.16 3.27±0.27   1.62±0.11 2.05±0.14   0.001 0.001 0.22 
 
Lean and diet-induced obese rats were fed low- and high-fat diets, respectively.  Rats in each dietary group 
received drinking water containing either 1.51% of L-arginine⋅HCl or 2.55% L-alanine (isonitrogenous 
control) for 12 wks. At the end of the experiment, RP adipose tissue was dissected and adipocytes were 
isolated using an enzymatic method. Data are expressed as means ± SEM (n=8/treatment group).   
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Fig 3.1. Morphology of adipocytes isolated from rat RP adipose tissue. Lean and diet-induced obese 
rats were fed low- and high-fat diets, respectively.  Rats in each dietary group received drinking 
water containing either 1.51% of L-arginine⋅HCl or 2.55% L-alanine (isonitrogenous control) for 12 
wks. At the end of the experiment, RP adipose tissue was dissected and adipocytes were isolated. 
Data are expressed as means ± SEM (n=8/treatment group).  Magnification scale was set at x10. 
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Fig 3.2. Size distribution of adipocyte from RP adipose tissue of rats.  Lean and diet-induced obese 
rats were fed low- and high-fat diets, respectively. Rats in each dietary group received drinking water 
containing either 1.51% of L-arginine⋅HCl or 2.55% L-alanine (isonitrogenous control) for 12 wks. 
At the end of the experiment, RP adipose tissue was dissected, adipocytes were isolated using an 
enzymatic method, and their sizes were determined under a microscope. Data are expressed as means 
± SEM (n=8/treatment group).  P values are summarized below: 
 
  Diameter of adipocytes (µm) 
P value 45 55 65 75 85 95 105 115 125 135 145 
Diet 0.13 0.005 0.002 0.001 0.052 0.51 0.001 0.0005 0.015 0.086 0.13 
AA 0.13 0.020 0.003 0.004 0.23 0.16 0.001 0.0005 0.14 0.62 0.021 
Diet x AA 0.19 0.056 0.016 0.14 0.052 0.011 0.050 0.17 0.60 0.80 0.21 
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Lactate release and lipolysis in RP adipose tissue 
Table 3.2 summarizes the effects of high-fat feeding and arginine treatment on lactate 
release (an indicator of glycolysis) and lipolysis in RP adipose tissue. Lactate release 
from the RP adipose tissue per gram tissue was reduced (P<0.001) in response to high-
fat feeding, and dietary arginine supplementation increased lactate production 
(P<0.005). When data are expressed per 106 adipocytes, lactate release was unaltered by 
either high-fat feeding or dietary arginine supplementation. Both basal and NE-
stimulated rates of lipolysis per gram tissue or per 100 mg lipid were lower (P<0.001) in 
rats fed a high-fat diet than in rats fed a low-fat diet. Dietary arginine supplementation 
increased (P<0.05) basal lipolysis and had no effect on NE-stimulated lipolysis. 
However, when data are expressed per 106 adipocytes, basal lipolysis did not differ 
either between rats fed the low- and high-fat diets or between alanine- and arginine-
supplemented rats, whereas NE-stimulated lipolysis was lower in response to the 
arginine treatment due to the increased density of adipocytes (P<0.05).  
NO production gastrocnemius muscle and fat 
High-fat feeding did not affect NO synthesis in either gastrocnemius muscle or RP 
adipose tissue (Table 3.3). Dietary arginine supplementation increased (P<0.05) NO 
production in gastrocnemius muscle by 25%, but had no effect on RP adipose tissue, 
compared with alanine-supplemented rats.  
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Table 3.2.   Lactate release and lipolysis in RPl adipose tissue 
 
Low fat   High fat   P  value 
Variables 
Alanine Arginine   Alanine Arginine   Diet AA 
Diet  
x AA 
Lactate release          
µmol lactate/g tissue ⋅ h 1.10±0.06 1.35±0.14  0.84±0.07 1.02±0.04  0.001 0.004 0.67 
µmol lactate 
/106 adipocytes ⋅ h 0.52±0.05 0.42±0.04  0.54±0.06 0.52±0.05  0.23 0.23 0.39 
Lipolysis         
µmol glycerol/g tissue ⋅ h 
        
       Basal 1.36±0.07 1.54±0.10  0.90±0.33 1.20±0.15  0.001 0.035 0.60 
       NE-stimulated 7.95±0.66 7.27±0.74  5.11±0.33 5.93±0.70  0.001 0.78 0.47 
µmol glycerol/100 mg lipid ⋅ h 
        
       Basal 0.17±0.01 0.19±0.01  0.11±0.01 0.15±0.02  0.002 0.03 0.46 
       NE-stimulated 0.98±0.08 0.89±0.09  0.62±0.04 0.65±0.09  0.001 0.75 0.46 
µmol glycerol/106 adipocytes ⋅ h 
        
       Basal 0.68±0.06 0.51±0.03  0.57±0.07 0.59±0.07  0.92 0.23 0.13 
       NE-stimulated 3.97±0.46 2.35±0.14   3.20±0.19 2.83±0.55   0.71 0.016 0.11 
 
Lean and diet-induced obese rats were fed low- and high-fat diets, respectively.  Rats in each dietary group 
received drinking water containing either 1.51% of L-arginine⋅HCl or 2.55% L-alanine (isonitrogenous 
control) for 12 wks. At the end of the experiment, RP adipose tissue were collected and lactate and 
glycerol were measured in tissue incubation media. Data are expressed as means ± SEM (n=8/treatment 
group). 
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Table 3.3. Nitrite production in gastrocnemius muscle and RP adipose tissue of rats 
Low fat   High fat   P value 
Nitrite production  
Alanine Arginine   Alanine Arginine   Diet AA Diet x AA 
Gastrocnemius muscle        
 nmol/g tissue ⋅ h 0.23±0.02 0.29±0.02  0.21±0.03 0.26±0.02  0.23 0.032 0.83 
RP adipose tissue         
 nmol/g tissue ⋅ h 0.17±0.02 0.19±0.02  0.11±0.02 0.16±0.02  0.61 0.081 0.59 
 pmol/106 adipocytes ⋅ h 78±6 63±9   72±9 81±9   0.53 0.79 0.23 
 
Lean and diet-induced obese rats were fed low- and high-fat diets, respectively.  Rats in each dietary group 
received drinking water containing either 1.51% of L-arginine⋅HCl or 2.55% L-alanine (isonitrogenous 
control) for 12 wks. At the end of the experiment, tissues were collected and nitrite/nitrate was measured 
in tissue incubation media. Data are expressed as means ± SEM (n=8/treatment group). 
 
 
Oxidation of glucose and fatty acids in muscle and RP adipose tissue 
The effects of high-fat diet and arginine treatment on glucose and oleic acid oxidation in 
EDL muscle, soleus muscle, and RP adipose tissue are summarized in Table 3.4. 
Glucose oxidation per gram tissue in all three tissues was 18%, 28%, and 76% lower 
(P<0.05), respectively, in rats fed the high-fat diet than in rats fed the low-fat diet. 
Glucose oxidation in RP adipose tissue per 106 adipocytes was approximately 64% 
lower in high-fat-fed rats, compared with low-fat-fed rats. Oleic acid oxidation in 
skeletal muscles did not differ between rats fed the low- and high-fat diets (P>0.05). In 
RP adipose tissue, when data were expressed per gram tissue or 106 adipocytes, oleic 
acid oxidation increased (P<0.001) by 33% and 79%, respectively, in high-fat-fed rats, 
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in comparison with low-fat-fed rats. Dietary arginine supplementation increased 
(P<0.05) glucose and oleic acid oxidation per gram tissue in skeletal muscles and RP 
adipose tissue. However, when data were expressed per 106 adipocytes, neither glucose 
nor oleic acid oxidation in RP adipose tissue differed between alanine- and arginine-
supplemented rats.   
 
 
Table 3.4. Glucose and oleic acid oxidation in EDL muscle, soleus muscle and RP adipose tissue  
Low fat   High fat   P value 
Tissues 
Alanine Arginine  Alanine Arginine  Diet AA Diet x AA 
Per g tissue          
Glucose oxidation  (nmol glucose/g tissue ⋅ h) 
       
    EDL muscle 34.4±4.0 44.1±2.0  28.5±2.7 35.9±2.5  0.039 0.015 0.73 
    Soleus muscle 38.1±3.8 49.0±5.6  31.0±2.4 31.4±5.1  0.009 0.04 0.40 
    RP adipose tissue 346±59 595±51  104±10 120±14  0.001 0.014 0.098 
Oleic acid oxidation (nmol oleic acid/g tissue ⋅ h) 
      
   EDL muscle 1.51±0.28 2.77±0.49  1.70±0.22 1.94±0.15  0.34 0.03 0.13 
   Soleus muscle 3.46±0.45 4.64±0.41  3.45±0.36 3.97±0.22  0.35 0.027 0.38 
   RP adipose tissue 0.80±0.06 0.93±0.07  1.05±0.06 1.25±0.08  0.001 0.036 0.63 
Per 106 adipocytes          
Glucose oxidation (nmol glucose/106 adipocytes ⋅ h) 
     
RP adipose tissue 171±32 192±15  67±9 62±7  0.001 0.72 0.55 
Oleic acid oxidation (nmol oleic acid/106 adipocytes⋅h) 
     
RP adipose tissue 0.41±0.05 0.31±0.03   0.67±0.06 0.62±0.05   0.001 0.18 0.63 
 
Lean and diet-induced obese rats were fed low- and high-fat diets, respectively.  Rats in each dietary group 
received drinking water containing either 1.51% of L-arginine⋅HCl or 2.55% L-alanine (isonitrogenous 
control) for 12 wks. At the end of the experiment, tissues were measured glucose and oleic acid oxidation. 
Data are expressed as means ± SEM (n=8/treatment group). 
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Discussion 
Oxidation of energy substrates in skeletal muscle, liver and adipose tissue plays an 
important role in fuel homeostasis and fat accretion of animals (Jobgen et al. 2006).  
Therefore, to provide a metabolic basis for fat loss in arginine-supplemented DIO rats 
(Chapter II), we chose to study glucose and oleic acid oxidation in EDL muscle 
(primarily glycolytic fiber), soleus muscle (primarily oxidative fiber), and RP adipose 
tissue. In addition, the production of lactate and glycerol from adipose tissue was 
measured as indicators of glycolysis and lipolysis, respectively (Fried et al. 1993b).  
Berger and Barnard (1999) reported that two months of high-fat feeding increased 
the size of adipocytes and reduced their number in rats per gram tissue. Consistent with 
this finding, results of our study demonstrated a 15% increase in the size of adipocytes 
and a 32% reduction in their density in the RP adipose tissue of rats fed the high-fat diet, 
compared with rats fed the low-fat diet (Table 3.1).  Because high-fat feeding did not 
affect lipolysis per 106 adipocytes (Table 3.2), the increased synthesis of triglycerides 
may be the major factor for the hypertrophy of the RP adipose tissue in DIO rats (Table 
3.1), which is consistent with the report that high-fat diet increased the activity of 
lipoprotein lipase (LPL) in white adipose tissue (Robert et al. 2002). A novel finding 
from the present study is that dietary arginine supplementation reduced the size of 
adipocytes by enhancing the loss of their stored fat, without affecting the total number of 
adipocytes (Table 3.1).  This outcome likely resulted from an increase in the basal 
hydrolysis of triglycerides and the subsequent oxidation of fatty acids per gram tissue in 
the fat depots (Tables 3.2 and 3.4).  In support of this notion, physiological levels of 
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nitric oxide, whose production in adipose tissue increased in response to arginine 
treatment (Table 3.3), stimulated basal lipolysis in human adipose tissue (Wu et al. 
2007a) and rat adipocytes (Canova et al. 2006). 
Dietary fat intake is known to regulate muscle glucose oxidation (Oakes et al. 1997). 
Accordingly, glucose oxidation was lower in both EDL and soleus muscles of rats fed 
the high-fat diet, when compared with rats fed the low-fat diet (Table 3.4). This result 
can be explained by reduced glucose uptake (Todd et al. 2005) and increased 
concentrations of intramuscular lipids for oxidation (Chapter II) in DIO rats.  The acetyl-
CoA derived from fatty acids can potently inhibit pyruvate dehydrogenase activity and 
results in the formation of citrate (an inhibitor of fructose-6-phosphate kinase-I), thereby 
decreasing glucose oxidation via glycolysis and the tricarboxylic-acid cycle (Newsholme 
et al. 1993).  In support of this view, there is an inverse relationship between 
intramuscular concentrations of triglycerides and the whole-body glucose oxidation in 
humans (Krssak et al. 1999; Pan et al. 1997).  
Another important finding from the present study is that the fat tissue of adult rats 
exhibited a much higher rate of glucose oxidation than skeletal muscle per gram tissue 
(Table 3.4).  Considering its greater mass in obese animals (Chapter II), white adipose 
tissue may play a quantitatively important role in regulating glucose homeostasis in DIO 
rats.  Interestingly, glucose oxidation decreased, but oleic acid oxidation increased, in 
the RP adipose tissue of rats fed the high-fat diet, in comparison with rats fed the low-fat 
diet (Tables 3.2 and 3.4). These results indicate that high-fat feeding reduced glucose 
oxidation in adipose tissue, shifting its utilization of energy substrates from glucose to 
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fatty acids.  These findings are similar to those previously reported by other investigators 
(Lichtenstein & Schwab, 2000).  
A novel and important finding from the present study is that dietary arginine 
supplementation increased the oxidation of both glucose and fatty acids in skeletal 
muscle.  An increase in muscular NO production within the physiological range may 
play a role in mediating this beneficial action of the arginine treatment (Table 3.3). 
Emerging evidence shows that NO regulates the metabolism of energy substrates in 
insulin-sensitive tissues (Jobgen et al. 2006).  For example, sodium nitroprusside (SNP), 
an NO donor, increased glucose transport and oxidation in isolated muscle (Balon & 
Nadler, 1997; Young et al. 1997). Consequently, an inhibition of NO synthesis reduced 
both basal and exercise-stimulated glucose transport in skeletal muscle in both in vitro 
and in vivo studies (Bradley et al. 1999; Balon & Nadler, 1997; Roberts et al. 1997; 
Kingwell et al. 2002). The underlying mechanisms may involve the cellular signaling 
cascade, which includes soluble guanylyl cyclase (the target of NO) and cGMP-
dependent protein kinase (Young & Leighton, 1998a). In support of this view, Garcia-
Villafranca et al. (2003) found that NO and cGMP increased fatty acid oxidation and 
reduce fatty acid synthesis in rat hepatocytes.  Additionally, the NO/cGMP pathway has 
been reported to trigger mitochondrial biogenesis in different mammalian cell types and 
tissues through the activation of peroxisome proliferators-activator receptor γ coactivator 
1α (PGC-1α) (Nisoli et al. 2003).  The outcome is to increase the mitochondrial 
oxidation of energy substrates, thereby reducing their availability for fat accretion in the 
body (Nisoli et al. 2004a).  Indeed, our previous study with ZDF rats showed that dietary 
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arginine supplementation increased mRNA levels for PGC-1α in RP adipose tissue (Fu 
et al. 2005).  At present, it is unknown whether arginine treatment also increases PGC-
1α expression in other insulin-sensitive tissues of animals.   
A role for NO in regulating adipose tissue metabolism remains elusive, primarily due 
to the conflicting reports of in vitro studies involving extremely high doses of NO 
donors (up to 2 mM).  NO may act to stimulate the oxidation of energy substrates at 
physiological levels but to suppress this event at excessive levels (Lincova et al. 2002; 
McGrowder et al. 2006).  In addition, the function of NO in adipose tissue may also be 
dependent on the location and types of tissues (Canova et al. 2005).  On the basis of per 
106 adipocytes, we found that arginine supplementation did not affect NO production, 
basal lipolysis or substrate oxidation in the RP adipose tissue, suggesting that arginine 
may have only a modest effect on glucose or fatty acid metabolism in the adipose tissue 
of DIO rats after a 12-wk period of its dietary supplementation.  Thus, we suggest that 
liver and skeletal muscle may play a quantitatively more important role than white 
adipose tissue in the anti-obesity action of arginine. 
In sum, results of our study indicate that dietary arginine supplementation decreased 
the size of adipocytes and increased the oxidation of glucose and fatty acids in skeletal 
muscle. These findings provide a metabolic basis for explaining an anti-obesity effect of 
arginine in DIO rats. Further research is necessary to elucidate the underlying molecular 
mechanisms. 
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CHAPTER IV 
DIETARY L-ARGININE SUPPLEMENTATION INCREASES HEPATIC 
EXPRESSION OF AMP-ACTIVATED PROTEIN KINASE IN RATS  
 
The goal of this study was to elucidate the molecular mechanisms responsible for the 
anti-obesity effect of arginine supplementation in diet-induced obese rats. Male Sprague-
Dawley rats were fed either a low-fat or high-fat diet for 15 wks. Thereafter, lean or 
obese rats were pair-fed their same respective diets and received drinking water 
containing either 1.51% L-arginine-HCl or 2.55% alanine (isonitrogenous control) for 12 
wks. Gene and protein expression of key enzymes in the metabolism of energy 
substrates were determined using real-time PCR and western blotting techniques. The 
mRNA levels of hepatic fatty acid synthase and stearoyl-CoA desaturase were reduced 
but those of AMP-activated protein kinase (AMPK), peroxisome proliferator activator 
receptor  coactivator-1  and carnitine palmitoyltransferase I (CPT-I) as well as skeletal 
muscle CPT-I were increased by arginine treatment. The protein expression and activity 
of hepatic AMPK markedly increased but the activity of hepatic acetyl-CoA carboxylase 
(ACC) decreased in response to dietary arginine supplementation. Collectively, our 
results indicate that liver is the major target for the action of dietary arginine 
supplementation on reducing fat mass in DIO rats by inhibiting fatty acid synthesis and 
increasing fatty acid oxidation via the AMPK-ACC signaling pathway.  Additionally, 
increased CPT-I expression in skeletal muscle may also contribute to the enhanced 
oxidation of long-chain fatty acids in arginine-supplemented rats.      
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AMP-activated protein kinase (AMPK) is a heterotrimeric enzyme consisting of 3 
subunits: a catalytic  subunit and two regulatory units  and γ (Cheung et al. 2000; 
Hardie & Carling, 1997). AMPK (a sensor for cellular energy) is expressed in a variety 
of tissues (including liver, heart, muscles, adipose tissues) and plays an important role in 
regulating glucose and fatty acid metabolism in animals (Kahn et al. 2005a). The overall 
effect of AMPK activation is to switch off ATP-consuming pathways (including 
lipogenesis and gluconeogenesis), while turning on ATP-producing pathways (including 
fatty acid and glucose oxidation) (Kahn et al. 2005a; Carling, 2005; Steinberg et al. 
2006).  
Liver and adipose tissue are the primary and secondary sites, respectively, for de 
novo fatty acid synthesis in both human and rodents (Bergen & Mersmann, 2005). 
Acetyl-CoA carboxylase (ACC) is the rate-controlling enzyme for the synthesis of 
malonyl-CoA, a precursor for de novo fatty acid synthesis. There are two major isoforms 
of ACC, ACC1 (or ACCα) and ACC2 (or ACCβ), which are encoded by two different 
genes.  The malonyl-CoA synthesized by ACC1 is used for fatty acid synthesis, whereas 
the malonyl-CoA produced by ACC2 is an allosteric inhibitor of carnitine 
palmitoyltransferase I (CPT-I), a rate-controlling enzyme for fatty acid oxidation 
(Viollet et al. 2006). Malonyl-CoA decarboxylase (MCD) is an enzyme that converts 
malonyl-CoA back to acetyl-CoA. Both ACC and MCD are downstream targets of 
AMPK. In addition, peroxisome proliferator activator receptor  coactivator-1  (PGC-
1), which is an important transcription coactivator and a master regulator of 
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mitochondrial biogenesis and oxidative phosphorylation (Puigserver, 2005), may 
regulate the expression of AMPK and the oxidation of energy substrates (Nisoli et al. 
2003; Jobgen et al. 2006).  Therefore, the AMPK-ACC system has emerged as a key 
pharmacological target for treating obesity and the metabolic syndrome (Ruderman & 
Prentki, 2004). 
We recently found that dietary arginine supplementation increased the oxidation of 
glucose and fatty acids in skeletal muscle, reduced body fat and serum concentrations of 
triglycerides, enhanced the mass of skeletal muscle, and improved insulin sensitivity in 
diet-induced obese rats (Chapters II and III).  The present study was conducted to test 
the hypothesis that dietary arginine supplementation regulates expression of AMPK, 
ACC, and PGC-1, and possibly other key enzymes involved in the metabolism of 
energy substrates in insulin-sensitive tissues.  
 
Materials and methods 
Animals  
Male Sprague-Dawley rats from Harlan Labs (Indianapolis, IN) were used in the present 
study.  The experimental design was detailed in Chapter II.  Briefly, 4- wk-old male 
Sprague-Dawley rats were fed either low- or high-fat diets for 15 wks (n=16/diet).  
Thereafter, lean or obese rats were then fed their respective diets and received drinking 
water containing either 1.51% L-arginine-HCl or 2.55% alanine (isonitrogenous control)  
(n = 8/treatment group). After 12 wks of treatment, rats were euthanized and tissues 
were isolated. Tissues for RNA analysis were immediately placed in RNAlater solution 
  
80 
(Ambion/Applied Biosystems, Austin, TX) and stored at -80oC until analysis. Tissues 
for western blot analysis were snap-frozen in liquid nitrogen and stored at -80oC until 
analysis. 
RNA extraction and real-time polymerase chain reaction analysis (RT-PCR) 
Tissues were minced on ice and homogenized in TRIzol (Invitrogen, Carlsbad, CA). 
Total RNA was isolated according to the manufacture’s recommendation. Briefly, RNA 
was precipitated with isopropanol, washed with 70% ethanol and resuspended in DEPC-
treated water. The quantity and quality of RNA were assessed by measuring the 
absorbance at 280 and 260 nm, as well as by electrophoresis on 1.25% agarose gels. 
First-strand cDNAs were synthesized from 1 g of total RNA using oligo 
(deoxythymidine) primers, random hexamer primers and SuperScript II Reverse 
Transcriptase as described previously (Hayashi et al. 2004). RT-PCR analysis was 
performed using the SYBR Green method and the ABI 7900 Sequence Detection System 
(Applied Biosystems, Foster City, CA). The thermal cycling parameters were as follows: 
50oC for 2 min, 95oC for 10 min, followed by 40 cycles of 95oC for 15 sec and 60oC for 
1 min.  Primers were designed using Primer Express Software Version 1.5 (Applied 
Biosystems, Foster City, CA). The information on primer pairs for the selected genes, 
their specific locations in cDNA sequences and the product sizes are summarized in 
Table 4.1. All the data were normalized with the GAPDH gene in the same samples 
(Barber et al. 2005), and data are expressed as the relative values to those of alanine-
supplemented rats fed the low-fat diet. 
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Table 4.1.  Primers of genes for real-time PCR analysis 
Gene 
Accession 
number Forward primer Reverse primer 
cDNA 
location Size  CDs 
AMPKα NM_023991 ACACCTCAGCGCTCCTGTTC CTGTGCTGGAATCGACACT 1451–1527 67 8-1666 
PGC-1α NM_031347 CAACGCGGACAGAACTGAGA CCGCAGATTTACGGTGCAT 2057–2127 71 42-2432 
FAS NM_017332 GGCCCTACCTTAACACGACTCA GAACACAGTGATGGAACCTTCAAT 6745-6834 90 82-7599 
SCD-1 NM_139192 CCTCCTGCTCATGTGCTTCA GGCTGTGCAGGAAAGTTTCG 762-835 74 103-1179 
ACC1 NM_022193 TGGGCACCCCAGAGCTAAG AACTCCTCCCGCTCCTTCAA 6449-6518 70 1-7038 
ACC2 NM_053922 GCGCCTACATCGTGGACAGT GGCACCGGGAGGGATATAGA 6518-6585 68 7-7371 
MCD NM_053477 CACGGGCGACCCTGTTC TCTCAGACTTCGCCCACTCA 1095-1162 68 1-1476 
CPT-I a 
(liver) 
 
NM_031559 GCACTATGGAGTCCTGCAACTTT CCTCTGCTCTGCCGTTGAC 1925-1989 65 
 
103-2424 
CPT-I b 
(muscle) 
 
NM_013200 
 
 GCGGATGCAGTGGGACAT 
 
GCCTTGGCTACTTGGTACGAA 
 
1587-1655 
 
69 
 
40-2358 
UCP-3 NM_013167 GGATTCATGCCCTCCTTTCTG CGTTTCAGCTGCTCGTAGGTT 939-1012 74 129-1055 
GLUT-4 NM_012751 TGTGGCCTTCTTTGAGATTGG CTGAAGAGCTCGGCCACAA 1313-1375 69 141-1670 
HSL NM_012859 CCTCTACTCGTCACCCATAGTCAA GGCAGGGTCTTCAGCATGA 3094-3171 78 194-3400 
LPL NM_012598 CCCAGCTTTGTCATCGAGAAG CCTGGCACAGAAGATGACCTTT 1444-1515 72 175-1599 
Perilipin NM_013094 GCTGTCTCCTCCACCAAAGG ACCACAGTGTCTACCACGTTATCC 1210-1292 83 88-1641 
NOS-1 NM_052799 CGCACCCTTCCGAAGCT GCACGGATTCATTCCTTTGTG 3861–3927 67 102-4493 
NOS-3 NM_021838 GGACATTTTCGGACTCACATTG GCTGTCGCTCCTGCAAAGA 3474-3556 83 7-3615 
GAPDH NM_017008 GGGCAGCCCAGAACATCAT CCAGTGAGCTTCCCGTTCAG 1445-1532 88 850-1851 
 
Abbreviations used: AMPK, AMP-activated protein kinase; PGC-1α, peroxisome proliferator activator 
receptor  coactivator-1 ; FAS, fatty acid synthase; SCD-1, stearoyl-CoA desaturase-1; ACC, acetyl-CoA 
carboxylase; MCD, malonyl-CoA decarboxylase; CPT-1, carnitine palmitoyltransferase I; UCP; 
uncoupling protein; GLUT-4, glucose transporter-4; HSL, hormone-sensitive lipase; LPL, lipoprotein 
lipase; NOS-1, nitric oxide synthase 1; NOS-3, nitric oxide synthase 3; GAPDH, glyceraldehyde-3-
phosphate dehydrogenase 
 
 
Isolation of mitochondria  
Mitochondria were isolated from brown adipose tissue (BAT) followed the procedure of 
Xiao et al. (2004) with modifications. Briefly, BAT was minced and homogenized in an 
ice-cold buffer containing 100 mM KCl, 50 mM Tris-HCl (pH 7.5), 5 mM MgCl2, 1 mM 
EDTA, 0.2 mM ATP and 1x protease inhibitor cocktail  (Calbiochem La Jolla,  CA).   
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After incubation on ice for 10 min, the homogenate was centrifuged at 600 x g for 10 
min at 4oC. The supernatant fluid was collected and then centrifuged at 14,000 x g to 
obtain mitochondria. The mitochondria-enriched pellet was resuspended in a lysis buffer 
that consisted of 20 mM Tris-HCl (pH 7.4), 50 mM NaCl, 50 mM NaF, 50 mM of 
EDTA, 1% Triton X-100 and 1x protease inhibitor cocktail. The protein content was 
determined using the bicinchoninic acid (BCA) protocol (Pierce, Rockford, IL). 
Western blot analysis     
Frozen tissues of liver, gastrocnemius muscle, extensor digitorum longus (EDL) muscle, 
and retroperitoneal (RP) adipose tissue were ground to powder under liquid nitrogen and 
then homogenized in the lysis buffer containing 20 mM Tris-HCl (pH 7.4), 50 mM 
NaCl, 50 mM NaF, 50 mM of EDTA, 1% Triton X-100, 1x protease inhibitor cocktail 
and 1x phosphatase inhibitor cocktail (Calbiochem, La Jolla, CA). For fat tissues, the 
homogenate was incubated at 37oC for 1 h, during which it was mixed thoroughly by 
vortexing every 5-10 min.  The samples were then centrifuged for 5 min at 10,000 x g at 
room temperature. The infranatants below fat was used for protein assay and western 
blot. For liver and muscle samples, homogenates were incubated on ice for 30 min, and 
then were centrifuged at 10,000 g for 10 min. The supernatant was used for protein assay 
and western blot. Proteins in homogenates were analyzed using the BCA method, and 
the samples were subsequently diluted with 2x Laemmli buffer (125 mM Tris-HCl pH 
6.8, 4% w/v SDS, 10% 2-mercaptoethanol, 12% glycerol, and 0.004% w/v bromphenol 
blue) and heated in boiling water for 5 min. Aliquots of samples were loaded onto SDS-
polyacrylamide gels. After separation on 4-12% gels, proteins were transferred to a 
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nitrocellulose membrane (Bio-Rad, Hercules, CA) under 12V overnight, using the Bio-
Rad Transblot apparatus (Hercules, CA). Membranes were blocked in 5% fat-free dry 
milk in TTBS (20 mM Tris/150 mM NaCl, pH 7.5, and 0.1% Tween-20) for 3 h and then 
were incubated with the following primary antibodies overnight at 4oC with gentle 
rocking: AMPK (Cell Signaling, 1:1000), phosphorylated AMPK (Thr172) (Cell 
Signaling, 1:1000), ACC (Cell Signaling, 1:1000), phosphorylated ACC (Ser79) (Cell 
Signaling, 1:1000), or UCP-1 (Santa Cruz, 1:200). After washing three times with 
TTBS, the membranes were incubated at room temperature for 2-3 h with secondary 
antibodies at 1:50,000 (peroxidase-labeled donkey anti-goat or anti-rabbit IgG, Jackson 
Immuno Research). Finally, the membranes were washed with TTBS, followed by 
development using Supersignal West Dura Extended Duration Substrate according to the 
manufacturer’s instructions (Pierce, Rockford, IL). The signals were detected on 
Fujifilm LAS-3000 (Tokyo, Japan).  
Protein kinase B (PKB) and ribosomal protein S6 kinase (S6K1) in EDL muscle 
were analyzed as described by Suyawan et al. (2004). Briefly, proteins were separated 
on 10% SDS-polyacrylamide gels, and transferred to polyvinylidenedifluoride (PVDF) 
membrane (Bio-Rad, Hercules, CA). Membranes were then incubated with antibodies 
against phosphorylated PKB (Thr473) (Cell Signaling, 1:1000) or phorsphorylated S6K1 
(Thr389) (Cell Signaling, 1:1000) to assess the phosphorylation of PKB and S6K1. To 
assess the total PKB and total S6K1, membranes were then stripped and reprobed with 
antibodies against PKB (Cell Signaling, 1:1000) or S6K1 (Santa Cruz, 1:1000). After 
incubation with secondary antibodies (goat-anti-rabbit IgG, Bio-Rad, 1:5000), the blots 
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were developed using an enhanced chemiluminescence kit (Amersham, Arlington 
Heights, IL), and visualized by a ChemiDoc-It imaging system (UVP, Upland, CA). All 
data are expressed as the relative values to those of alanine-supplemented rats fed the 
low-fat diet. 
Data analysis   
Results were expressed as means ± SEM. Statistical analysis were performed using two-
way ANOVA with Tukey multiple comparison test to determine the effects of diet, 
amino acid (AA), and the interaction between diet and AA (diet x AA).  Probability 
values  0.05 were taken to indicate statistical significance.   
 
Results 
mRNA levels for genes involved in metabolism of energy substrates in liver, 
gastrocnemius muscle and RP adipose tissue       
The mRNA levels for major genes involved in the oxidation of energy substrates 
increased (P<0.05) in the liver of arginine-supplemented rats: CPT-I (1.9-fold), AMPK 
(1.5-fold), and PGC-1α (1.6-fold), when compared with alanine-supplemented rats 
(Table 4.2).  Hepatic mRNA levels for key lipogenic enzymes, including stearoyl-CoA 
desaturase 1 (SCD-1) and ACC1, were lower in rats fed the high-fat diet (P<0.05) than 
in rats fed the low-fat diet.  In contrast, the arginine treatment reduced (P<0.05) hepatic 
expression of two key lipogenic genes: fatty acid synthase (FAS; -60%) and SCD-1 (-
40%).   Hepatic mRNA levels for MCD decreased (P<0.01) in rats fed the high-fat diet, 
but increased (P<0.05) in response to dietary arginine supplementation.  
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Gastrocnemius muscle contains both fast-twitch white and fast-twitch red fiber types 
(Raja et al. 2003).  Among all the genes studied in muscle, only CPT-1 exhibited an 
increase (P<0.05) in its mRNA levels in response to dietary arginine supplementation, 
while mRNA levels for AMPK, PGC-1α, glucose transporter-4 (GLUT-4), uncoupling 
protein-3 (UCP-3), and two NOS isoforms (NOS-1 and NOS-3) did not differ between 
alanine- and arginine-supplemented rats (Table 4.3).  mRNA levels for all these genes 
did not differ between rats fed the low- and high-fat diets. 
 
 
Table 4.2.  Relative mRNA levels for key genes involved in energy metabolism in rat liver  
Low-fat diet   High-fat diet   P value 
Genes 
Alanine Arginine  Alanine Arginine  Diet AA Diet x AA 
CPT-I 1.00±0.21 2.11±0.15  1.02±0.13 1.72±0.46  0.53 0.04 0.46 
AMPKα 1.00±0.15 1.59±0.12  1.00±0.07 1.29±0.30  0.44 0.03 0.45 
PGC-1α 1.00±0.15 1.67±0.11  0.97±0.13 1.39±0.27  0.41 0.006 0.51 
FAS 1.00±0.26 0.39±0.08  0.49±0.11 0.35±0.09  0.12 0.021 0.11 
SCD-1 1.00±0.09 0.62±0.19  0.44±0.16 0.24±0.07  0.001 0.043 0.51 
ACC1 1.00±0.17 0.90±0.17  0.63±0.13 0.48±0.07  0.012 0.39 0.89 
ACC2 1.00±0.07 0.82±0.11  0.90±0.12 0.83±0.18  0.70 0.35 0.68 
MCD 1.00±0.21 1.76±0.26   0.63±0.08 0.77±0.19   0.002 0.031 0.50 
 
Lean and obese rats, which were fed low (LF)- and high-fat (HF) diets, respectively, received drinking 
water containing either 1.51% of L-arginine⋅HCl or 2.55% L-alanine (isonitrogenous control) for 12 wks. 
At the end of the experiment, tissues were collected and mRNA levels were measured using RT-PCR. 
Data are expressed as means ± SEM (n=6-8/treatment group). Data are expressed as the relative values to 
those of alanine-supplemented rats fed the low-fat diet.  
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Table 4.3.  Relative mRNA levels for key genes involved in energy metabolism in rat gastrocnemius 
muscle 
Low-fat  diet   High-fat diet   P value 
Genes 
Alanine Arginine  Alanine Arginine  Diet AA Diet x AA 
AMPKα 1.00±0.13 1.12±0.12  0.81±0.12 0.88±0.11  0.14 0.51 0.86 
PGC-1α 1.00±0.25 1.16±0.22  1.02±0.23 0.92±0.16  0.67 0.91 0.61 
CPT-I 1.00±0.16 1.48±0.47  1.05±0.25 1.65±0.30  0.73 0.032 0.63 
GLUT-4 1.00±0.12 1.25±0.27  1.12±0.13 1.29±0.27  0.74 0.39 0.87 
UCP-3 1.00±0.17 1.11±0.23  0.87±0.15 1.12±0.40  0.82 0.52 0.80 
NOS-3 1.00±0.25 1.20±0.23  1.53±0.21 1.26±0.20  0.22 0.89 0.33 
NOS-1 1.00±0.20 0.97±0.21   1.03±0.11 0.79±0.06   0.68 0.44 0.55 
 
Lean and obese rats, which were fed low (LF)- and high-fat (HF) diets, respectively, received drinking 
water containing either 1.51% of L-arginine⋅HCl or 2.55% L-alanine (isonitrogenous control) for 12 wks.   
At the end of the experiment, tissues were collected and mRNA levels were measured by RT-PCR. Data 
are expressed as means ± SEM (n=6-8/treatment group). Data are expressed as the relative values to those 
of alanine-supplemented rats fed the low-fat diet.  
 
 
 
In the RP adipose tissue, high-fat feeding decreased (P<0.05) the expression of key 
lipogenic genes, including FAS (-72%) and SCD-1 (-81%), whereas the expression of 
AMPK and GLUT-4 were reduced by 24% and 82% respectively in response to high-fat 
feeding (Table 4.4). Dietary arginine supplementation had no effect on expression of the 
genes for AMPK, hormone-sensitive lipase (HSL), perilipin, and lipoprotein lipase 
(LPL) in the adipose tissue.  However, the arginine treatment reduced (P<0.05) 
expression of PGC-1α, while increasing (P<0.05) expression of PPAR-γ (Table 4.4), an 
important transcription factor involved in lipogenesis (Rosen et al. 2000).  
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Table 4.4. Relative mRNA levels for key genes involved in energy metabolism in rat RP adipose 
tissue  
Low-fat  diet   High-fat diet   P value 
Genes 
Alanine Arginine  Alanine Arginine  Diet AA Diet x AA 
AMPKα 1.00±0.08 1.11±0.09  0.76±0.08 0.79±0.13  0.042 0.65 0.82 
PGC-1α 1.00±0.13 0.79±0.12  1.34±0.69 0.46±0.07  0.14 0.012 0.37 
GLUT-4 1.00±0.07 1.20±0.19  0.69±0.12 0.52±0.06  0.036 0.55 0.20 
FAS 1.00±0.19 1.48±0.16  0.39±0.05 0.31±0.06  0.001 0.14 0.044 
SCD-1 1.00±0.12 1.29±0.28  0.23±0.04 0.20±0.04  0.001 0.56 0.48 
PPAR-g 1.00±0.22 1.59±0.24  1.07±0.22 1.51±0.25  0.98 0.045 0.76 
LPL 1.00±0.14 0.73±0.19  0.80±0.21 0.90±0.29  0.97 0.69 0.39 
HSL 1.00±0.09 0.88±0.16  1.13±0.26 1.04±0.28  0.22 0.67 0.42 
Perilipin 1.00±0.19 0.98±0.25  1.08±0.26 1.16±0.11  0.41 0.63 0.46 
NOS-1 1.00±0.13 1.31±0.19   1.05±0.32 1.27±0.18   0.99 0.25 0.82 
 
Lean and obese rats, which were fed low (LF)- and high-fat (HF) diets, respectively, received drinking 
water containing either 1.51% of L-arginine⋅HCl or 2.55% L-alanine (isonitrogenous control) for 12 wks.  
At the end of the experiment, tissues were collected and mRNA levels were measured by RT-PCR. Data 
are expressed as means ± SEM (n=6-8/treatment group). Data are expressed as the relative values to those 
of alanine-supplemented rats fed the low-fat diet.  
 
 
Protein levels for AMPK and ACC in liver, gastrocnemius muscle and RP adipose tissue  
Hepatic protein levels for total AMPK (Fig. 4.1A) or phosphorylated AMPK (Fig. 4.1B) 
were not affected by high-fat diet, but increased (P<0.001) by 1.2- and 6.0-fold, 
respectively, in response to dietary arginine supplementation. The ratio of 
phosphorylated AMPK to total AMPK in the liver was 2.2-fold greater in arginine- than 
in alanine-supplemented rats (Fig. 4.1C). Hepatic protein levels for total ACC (both 
ACC1 and ACC2) did not differ among the four groups of rats (Fig. 4.2A), but the levels 
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for phosphorylated ACC were altered by both diet and arginine treatment (Fig. 4.2B).  
Particularly, in the liver of alanine-supplemented rats, ACC2 phosphorylation was 
undetectable or barely detectable in response to a low-fat or high-fat diet, respectively. 
In contrast, dietary arginine supplementation markedly increased (P<0.001) hepatic 
protein levels for both phosphorylated ACC1 and phosphorylated ACC2. There was an 
interaction (P<0.05) between diet and arginine treatment regarding the phosphorylation 
of ACC1, in that the effect of the arginine treatment was greater in lean than in obese 
rats (Fig. 4.2B). The ratio of phosphorylated ACC to total ACC (for both ACC1 and 
ACC2) also increased (P<0.05) in response to dietary arginine supplementation (Fig. 
4.2C). 
In contrast to the liver, protein levels for AMPK and ACC (both total and 
phosphorylated forms) in gastrocnemius muscle were not affected by either high-fat diet 
or arginine treatment (Fig 4.3 and 4.4).  Similar results were observed for AMPK 
expression in RP adipose tissue (Fig. 4.5).  However, high-fat diet decreased (P<0.05) 
protein levels for ACC2 (both total and phosphorylated forms) by approximately 80%, 
and reduced the amounts of ACC1 (both total and phosphorylated forms) below a 
detectable level (Fig. 4.6A, B). Dietary arginine supplementation had no effect in rats 
fed high-fat diet, but increased protein levels for phosphorylated ACC1 and ACC2 in 
rats fed the low-fat diet.  Also, the ratios of phosphorylated ACC1/total ACC1 and 
phosphorylated ACC2/ACC2 increased (P<0.05) by approximately 1.2- and 2.7-fold, 
respectively, in response to arginine supplementation. 
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Fig. 4.1. Relative protein levels for  total AMPK (A) and phosphorylated AMPK (P-AMPK; B) as 
well as the ratio of P-AMPK to total AMPK (C) in rat liver. Lean and obese rats, which were fed low 
(LF)- and high-fat (HF) diets, respectively, received drinking water containing either 1.51% of L-
arginine⋅HCl or 2.55% L-alanine (isonitrogenous control) for 12 wks. At the end of the experiment, 
tissues were collected and protein levels were measured. Proteins (30 µg) were separated on 4-12% 
SDS-polyacrylamide gels. Data are expressed as means ± SEM (n=8/treatment group). Data are 
expressed as the relative values to those of alanine-supplemented rats fed the low-fat diet.  
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Fig. 4.2. Relative protein levels for total ACC (A) and phosphorylated ACC (P-ACC; B) as well as 
the ratios of P-ACC to total ACC (C) in rat liver.  Lean and obese rats, which were fed low (LF)- and 
high-fat (HF) diets, respectively, received drinking water containing either 1.51% of L-arginine⋅HCl 
or 2.55% L-alanine (isonitrogenous control) for 12 wks. At the end of the experiment, tissues were 
collected and protein levels were measured. Proteins (30 µg) were separated on 4-12% SDS- 
polyacrylamide gels. Data are expressed as means ± SEM (n=8/treatment group). Data are 
expressed as the relative values to those of alanine-supplemented rats fed the low-fat diet. ND: not 
detectable.  
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Fig. 4.3. Relative protein levels for total AMPK (A) and phosphorylated AMPK (P-AMPK; B) as 
well as the ratio of P-AMPK to total AMPK (C) in rat gastrocnemius muscle. Lean and obese rats, 
which were fed low (LF)- and high-fat (HF) diets, respectively, received drinking water containing 
either 1.51% of L-arginine⋅HCl or 2.55% L-alanine (isonitrogenous control) for 12 wks.   At the end 
of the experiment, tissues were collected and protein levels were measured. Proteins (30 µg) were 
separated on 4-12% SDS-polyacrylamide gels. Data are expressed as means ± SEM (n=8/treatment 
group). Data are expressed as the relative values to those of alanine-supplemented rats fed the low-fat 
diet.  
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Fig. 4.4. Relative  protein levels for total ACC (A) and phosphorylated ACC (P-ACC; B) as well as 
the ratios of P-ACC to total ACC (C) in rat gastrocnemius muscle.  Lean and obese rats, which were 
fed low (LF)- and high-fat (HF) diets, respectively, received drinking water containing either 1.51% 
of L-arginine⋅HCl or 2.55% L-alanine (isonitrogenous control) for 12 wks.  At the end of the 
experiment, tissues were collected and protein levels were measured. Proteins (30 µg) were separated 
on 4-12% SDS-polyacrylamide gels. Data are expressed as means ± SEM (n=8/treatment group). 
Data are expressed as the relative values to those of alanine-supplemented rats fed the low-fat diet.  
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Fig. 4.5. Relative protein levels for total AMPK (A) and phosphorylated AMPK (P-AMPK; B) as 
well as the ratio of P-AMPK to total AMPK (C) in rat RP adipose tissue.  Lean and obese rats, which 
were fed low (LF)- and high-fat (HF) diets, respectively, received drinking water containing either 
1.51% of L-arginine⋅HCl or 2.55% L-alanine (isonitrogenous control) for 12 wks. At the end of the 
experiment, tissues were collected and protein levels were measured. Proteins (30 µg) were separated 
on 4-12% SDS-polyacrylamide gels. Data are expressed as means ± SEM (n=8/treatment group). 
Data are expressed as the relative values to those of alanine-supplemented rats fed the low-fat diet.  
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Fig. 4.6. Relative protein levels for total ACC (A) and phosphorylated ACC (P-ACC; B) as well as 
the ratios of P-ACC to total ACC (C) in rat RP adipose tissue.  Lean and obese rats, which were fed 
low (LF)- and high-fat (HF) diets, respectively, received drinking water containing either 1.51% of L-
arginine⋅HCl or 2.55% L-alanine (isonitrogenous control) for 12 wks.  At the end of the experiment, 
tissues were collected and protein levels were measured. Proteins (30 µg) were separated on 4-12% 
SDS-polyacrylamide gels. Data are expressed as means ± SEM (n=8/treatment group). Data are 
expressed as the relative values to those of alanine-supplemented rats fed the low-fat diet. ND: not 
detectable.  
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Protein levels for PKB and S6K1 in EDL muscle and uncoupling protein 1 (UCP-1) in 
brown adipose tissue        
Neither high-fat diet nor dietary arginine supplementation affected protein levels for 
total PKB or phosphorylated PKB in EDL muscle (Fig. 4.7).  Similar results were 
obtained for S6K1 (Fig. 4.8). Protein concentrations for UCP-1 in brown adipose tissue 
did not differ among the four groups of rats (Fig. 4.9).  
 
Discussion 
A novel and important finding from the present study is that dietary arginine 
supplementation enhanced hepatic expression of AMPK (indicated by increases in both 
mRNA and protein levels of AMPK) as well as hepatic AMPK phosphorylation. These 
results demonstrate for the first time that the arginine treatment increases AMPK 
expression and activity in the liver at transcriptional, translational, and post-translational 
levels. Phosphorylated AMPK is the active form of AMPK, and previous studies have 
established that the phosphorylation of AMPK is positively correlated to AMPK activity 
(Park et al. 2002b).  Along with the activation of AMPK, protein levels for 
phosphorylated ACC, which is negatively related to its activity (Park et al. 2002b), also 
increased in response to the arginine treatment. Moreover, there was an increase in 
hepatic mRNA expression of MCD in arginine-supplemented rats (Table 4.2).   Further, 
PGC-1 mRNA expression was elevated in the liver of arginine-supplemented rats. 
These changes in hepatic expression and activity of AMPK, ACC-2, MCD and PGC-1 
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in response to dietary arginine supplementation favor the hepatic oxidation of long-chain 
fatty acids (Stanley et al. 2005; Viollet et al. 2006).  
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Fig. 4.7. Relative protein levels for PKB (A) and phosphorylated PKB (P-PKB; B) as well as the 
ratio of P-PKB to total PKB (C) in rat EDL muscle. Lean and obese rats, which were fed low (LF)- 
and high-fat (HF) diets, respectively, received drinking water containing either 1.51% of L-
arginine⋅HCl or 2.55% L-alanine (isonitrogenous control) for 12 wks. At the end of the experiment, 
tissues were collected and protein levels were measured. Proteins (50 µg) were separated on 10% 
SDS-polyacrylamide gels. Data are expressed as means ± SEM (n=8/treatment group). Data are 
expressed as the relative values to those of alanine-supplemented rats fed the low-fat diet.  
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Fig. 4.8. Relative protein levels for S6K1 (A) and phosphorylated S6K1 (P-S6K1; B) as well as the 
ratio of P-S6K1 to total S6K1 (C) in rat EDL muscle.  Lean and obese rats, which were fed low (LF)- 
and high-fat (HF) diets, respectively, received drinking water containing either 1.51% of L-
arginine⋅HCl or 2.55% L-alanine (isonitrogenous control) for 12 wks. At the end of the experiment, 
tissues were collected and protein levels were measured. Proteins (50 µg) were separated on 10% 
SDS-polyacrylamide gels. Data are expressed as means ± SEM (n=8/treatment group). Data are 
expressed as the relative values to those of alanine-supplemented rats fed the low-fat diet.  
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Fig. 4.9. Relative protein levels for UCP-1 in rat brown adipose tissue.  Lean and obese rats, which 
were fed low (LF) and high-fat (HF) diets, respectively, received drinking water containing either 
1.51% of L-arginine⋅HCl or 2.55% L-alanine (isonitrogenous control) for 12 wks. At the end of the 
experiment, brown adipose tissues were collected and mitochondria were isolated. Mitochondrial 
proteins (10 µg) were separated on 10% SDS- polyacrylamide gels. Data are expressed as means ± 
SEM (n=8/treatment group).  Data are expressed as the relative values to those of alanine-
supplemented rats fed the low-fat diet.  
 
      
 
Liver is the major site for the de novo synthesis of fatty acids in rats (Jobgen et al. 
2006).  In addition to the activation of the hepatic AMPK-ACC system, dietary arginine 
supplementation reduced hepatic expression of key genes that are involved in fatty acid 
synthesis, including FAS and SCD-1 (Table 4.2).  In arginine-supplemented rats, the 
reduced expression of hepatic lipogenic genes, coupled with the decreased activity of 
ACC1, is expected to decrease the synthesis of fatty acids and triglycerides in the liver.  
Indeed, it has been shown that the deficiency of SCD-1, a key lipogenic enzyme in 
monounsaturated fatty acid synthsis, resulted in a reduced synthesis of triglycerides and 
 
UCP-1 
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an increased oxidation of fatty acids (Dobrzyn & Ntambi, 2005). It is not known whether 
arginine directly regulates hepatic gene expression or whether its effect is mediated by 
NO or other metabolites. However, there is growing evidence that physiological levels 
of NO reduce fatty acid synthesis and increase fatty oxidation in rat hepatocytes (Garcia-
Villafranca et al. 2003).  
Skeletal muscle also plays a crucial role in the homeostasis of glucose and fatty acids 
(Jobgen et al. 2006).  Results from this dissertation research indicate that the oxidation 
of these substrates in skeletal muscle was decreased by high-fat feeding but increased in 
response to dietary arginine supplementation (Chapter III).  Physiological levels of NO, 
synthesized from arginine, may stimulate glucose transport and oxidation by muscle 
cells (Jobgen et al. 2006). Additionally, the higher expression of CPT-I in gastrocnemius 
muscle of arginine-supplemented rats may explain an increase in the oxidation of long-
chain fatty acids.  In contrast, the expression of AMPK or ACC in gastrocnemius muscle 
was not affected by high-fat diet or arginine treatment (Fig. 4.6).  This result is 
consistent with the recent report that total AMPK and phosphorylated AMPK in soleus 
muscle did not differ between mice fed low- and high-fat diets (Martin et al. 2006).  
These findings, however, are not consistent with the observation of Liu et al. (2006) that 
feeding male Wistar rats a high-fat diet for 5 months reduced both mRNA and protein 
levels for AMPK in skeletal muscle. This discrepancy may result from differences in the 
length of high-fat feeding and the fiber type of skeletal muscle studied.  
Dietary arginine supplementation increased skeletal muscle mass in rats fed low- and 
high-fat diets (Chapter II).  This anabolic effect may occur through the nutrient-signaling 
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pathway, which includes the activation of PKB/Akt and mammalian target of rapamycin 
(mTOR) (Dann & Thomas, 2006). mTOR mediates mRNA translation mainly through 
phosphorylation of its two downstream targets, key translation regulators: ribosomal 
S6K1 and eIF4E-binding protein-I (4E-BP1) (Holz et al. 2005).  Interestingly, neither 
high-fat diet nor dietary arginine supplementation affected protein levels for PKB or 
S6K1 (both total and phosphorylated forms) in EDL muscle (Fig. 4.7 and 4.8).  It is 
possible that the arginine treatment can inhibit protein degradation in skeletal muscle.  
Further studies are necessary to test this hypothesis.   
In contrast to the liver, dietary arginine supplementation increased expression of 
some key lipogenic genes in rat adipose tissue, as reported by Yan et al. (2002) for 
preadipocytes during their differentiation. In addition, PGC-1α was reduced by the 
arginine treatment (Table 4.4). The major function of white adipose tissue is to store 
lipid and release free fatty acids as an energy source for other tissues, such as liver and 
skeletal muscles (Frayn et al. 2003; Gaidhu et al. 2006). Therefore, dietary arginine 
supplementation may be capable of increasing the formation of triglycerides from the 
existing fatty acids and the glucose-derived glycerol.  However, there is little de novo 
synthesis of fatty acids in the white adipose tissue of adult rats (Jobgen et al. 2006), and 
therefore, conversion of glucose into fatty acids is virtually absent from this tissue in 7- 
to 8-month-old rats.   
Brown adipose tissue is rich in mitochondria, where fatty acid oxidation results in 
the production of heat rather than ATP, because of the presence of UCP-1 (Himms-
Hagen, 2001). Although dietary arginine supplementation did not affect UCP-1 
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concentrations in brown adipose tissue (Fig. 4.9), an increase in its mass brought about 
by the arginine treatment (Chapter II) is expected to enhance fatty acid oxidation in this 
tissue. This may provide another important mechanism for the loss of fat mass in 
arginine-supplemented DIO rats (Chapter II).    
In summary, dietary arginine supplementation increased expression of key enzymes 
for glucose and fatty acid oxidation in the liver and expression of CPT-1 in skeletal 
muscle, while decreasing hepatic expression of key enzymes for lipogenesis. These 
coordinate changes in gene expression among insulin-sensitive tissues provide a 
molecular mechanism for the loss of excess fat mass in DIO rats in response to dietary 
arginine supplementation.  
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CHAPTER V 
L-ARGININE INCREASES AMPK PHOSPHORYLATION AND OXIDATION 
OF ENERGY SUBSTRATES IN HEPATOCYTES, SKELETAL MUSCLE 
CELLS AND ADIPOCYTES 
 
Previous work has shown that dietary arginine supplementation reduced fat mass in 
obese rats.  The present study was conducted with cell models to define direct effects of 
arginine on energy-substrate oxidation in hepatocytes, skeletal muscle cells, and 
adipocytes.  BNL CL2 mouse hepatocytes, C2C12 mouse myotubes and 3T3-L1 mouse 
adipocytes were treated with different extracellular concentrations of L-arginine (0, 15, 
50, 100 and 400 µM) or 400 µM arginine + 0.5 mM  NG-nitro-L-arginine methyl ester 
(L-NAME; a NOS inhibitor) for 48 h.  Increasing arginine concentrations dose-
dependently increased glucose and oleic acid oxidation in all three cell types, lactate 
release from C2C12 cells, and oleic acid incorporation into lipids in BNL CL.2 and 3T3-
L1 cells.  Arginine at 400 µM also stimulated the phosphorylation of AMP-activated 
protein kinase (AMPK) in all three cell types and increased NO production in C2C12 
and BNL CL.2 cells.  The inhibition of NOS by L-NAME moderately reduced glucose 
and oleic acid oxidation, lactate release, and the phosphorylation of AMPK and acetyl-
CoA carboxylase (ACC) in BNL CL.2 cells, but had no effect on C2C12 or 3T3-L1 
cells.  Collectively, these results indicate that arginine increased AMPK activity and 
energy-substrate oxidation in BNL CL.2, C2C12 and 3T3-L1 cells through both NO-
dependent and independent mechanisms.   
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Nitric oxide (NO) is a free radical produced from L-arginine (Arg) by NO synthases 
(NOS) (Wu & Morris, 1998).  Three isoforms of the NOS are expressed in various 
tissues, including insulin-sensitive tissues (liver, muscle and adipose tissue) that play an 
important role in whole body homeostasis of energy substrates (Jobgen et al. 2006).  In 
cell culture models, NO production has been detected for hepatocytes (Nicholls-
Grzemski et al. 1999), skeletal muscle cells (Williams et al. 1994) and adipocytes (Yan 
et al. 2002) under both basal and stimulated conditions. The actions of NO are mediated 
primarily by the activation of guanylyl cyclase and the resultant production of guanosine 
3',5'-cyclic monophosphate (cGMP) (Denninger & Marletta, 1999).  
Our previous studies using Zucker diabetic fatty rats (Fu et al. 2005) and diet-
induced obese rats (Chapter III) demonstrated that dietary L-arginine supplementation 
increased glucose and fatty acid oxidation in muscle and adipose tissue, therefore 
reducing body fat mass.  Further, we found that this beneficial effect of arginine was 
mediated partially through the activation of hepatic AMP-activated protein kinase 
(AMPK) (Chapter IV). There is growing evidence that NO regulates energy metabolism 
in cells and animals (Jobgen et al. 2006). Therefore, we hypothesized that L-arginine 
increased energy metabolism through enhancing NO production and activating AMPK. 
This hypothesis was tested using established cell models for hepatocytes, skeletal muscle 
cells and adipocytes (Wang & Watford, 2007). 
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Materials and methods 
Materials    
BNL CL.2 mouse hepatocytes, C2C12 mouse skeletal muscle cells and 3T3-L1 mouse 
preadipocytes were obtained from ATCC (Manassa, VA).  Dulbecco’s modified Eagle 
medium (DMEM) with or without arginine, horse serum, trypsin-EDTA solution, 
penicillin (10,000 U/mL), streptomycin (10,000 µg/mL), and 4-12% NuPAGE Bis-Tris 
gels were purchased from Invitrogen (Grand Island, NY).  Fetal bovine serum (FBS), 
NCS-II, and the bicinchoninic acid kit were procured from Hyclone (Logan, UT),  
Amersham (Piscataway, NJ), and Pierce (Rockford, IL), respectively. HPLC-grade 
methanol and water were purchased from Fisher Scientific (Houston, TX).  D-[U-
14C]glucose and [1-14C]oleic acid were products of American Radiolabeled Chemicals 
(St Louis, MO).  Protease inhibitor and phosphatase inhibitor cocktails were obtained 
from Calbiochem (La Jolla, CA).  Unless indicated, all other chemicals were procured 
from Sigma-Aldrich (St Louis, MO). 
Cell culture   
BNL CL.2 cells, C2C12 cells, and 3T3-L1 cells were cultured in 100-mm dishes with 
DMEM containing 10% FBS and 100 U/mL penicillin plus 100 µg/mL streptomycin 
until 75-80% confluent. Cells were trypsinized and split into 25 cm2 Falcon flasks with 
approximately 2 x 105 cells per flask and maintained at 37oC in a 5% CO2 incubator.  
The basal DMEM contained 25 mM glucose, 4 mM glutamine, and 0.4 mM arginine.  
For the experiment, BNL CL.2 cells at confluence were used directly, whereas 
differentiated C2C12 and 3T3-L1 cells were employed.  After C2C12 cells reached 
  
105 
confluence, differentiation was initiated by substituting 10% FBS with 2% horse serum 
in the culture medium. The medium was changed every two days.  Four days after the 
initiation of differentiation, myotubes were formed and then used for the experiment.  
For differentiating 3T3-L1 cells, they were cultured in DMEM with 10% FBS until 
confluence. Two days post-confluence, differentiation was initiated by switching the 
cells to DMEM containing 10% FBS, 10 µg/mL insulin, 0.5 mM 3-isobutyl-1-
methylxanthine, and 10 µM dexamethasone.  Two days later, the medium was changed 
to DMEM containing 10% FBS and 10 µg/mL insulin. After an additional 2 d, cells 
were switched to DMEM containing 10% FBS. The medium was then changed every 
other day. Eight days after the initiation of cell differentiation, mature adipocytes were 
obtained and then used for the experiment.   
The day before performing an experiment, 3T3-L1 adipocytes and BNL CL.2 
hepatocytes were switched to DMEM containing 0.5% FBS for overnight, whereas 
C2C12 cells were maintained in DMEM containing 2% horse serum. The concentrations 
of serum were chosen on the basis of the consideration that a high level might mask the 
effect of arginine, while cell viability might be compromised in serum-free medium.  On 
the day of the experiment, all cells were switched to arginine-free DMEM containing 
0.5% FBS, and this culture medium contained 0.7 µM arginine.   L-Arginine was then 
added to the medium to provide a concentration of 0, 15, 50, 100, or 400 µM.   In some 
experiments, culture media contained 400 µM arginine plus 500 µM NG-nitro-L-arginine 
methyl ester (L-NAME, a NOS inhibitor). To ensure optimal inhibition of NO 
production in cells, L-NAME was added to the media 1 h earlier than arginine.  All the 
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cells were cultured at 37oC for 48 h, with the medium changed every 24 h.  At the end of 
the 48-h culture period, cells were used for biochemical studies and the media were 
analyzed for nitrite (an indicator of NO synthesis). 
Glucose and oleic acid oxidation 
Cells were rinsed with PBS three times, and were then incubated in the same flasks at 
37oC in 2 mL of oxygenated (95%O2/5%CO2) Krebs bicarbonate buffer (KRB, pH 7.4) 
containing 5 mM of D-glucose and either 0.5 Ci D-[U-14C] glucose or 0.2 mM oleic 
acid plus 0.5 Ci [1-14C]oleic acid.  Arginine or L-NAME was added to incubation 
medium to obtain the same respective concentration as in the previous 48-h culture 
medium.  The flasks were sealed tightly with rubber stoppers fitted with hanging center-
wells.  At the end of a 2-h incubation period, flasks were placed in the straight-up 
position, and 0.2 mL NCS-II was added through the stopper into a 500-l 
microcentrifuge tube placed in the center-well, followed by addition of 0.2 mL of 1.5 M 
HClO4 to the incubation medium. After an additional 1-h incubation, the microcentrifuge 
tubes with NCS-II were carefully transferred to scintillation vials.  Fifteen milliliters of 
counting cocktail were added to the vials and 14C radioactivity was determined by a 
Packard liquid scintillation counter. The specific activities of D-[U-14C] glucose and [1-
14C] oleic acid in the incubation media were used to calculate the rate of 14CO2 
production.  Lactate in the acidified medium was analyzed using an enzymatic method 
(Wu et al. 1995).   The cells were lysed and collected for the determination of protein 
concentration using the bicinchoninic acid kit.  
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Glucose and oleic acid incorporation into lipids  
The determination of D-[U-14C] glucose incorporated into lipids was performed as 
described by Ceddia et al. (2000).  Briefly, the acidified incubation medium was 
collected and mixed with 5 mL of Doles’s reagent (isopropanol/n-heptane/H2SO4; 
4:1:0.25, v/v/v) (Dole & Meinertz, 1960). The heptane layer, which contained lipid, was 
carefully transferred to scintillation counting vials and dried under a fumehood. Then, 15 
mL of counting cocktail was added to the vials for the measurement of 14C radioactivity. 
The incorporation of [1-14C] oleic acid into lipids was determined as described by 
Oliveira and Vaughan (1964) with modifications. Briefly, the acidified incubation 
medium was mixed with 15 mL of a chloroform-methanol solution (2:1, v/v).  After 
shaking for 20 min, 9 mL of 4% Na2CO3 (w/v in water) was added, followed by 20 
minutes of mixing.  The tubes were then centrifuged to allow the separation of aqueous 
and chloroform layers. The chloroform layer was transferred into clean tubes and 
subjected to two more washes with 4% Na2CO3.  After the chloroform layer was 
transferred to a scintillation vial and dried under a fumehood, 15 mL of counting cocktail 
was added to the vials for the measurement of 14C radioactivity. 
Nitrite analysis 
Nitrite in cell culture medium was analyzed using an HPLC method as described by Li et 
al. (2000).  This technique offers the advantages of high sensitivity and specificity for 
the determination of nitrite as an oxidation product of nitric oxide (Jobgen et al. 2007). 
The medium without cells was included as blanks. 
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Western blot analysis 
BNL CL.2 cells, C2C12 cells, and 3T3-L1 cells were cultured for 48 h in the presence of 
0, 50, 400 µM L-arginine, or 400 µM L-arginine plus 500 µM L-NAME, as described 
above.  After the 48-h culture period, cells were washed with PBS three times, followed 
by lysis in a buffer containing 20 mM Tris-HCl (pH 7.4), 50 mM NaCl, 50 mM NaF, 50 
mM of EDTA, 1% Triton X-100, 1x protease inhibitor cocktail, and 1x phosphatase 
inhibitor cocktail.  Cells were then scraped off into tubes and centrifuged for 10 min at 
10,000 x g.  Protein content in the supernatant fraction was analyzed using the 
bicinchoninic acid kit.  For western blot analysis, 30 µg of protein in a sample was 
separated on 4-12% polyacrylamide gradient gels, transferred to nitrocellulose 
membranes, blocked with 5% fat-free dry milk in TTBS, and incubated with the 
antibodies to AMPK, phosphor-Thr172-AMPK, ACC and phosphor-Ser79-ACC. The 
detailed procedures were described in Chapter IV. 
Statistical analysis 
Data, expressed as means ± SEM, were analyzed using one-way ANOVA.  The Tukey 
multiple comparison method was used to determine differences among the means of the 
treatment groups for 0-400 µM arginine.  A t-test was employed to analyze the data for 
cells treated with either 400 µM arginine or 400 µM arginine plus 0.5 mM L-NAME. 
Probability values ≤ 0.05 were taken to indicate statistical significance.   
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Results 
BNL CL.2 mouse hepatocytes 
Table 5.1 summarizes data on glucose and oleic acid oxidation, lactate production, and 
the incorporation of glucose and oleic acid into lipids in BNL CL.2 cells.  There were no 
differences in glucose oxidation, oleic acid oxidation, or the incorporation of oleic acid 
into lipids between 0 and 50 µM arginine. However, increasing medium concentrations 
of arginine from 50 to 400 µM increased (P<0.05) glucose and oleic acid oxidation, as 
well as the incorporation of oleic acid into lipids.  Exposure of the cells up to 400 µM 
arginine had no effect on lactate production or the incorporation of glucose into lipids.  
In the presence of various concentrations of arginine, 70-80% of metabolized glucose 
carbons appeared as lactate, whereas 85-90% of metabolized oleic acid was incorporated 
into lipids in BNL CL.2 cells.    
Total and phosphorylated levels of AMPK and ACC in BNL CL.2 cells are 
presented in Figs. 5.1 and 5.2, respectively. There were no differences in total or 
phosphorylated AMPK or ACC between 0 and 50 µM arginine. Increasing arginine 
concentrations from 50 to 400 µM had no effect on total AMPK levels but increased 
(P<0.05) phosphorylated AMPK levels by approximately 110%, and therefore, the ratio 
of phosphorylated AMPK to total AMPK by 80%. Compared with 0 or 50 µM arginine, 
exposure of the cells to 400 µM arginine did not affect total or phosphorylated levels of 
ACC, or the ratio of phosphorylated ACC to total ACC. 
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Table 5.1. Glucose and oleic acid metabolism in BNL CL.2 cells 
 
Medium arginine level (µM) 
Variables 
0 15 50 100 400 
P 
value 
Glucose oxidation 
(nmol glucose/mg protein⋅h) 24.5±2.2c 31.6±0.84c 33.6±3.2bc 42.9±2.3ab 53.2±2.5a 0.0005 
Oleic acid oxidation 
(nmol oleic acid/mg protein⋅h) 0.99±0.05b 1.01±0.07b 1.10±0.05b 1.74±0.11a 2.08±0.12a 0.0005 
Lactate release  
(nmol lactate/mg protein⋅h) 218±16 218±34 207±10 262±29 250±19 0.49 
Glucose incorporation into lipids 
(nmol glucose/mg protein⋅h) 0.85±0.04 1.01±0.13 0.96±0.06 1.08±0.09 0.82±0.09 0.23 
Oleic acid incorporation into lipids 
(nmol oleic acid/mg protein⋅h) 7.73±0.81b 6.18±0.81b 8.39±1.53b 15.92±1.31a 18.89±2.51a 0.0005 
 
Cells were incubated for 48 h in DMEM containing 0, 15, 50, 100 or 400 µM arginine. Data are expressed 
as means ± SEM, n=5.  Means with different superscript letters in a row are different (P<0.05).  
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Fig. 5.1.  Relative protein levels for total AMPK, phosphorylated AMPK (P-AMPK) and the ratio of 
P-AMPK to total AMPK in BNL CL.2 cells. Cells were cultured for 48 h in DMEM containing 0, 50 
or 400 µM arginine. Data are expressed as means ±SEM, n=4.  Means with different letters are 
different (P<0.05).  
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Fig. 5.2.  Relative protein levels for total ACC, phosphorylated ACC (P-ACC) and the ratio of P-
ACC to total ACC in BNL CL.2 cells. Cells were cultured for 48 h in DMEM containing 0, 50 or 400 
µM arginine. Data are expressed as means ±SEM, n=4.  
 
 
 
C2C12 skeletal muscle cells 
In C2C12 myotubes, increasing extracellular concentrations of arginine from 0 to 50 µM 
increased (P<0.05) oleic acid oxidation but had no effect on glucose oxidation or lactate 
production (Table 5.2).  Increasing arginine concentration from 50 to 400 µM increased 
(P<0.05) glucose oxidation and lactate production, but had no effect on oleic acid 
oxidation.  The rate of oleic acid oxidation was 23% greater (P<0.05) in the presence of 
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400 µM arginine than in the absence of its addition. In the presence of various levels of 
arginine, 88-91% of metabolized glucose carbons appeared as lactate.   
Increasing extracellular concentrations of arginine from 0 to 50 and 400 µM had no 
effect on total AMPK levels in C2C12 myotubes but progressively increased (P<0.05) 
phosphorylated AMPK levels by 117% and 256%, respectively, and thus the ratio of 
phosphorylated AMPK to total AMPK by 92% and 231 %, respectively (Fig. 5.3). 
Arginine at 50 µM increased (P<0.05) both total ACC and phosphorylated ACC levels 
approximately by 100%, and arginine at 400 µM further increased (P<0.05) total ACC 
and phosphorylated ACC levels by 174% and 236%, respectively, in comparison with 
the values obtained at 0 µM arginine.  As a result, the ratio of phosphorylated ACC to 
ACC was not changed by 50 µM arginine, but was increased by 400 µM arginine 
(P<0.05) (Fig. 5.4). 
 
 
Table 5.2. Glucose and oleic acid metabolism in C2C12 myotubes 
 
Medium arginine level (µM) 
Variables 
0 15 50 100 400 
P value 
Glucose oxidation  
(nmol glucose/mg protein⋅h) 11.5±0.4c 11.3±0.4c 13.4±1.1c 18.6±1.0b 22.3±0.9a 0.0005 
Oleic acid oxidation  
(nmol oleic acid/mg protein⋅h) 1.46±0.08b 1.66±0.03ab 1.75±0.08a 1.72±0.08a 1.80±0.03a 0.030 
Lactate release  
(nmol lactate/mg protein⋅h) 176±10b 196±7.8b 251±11b 436±29a 453±26a 0.0005 
 
Cells were incubated for 48 h in DMEM containing 0, 15, 50, 100 or 400 µM arginine. Data are expressed 
as means ± SEM, n=6.  Means with different superscript letters in a row are different (P<0.05).  
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Fig. 5.3.  Relative protein levels for total AMPK, phosphorylated AMPK (P-AMPK) and the ratio of 
P-AMPK to total AMPK in C2C12 myotubes. Cells were cultured for 48 h in DMEM containing 0, 
50 or 400 µM arginine. Data are expressed as means ±SEM, n=4.  Means with different letters are 
different (P<0.05). 
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Fig. 5.4.  Relative protein levels for total ACC, phosphorylated ACC (P-ACC) and the ratio of P-
ACC to total ACC in C2C12 myotubes. Cells were cultured for 48 h in DMEM containing 0, 50 or 
400 µM arginine. Data are expressed as means ±SEM, n=4. Means with different letters are different 
(P<0.05). 
 
 
 
3T3-L1 adipocytes  
Table 5.3 summarizes the effect of arginine on glucose and oleic acid metabolism in 
3T3-L1 cells.  Lactate was the major product of glucose metabolism in adipocytes, 
representing 80-82% of the metabolized glucose carbons. Increasing extracellular 
concentrations of arginine from 0 up to 400 µM did not affect lactate production or the 
incorporation of glucose into lipids.  The rates of glucose oxidation did not differ 
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between 0 and 100 µM arginine, but were 45% greater (P<0.05) in the presence of 400 
µM arginine than in the absence of its addition. Incorporation into lipids was the major 
fate (80-90%) of oleic acid utilization by 3T3-L1 cells. Increasing extracellular 
concentrations of arginine from 0 to 50 µM had no effect on the oxidation of oleic acid 
or its incorporation into lipids. However, the rates of oleic acid oxidation were 
approximately 40% greater (P<0.05) in the presence of 100-400 µM arginine than in its 
absence.  Also, increasing arginine concentration from 50 to 100 and 400 µM increased 
(P<0.05) the incorporation of oleic acid into lipids by 136% and 190%, respectively.    
 
 
Table 5.3. Glucose and oleic acid metabolism in 3T3-L1 adipocytes 
 
Medium arginine level (µM) 
Variables 
0 15 50 100 400 
P 
value 
Glucose oxidation 
(nmol glucose/mg protein⋅h) 12.1±0.4b 14.4±1.2ab 15.5±1.3ab 16.1±0.9ab 17.6±1.6a 0.037 
Oleic acid oxidation 
(nmol oleic acid/mg protein⋅h) 1.77±0.07c 2.04±0.08bc 2.12±0.10abc 2.40±0.09ab 2.48±0.16a 0.001 
Lactate release  
(nmol lactate/mg protein⋅h) 197±17 184±5 204±17 200±5 203±10 0.78 
Glucose incorporation into lipids  
(nmol glucose/mg protein⋅h) 9.54±0.53 11.1±0.74 9.35±0.43 11.0±0.44 9.73±1.05 0.25 
Oleic acid incorporation into lipids  
(nmol oleic acid/mg protein⋅h) 6.40±1.12b 6.88±1.98b 10.9±1.38b 25.7±3.64a 31.6±3.05a 0.0005 
 
Cells were incubated for 48 h in DMEM containing 0, 15, 50, 100 or 400 µM of arginine. Data are 
expressed as means ± SEM, n=5.  Means with different superscript letters in a row are different (P<0.05).  
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Fig. 5.5.  Relative protein levels for total AMPK, phosphorylated AMPK (P-AMPK) and the ratio of 
P-AMPK to total AMPK in 3T3-L1 adipocytes. Cells were cultured for 48 h in DMEM containing 0, 
50 or 400 µM arginine. Data are expressed as means ±SEM, n=4. Means with different letters are 
different (P<0.05). 
 
 
 
Increasing extracellular concentrations of arginine from 0 to 400 µM did not affect 
total AMPK but increased (P<0.05) phosphorylated AMPK levels. Arginine at 400 µM 
increased (P<0.05) the ratio of phosphorylated AMPK to total AMPK by approximately 
90% compared to 0 µM arginine (Fig. 5.5). In contrast, increasing arginine 
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concentrations from 0 to 400 µM had no effect on total or phosphorylated ACC levels, 
or the ratio of phosphorylated AMPK to total AMPK (Fig. 5.6). 
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Fig. 5.6.  Relative protein levels for total ACC, phosphorylated ACC (P-ACC) and the ratio of P-
ACC to total ACC in 3T3-L1 adipocytes. Cells were cultured for 48 h in DMEM containing 0, 50 or 
400 µM arginine. Data are expressed as means ±SEM, n=4. Means with different letters are different 
(P<0.05). 
 
 
 
NO synthesis 
Increasing extracellular concentrations of arginine from 0 to 400 µM did not affect 
nitrite production in 3T3-L1 cells (Table 5.4).   In both BNL CL.2 and C2C12 cells, 
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nitrite production did not differ between 0 and 100 µM arginine (Table 5.4).  However, 
rates of NO synthesis were 42% and 47% greater (P<0.05) in the presence of 400 µM 
arginine than in its absence in BNL CL.2 and C2C12 cells, respectively. 
 
 
Table 5.4.  The effect of arginine on nitrite production in BNL CL.2, C2C12 and 3T3-L1 cells  
 
Nitrite Medium arginine level (µM) 
(pmol/mg protein⋅24h) 0 50 100 400 
P value 
BNL CL.2 112±12b 119±10ab 125±13ab 159±4a 0.020 
C2C12 351±19b 372±61ab 363±15ab 516±41a 0.025 
3T3-L1 200±18 207±16 232±28 264±27 0.45 
 
Cells were incubated for 48 h in DMEM containing 0, 15, 50, 100 or 400 µM of arginine. Data are 
expressed as means ± SEM, n=5.  Means with different superscript letters in a row are different (P<0.05). 
 
 
 
Effect of L-NAME on BNL CL.2, C2C12 and 3T3-L1 cells 
Addition of 0.5 mM L-NAME to culture media reduced (P<0.05) glucose oxidation, 
oleic acid oxidation and lactate production by approximately 20% in BNL CL.2 cells but 
had no effect on the incorporation of glucose or oleic acid into lipids, compared with the 
absence of the NOS inhibitor (Fig. 5.7A).  L-NAME treatment did not affect total or 
phosphorylated AMPK levels, but reduced the ratio of phosphorylated AMPK to total 
AMPK (P<0.05). Total ACC levels were not altered by 0.5 mM L-NAME, but both 
phosphorylated ACC levels and the ratio of phosphorylated ACC to total ACC in 
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hepatocytes were reduced (P<0.05) by L-NAME treatment (Fig. 5.7B).  In C2C12 
myotubes (Fig. 5.8) or 3T3-L1 adipocytes (Fig. 5.9), 500 M L-NAME did not affect 
glucose oxidation, oleic acid oxidation, lactate release, or protein levels for AMPK and 
ACC.  
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Fig. 5.7.  The effect of L-NAME on glucose and oleic acid oxidation, lactate release, glucose and 
oleic acid incorporation into lipids (A) as well as total and phosphorylated levels of AMPK and ACC 
(B) in BNL CL.2 cells.  Cells were cultured for 48 h in DMEM containing either 400 µM arginine 
(open bars) or 400 µM arginine plus 0.5 mM L-NAME (black bars). Data are expressed as means 
±SEM, n=5 for biochemical assays and n=4 for western blots. * P< 0.05: Different from the group 
without L-NAME. 
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Fig. 5.8.  The effect of L-NAME on glucose and oleic acid oxidation, lactate release, glucose and 
oleic acid incorporation into lipids (A) as well as total and phosphorylated levels of AMPK and ACC 
(B) in C2C12 myotubes.  Cells were cultured for 48 h in DMEM containing either 400 µM arginine 
(open bars) or 400 µM arginine plus 0.5 mM L-NAME (black bars). Data are expressed as means 
±SEM, n=6 for biochemical assays and n=4 for western blots.  
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Fig. 5.9.  The effect of L-NAME on glucose and oleic acid oxidation, lactate release, glucose and 
oleic acid incorporation into lipids (A) as well as total and phosphorylated levels of AMPK and ACC 
(B) in 3T3-L1 adipocytes.  Cells were cultured for 48 h in DMEM containing either 400 µM arginine 
(open bars) or 400 µM arginine plus 0.5 mM L-NAME (black bars). Data are expressed as means 
±SEM, n=5 for biochemical assays and n=4 for western blots.  
 
 
 
Discussion 
Plasma concentrations of arginine in healthy overnight-fasted and fed adults are 
approximately 100 and 200 M, respectively (Wu & Morris, 1998). Dietary 
supplementation with 1% arginine to animals can increase plasma arginine 
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concentrations to 500 M (Wu et al. 2007b).  Interestingly, as low as 15 and 30 M 
arginine are present in the plasma of liver-transplant recipients (Reid et al. 2007) and 
preterm infants (Wu et al. 2004b), due to the release of arginase from liver and the 
underdevelopment of endogenous arginine synthesis pathways, respectively.  In contrast, 
porcine allantoic fluid contains 4 to 6 mM arginine during early gestation (Wu et al. 
1996; 1998).  Thus, the concentrations of arginine used in the present study (15 to 400 
M) are within the physiological and pathological ranges found in mammals, and the 
findings are of nutritional and clinical relevance.    
In BNL CL.2 hepatocytes, C2C12 myotubes and 3T3-L1 adipocytes, glucose and 
oleic acid oxidation increased in response to elevated extracellular concentrations of 
arginine from 0 to 400 µM (Tables 5.1, 5.2 and 5.3), indicating a role for arginine in 
stimulating energy substrate oxidation in these cells.  In addition, the arginine treatment 
enhanced glycolysis in muscle cells, as indicated by the increased production of lactate 
(Table 5.2). These results were consistent with the findings of the previous in vivo 
studies that dietary arginine supplementation increased the metabolism of energy 
substrates in skeletal muscle and adipose tissue (Chapter III; Fu et al. 2005).  
 We found that phosphorylated AMPK levels in all the three cell types used in the 
present study were increased in response to an increase in extracellular concentrations of 
arginine from 0 to 400 M (Fig. 5.1, 5.3 and 5.5).   This result may provide a mechanism 
for explaining the increased oxidation of glucose and fatty acid in arginine-treated 
hepatocytes, muscle cells and adipocytes, on the basis of the previous reports that 
AMPK phosphorylation promotes substrate oxidation in insulin-sensitive cells (Kahn et 
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al. 2005a).  Also, in C2C12 cells, the levels of phosphorylated ACC, a downstream 
target of AMPK, increased in response to the arginine supplementation. Malonyl-CoA, a 
product of ACC, is a potent inhibitor of carnitine palmitoyltransferase I (CPT-I).  Thus, 
the inactivation of ACC via its phosphorylation will lead to an increase in the activity of 
CPT-I (Viollet et al. 2006), thereby facilitating the transport of long-chain fatty acids 
from the cytosol to mitochondria for oxidation in arginine-treated C2C12 cells.  
Arginine is catabolized by multiple pathways to form NO, ornithine and proline in 
cultured cells (Wu & Morris, 1998).  The addition of 0.1 mM ornithine plus proline (the 
major products of arginine catabolism via the arginase pathway) to culture medium had 
no effect on glucose or oleic acid oxidation in endothelial cells or enterocytes (G. Wu, 
unpublished data).  These results suggest that ornithine or proline do not mediate the 
effect of arginine on metabolism in these cell types.  Whether ornithine and proline 
affect substrate metabolism in BNL CL.2 hepatocytes, C2C12 myotubes and 3T3-L1 
adipocytes remains to be determined. 
Interestingly, increasing extracellular concentrations of arginine from 0 to 400 M 
increased NO synthesis in BNL CL.2 cells, as reported for arginine-treated rat 
hepatocytes (Morita et al. 1996).  However, an inhibition of NO synthesis only 
moderately attenuated the effect of arginine on the phosphorylation of AMPK and ACC 
as well as glucose oxidation, glycolysis, and oleic acid oxidation in BNL CL.2 cells (Fig. 
5.4). This result is consistent with the report that NO or cGMP can stimulate fatty acid 
oxidation through reducing ACC activity and enhancing CPT-I activity in rat 
hepatocytes (Garcia-Villafranca et al. 2005).  However, an inhibition of NO synthesis 
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had no effect on AMPK and ACC phosphorylation or glucose and oleic acid metabolism 
in C2C12 cells and 3T3-L1 cells (Fig. 5.5 and 5.6).   These findings suggest that, under 
the experimental conditions used in the present study where culture medium contained 4 
mM glutamine to reduce NO synthesis (Meininger & Wu 1997; Houdijk et al. 1998; Wu 
et al. 2001), NO was not a major regulator of AMPK and ACC activity or the oxidation 
of energy substrates in these three cell types. Consistent with this view are the following 
observations.  First, NO synthesis in 3T3-L1 cells did not differ between 0 and 400 M 
arginine (Table 5.4).  Second, increasing extracellular concentrations of arginine from 0 
to 100 M increased glucose and oleic acid oxidation in BNL CL.2 cells (Table 5.1) and 
C2C12 cells (Table 5.2) but did not affect NO production in these two cell types (Table 
5.4).  It is possible that arginine catabolism is not necessary for exerting its stimulatory 
effect on substrate oxidation in hepatocytes, adipocytes and muscle cells and that this 
amino acid may directly activate AMPK in a cell-specific manner.  In support of this 
notion, previous studies have shown that arginine can directly increase expression of 
GTP cyclohydrolase-I in endothelial cells (Shi et al. 2004) and stimulate mTOR 
phosphorylation in intestinal cells (Rhoads et al. 2007).  
In both BNL CL.2 cells and 3T3-L1 cells, arginine increased oleic acid incorporation 
into lipids. Liver and adipose tissue are the two major sites for de novo fatty acid 
synthesis in rodents (Bergen & Mersmann, 2005). Because free fatty acids are toxic to 
cells, an increase in their packaging into lipids may have important implications for cell 
integrity and the regulation of plasma concentrations of free fatty acids. This may help 
explain the finding that dietary arginine supplementation reduced the circulating levels 
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of free fatty acids in ZDF rats (Fu et al. 2005) and serum concentrations of triglycerides 
in diet-induced obese rats (Chapter II). 
 In sum, results of this study demonstrate that L-arginine enhances glucose and oleic 
acid oxidation in BNL CL2 hepatocytes, C2C12 myotubes and 3T3-L1 adipocytes in 
association with increased AMPK phosphorylation. This effect of arginine was mediated 
only to a small extent by an NO-dependent mechanism in BNL CL2 cells and was 
independent of NO production in C2C12 and 3T3-L1 cells. We suggest that arginine 
itself may directly activate AMPK, thereby stimulating the oxidation of energy 
substrates in insulin-sensitive cells. 
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CHAPTER VI 
SUMMARY AND DIRECTION OF FUTURE RESEARCH 
 
There is a substantial body of evidence showing the beneficial effect of L-arginine on 
ameliorating metabolic abnormalities, including hyperglycemia, dyslipidemia, and 
impaired NO synthesis in endothelial cells (Jobgen et al. 2006). Most recently, dietary 
arginine supplementation has been suggested to play a role in reducing fat mass in obese 
animals (Fu et al., 2005) and humans with type-II diabetes mellitus (Lucotti et al. 2006).  
The major purpose of this dissertation research is to determine the effect of dietary 
arginine supplementation on the oxidation of energy substrates in insulin-sensitive 
tissues of diet-induced obese (DIO) rats and to elucidate the underlying mechanisms.  
The first part of this study was designed to evaluate the effect of arginine on whole 
body metabolism in DIO versus lean rats (Chapter II).  High-fat feeding increased body 
weight, white adipose tissue mass, lipid concentrations in liver and muscle, serum 
cholesterol and leptin concentrations, and resulted in impaired glucose tolerance. 
Importantly, dietary arginine supplementation for 12 wks reduced white adipose tissue 
mass in different anatomical locations, while increasing brown fat and skeletal muscle 
masses. In addition, the arginine treatment reduced serum levels of glucose, triglycerides 
and leptin, as well as improved whole-body insulin sensitivity. Collectively, these 
findings indicate a potentially novel means of using arginine to treat the metabolic 
syndrome in obese subjects.  
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The second part of the work was conducted to investigate the metabolic basis for the 
anti-obesity effect of arginine (Chapter III).  Particularly, we focused on the oxidation of 
energy substrates in skeletal muscle and adipose tissue. Because of a concern about the 
biochemical viability of liver slices in incubation, the hepatic metabolism of glucose or 
oleic acid was not studied.  Our results indicated that arginine supplementation did not 
affect total adipocyte numbers in RP adipose tissue, but reduced adipocyte size, 
therefore shifting the cell size distribution to a smaller diameter. Notably, dietary 
arginine supplementation increased the oxidation of both glucose and oleic acid in 
skeletal muscle, the major site for the utilization of energy substrates in the body. 
Increases in both skeletal muscle mass and its oxidative capacity greatly facilitate the 
oxidation of glucose and fatty acids (including the fatty acids derived from adipose 
tissue), contributing to the loss of fat mass in DIO rats.  
Subsequent experiments were performed to define the molecular basis of the anti-
obesity property of arginine (Chapter IV). Dietary arginine supplementation greatly 
enhanced AMPK and ACC phosphorylation in liver but had no effect in gastrocnemius 
muscle or adipose tissues. In addition, the arginine treatment increased expression of the 
hepatic genes (CPT-1, AMPK, and PGC-1α) for glucose and fatty acid oxidation, while 
decreased expression of the hepatic genes (FAS and SCD-1) for fatty acid synthesis.  
Because the liver is the principal organ for both de novo fatty acid synthesis and fatty 
acid oxidation in rats and humans (Bergen & Mersmann, 2005), an inhibition of fatty 
acid synthesis and an increase in fatty acid oxidation in the liver provides a key 
molecular basis for the anti-obesity effect of arginine. These findings indicate that 
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dietary arginine supplementation coordinately regulates expression of key genes and 
activity of proteins that are involved in the metabolism of energy substrates, thereby 
reducing excessive fat and improving insulin sensitivity in diet-induced obese rats. 
Because dietary arginine supplementation can result in changes in the endocrine 
status and circulating levels of hormones and metabolites, it is not clear whether arginine 
itself can induce changes in expression of key genes responsible for nutrient metabolism 
in insulin-sensitive tissues and cells.  Thus, we used cell culture models to define an 
effect of arginine on the expression and phosphorylation of AMPK and ACC as well as 
oxidation of energy substrates (Chapter V).  Specifically, we asked the question of 
whether arginine regulated glucose and fatty acid metabolism via an NO-dependent 
mechanism.  BNL CL.2 mouse hepatocytes, differentiated C2C12 mouse skeletal muscle 
cells, and 3T3-L1 mouse adipocytes were treated with various levels of arginine (0-400 
µM) or 400 µM of arginine plus 500 µM L-NAME (an NOS inhibitor) in culture 
medium for 48 h. Increasing extracellular concentrations of arginine increased AMPK 
phosphorylation as well as both glucose and oleic acid oxidation in all the three cell 
types. NO synthesis was increased in BNL CL.2 and C2C12 cells cultured in the 
presence of 400 µM arginine in comparison with its absence.  However, NO production 
did not differ in 3T3-L1 cells cultured in the presence of 0 and 400 M arginine.  
Further, an inhibition of NO generation by L-NAME only modestly reduced the 
arginine-induced increases in AMPK and ACC phosphorylation as well as glucose and 
oleic acid oxidation in hepatocytes, and had no effect on these parameters in muscle cells 
or adipocytes. These findings suggest that arginine stimulates AMPK phosphorylation in 
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a cell-specific manner and that NO is not a major mediator of the arginine action in 
hepatocytes, skeletal muscle cells, or adipocytes. 
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Fig. 6.1. The proposed mechanisms responsible for the beneficial effect of L-arignine on the 
oxidation of energy substrates and the synthesis of triacylglycerol in animals. The symbol (+) denotes 
an increase in gene expression and/or enzyme activation. The symbol (-) denotes an inhibition of 
gene expression and/or enzyme activity. 
 
 
In conclusion, results of this dissertation research demonstrate that dietary arginine 
supplementation exerts a beneficial effect on increasing glucose and fatty acid oxidation 
in skeletal muscle, reducing body fat mass, and improving insulin sensitivity in diet-
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induced obese rats. Increases in gene expression of AMPK and its protein 
phosphorylation in liver may be the key mechanism responsible for the stimulatory 
action of arginine on substrate oxidation.  In addition, dietary arginine supplementation 
reduces hepatic expression of key lipogenic genes (FAS and SCD-1), thereby attenuating 
fat accretion in the body. Figure 6.1 outlines the proposed mechanisms responsible for 
the beneficial effect of L-arignine on the oxidation of energy-substrates and the synthesis 
of triacylglycerol in animals. Evidence from studies with cell culture models suggests 
that NO is not a major mediator of the beneficial effect of arginine on the oxidation of 
energy substrates in insulin-sensitive tissues.   
Further research is needed to better understand the mechanism whereby arginine 
regulates expression of the AMPK gene and its protein phosphorylation in a cell-specific 
manner.  The chemical structure of arginine with a unique guanidino group may play an 
important role in its action.  It is possible that this amino acid may directly regulate 
expression and phosphorylation of AMPK in various cell types.  The use of non-
metabolizable analogues of arginine (including D-arginine) may provide a tool to 
address this question. In addition, arginine supplementation does not affect the cell 
number of adipocytes in RP adipose tissue, while reducing their cell size due to the loss 
of intracellular lipids.  However, at 12-wk after the initiation of the arginine treatment, 
no increase in glycerol release from adipose tissue could be observed in diet-induced 
obese rats. Dietary arginine supplementation may stimulate lipolysis in adipocytes 
during the initial and mid phases of the treatment, and further studies are warranted to 
test this hypothesis. Finally, to thoroughly understand substrate metabolism at the whole-
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body level, research should be initiated to quantify energy expenditure in lean and obese 
rats treated with or without arginine.   
Obesity is a growing health problem for both humans and companion animals 
worldwide.  In addition, domestic animals have a great capacity for lipogenesis and fat 
storage, potentially leading to low-quality meat products. Thus, future research on 
arginine biochemistry and nutrition will provide a much-needed scientific basis for 
designing a novel, safe and effective means to prevent and treat obesity in mammals and 
to enhance the efficiency of livestock production.   
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